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1 Summary 
Site specific incorporation of non-canonical amino acids (NCAAs) into proteins is a 
powerful tool for e.g. studying the effects of post translational modifications, revealing 
enzymatic mechanisms, visualizing proteins in living cells or adding new functionalities to 
therapeutic and diagnostic proteins. The technology is based on orthogonal 
tRNA/aminoacyl-tRNA synthetase (aaRS) pairs, which do not interfere with the 
biosynthetic machinery of the host cell (e.g. E. coli).  
The tRNA/aaRS pair, which was used in this thesis originates from the archaeal strain 
Methanosarcina mazei. It is responsible for the ribosomal incorporation of pyrrolysine (Pyl), 
also known as the 22nd proteinogenic amino acid, in response to UAG ("amber-") codons. 
In the classic genetic code, these amber codons are stop codons and lead to translation 
termination. When transferring the tRNAPyl/PylRS-pair to e.g. E. coli, the incorporation of 
a NCAA in response to an amber codon competes with translation termination and is 
therefore called "amber suppression". 
In this thesis, the pyrrolysine system was exploited to incorporate three newly described 
posttranslational lysine modifications site specifically into histone H3, where they have 
been identified. The amino acids ε-N-propionyl-, ε-N-butyryl-, and ε-N-crotonyl-lysine 
were directly incorporated at the desired position to simulate the respective naturally 
occuring propionylation, butyrylation or crotonylation respectively. Comprehensive 
bioanalytical examinations of the modified histone, which included peptide mapping-MS 
and western blot analyses unambiguously proved the site specific and complete 
incorporation of these NCAAs. 
Although numerous NCAAs have already been incorporated into proteins by amber 
suppression, the structural diversity of these is of course limited. However, the 
introduction of NCAAs carrying bioorthogonal modification handles opens an infinite 
field of possibilities since it allows post translational, specific modifications of the protein 
of interest. One of the most promising handles are norbornenes, which could be 
introduced site specifically into proteins by the Carell group.1 The modification of 
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norbornens with tetrazines in inverse electron demand Diels-Alder reactions is one of the 
fastest bioorthogonal modification reactions described. 
Mechanistic studies in collaboration with the de Vivie-Riedle group revealed and 
explained that, due to a more stable transition state, exo-substituted hydroxymethyl 
norbornenes react around three-times faster than their endo substituted isomers.  
To analyze, whether this behavior could also be observed on the protein level, the endo 
substituted norbornyl lysine and two novel exo substituted norbornene amino acids were 
incorporated into model proteins. The acceptance of these new norbornene amino acids 
by the Pyl system including a PylRS triple mutant was supported with solid analytical data. 
The correct incorporation and complete labeling with fluorescent and PEGylated 
tetrazines was demonstrated by SDS-PAGE, intact-MS and peptide mapping analyses of 
the unmodified and modified protein species. A faster labeling reaction of the exo-
substituted norbornyl amino acids was not observed in these in vitro protein labeling 
studies. 
In collaboration with the Schneider group, crystal structures of the used PylRS triple 
mutant bearing the Pyl analogs demonstrated the versatility of the triple mutant developed 
in the Carell group.1  
In order to expand the set of bioorthogonal modification reactions, a novel click reaction, 
the aziridation of norbornenes using electron-deficient sulfonyl azides was developed. The 
reaction was characterized on small molecule level, on the peptide level and finally on the 
protein level using norbornene containing model proteins. The second order rate constant 
was determined to be k2 = 1.7 x 10
-3 M-1 s-1. This value is comparable to the rate constants of 
the strain-promoted azide–alkyne cycloaddition of the first generation which is commonly 
used for biomolecule labeling applications.2,3 Chemoselective protein conjugation with 
fluorescent, and immuno tags on the norbornene residue was proven by SDS-PAGE, 
Western blot as well as by peptide mapping and intact mass spectrometric studies. The 
reaction proceeds efficiently under mild conditions, does not require any catalysis and is 
orthogonal to functional groups of native proteins. Furthermore, sulfonyl azides are easily 
accessible compounds, which makes the newly developed labeling reaction an attractive 
alternative to the existing set of bioconjugation techniques.  
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A general challenge of the incorporation of NCAAs into proteins is that the amino acids 
have to be chemically synthesized in large quantities to reach the required millimolar 
concentrations during protein expression. Our idea was to circumvent these laborious 
syntheses and hand over the work to the biosynthetic machinery of the host cell. In this 
thesis, a Pyl-biosynthesis "hijacking" system was developed, that allowed the biosynthesis 
and incorporation of unnatural 3S-ethynylpyrrolysine (ePyl), a bifunctional reaction 
handle, by feeding E. coli cells with 3R-ethynyl-D-ornithine. The correct production and 
incorporation of the novel NCAA in a purified model protein was proved by extended 
analytics including mass spectrometric studies on intact and peptide level. It was shown, 
that site specifically incorporated ePyl can be modified by two different orthogonal click 
reactions at only one amino acid site providing access to highly modified proteins. 
Finally, to prove the feasibility of NCAA carrying proteins as useful tools in biomedical 
applications, site specifically modified human carbonic anhydrase-folic acid-conjugates 
(HCA-FA) were applied as targeting, pH responsive capping proteins for drug delivery in 
mesoporous silica-based nanocarriers (MSNs). The studies were carried out in 
collaboration with the groups of Prof. Bein and Prof. Bräuchle. Three key elements of the 
newly developed capping system arise from the site-specifically modified HCA-FA. First, 
the protein is large enough to block the gates of the MSN to prevent the cargo from 
escaping. Second, HCA binds phenyl-sulfonamide (phSA) and therefore sulfonamide-
functionalized MSNs (MSN-phSA) in a pH depended manner. At pH values below 7, 
typically present during endocytosis of MSNs, the enzyme releases MSN-phSA, which 
ensures the release of the cargo at the exact right moment. Third, the site-specific 
functionalization of HCA can direct the MSNs to a specific cell type.  
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2 Zusammenfassung 
Der ortsspezifische Einbau von nicht-kanonischen Aminosäuren (engl. abgekürzt NCAAs) 
in Proteine ist ein leistungsfähiges Werkzeug in der chemischen Biologie. Es kann unter 
anderem für die Untersuchung der Auswirkungen von posttranslationalen 
Modifikationen, für die Aufklärung enzymatischer Mechanismen, für die Visualisierung 
von Proteinen in lebenden Zellen oder zum Funktionalisieren therapeutischer und 
diagnostischer Proteine verwendet werden. Die Technologie basiert auf orthogonalen 
tRNA/Aminoacyl-tRNA-Synthetase (aaRS)-Paaren, die nicht in die 
Biosynthesemaschinerie der Wirtszelle (z.B. E. coli) eingreifen. Das in dieser Arbeit 
verwendete tRNA/aaRS-Paar stammt aus dem Archaea-Stamm Methanosarcina mazei. Es 
ist verantwortlich für den ribosomalen Einbau von Pyrrolysin (Pyl), das auch als 22. 
proteinogene Aminosäure bekannt ist. Pyl wird vom sogenannten "Amber Codon" codiert. 
Im klassischen genetischen Code ist dieses Codon ein Stopp-Signal und führt zur 
Termination der Translation. Wenn das tRNAPyl/PylRS-Paar z.B. in E. coli exprimiert wird, 
konkurriert der Einbau einer NCAA als Antwort auf ein Amber-Codon mit der 
Translationsterminierung und wird daher als amber suppression bezeichnet. 
In dieser Arbeit wurde das Pyrrolysin-System genutzt, um drei neu beschriebene 
posttranslationale Lysin-Modifikationen spezifisch an Positionen in Histon H3 zu 
integrieren, an denen sie identifiziert wurden. Die Aminosäuren ε-N-Propionyl-, ε-N-
Butyryl- und ε-N-Crotonyllysin wurden direkt an der gewünschten Position eingebaut, um 
die jeweilige natürlich vorkommende Propionylierung, Butyrylierung bzw. 
Crotonylierung zu simulieren. Umfassende bioanalytische Untersuchungen des 
modifizierten Histons mit peptide mapping-MS und Western-Blot-Analysen belegten den 
ortsspezifischen und vollständigen Einbau dieser NCAAs eindeutig. 
Obwohl zahlreiche NCAAs bereits durch amber suppression in Proteine eingebaut wurden, 
ist die strukturelle Vielfalt dieser Aminosäuren natürlich begrenzt. Die Einführung von 
NCAAs, die bioorthogonal modifizierbare funktionale Gruppen tragen, eröffnet jedoch 
nahezu unerschöpfliche Möglichkeiten, da sie spezifische Modifikationen von Proteinen 
nach deren Expression ermöglicht. Eine der Vielversprechendsten dieser funktionalen 
Einheiten sind Norbornene, die von der Carell-Gruppe spezifisch in Proteine eingebaut 
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werden können.1 Die Reaktion von Norbornenen mit Tetrazinen in invers Elektronen-
anfordernden Diels-Alder-Cycloadditionen ist eine der schnellsten beschriebenen 
bioorthogonalen Modifizierungsreaktionen. 
In mechanistischen Studien in Zusammenarbeit mit der Gruppe von Prof. de Vivie-Riedle 
konnte gezeigt und erklärt werden, dass exo-substituierte Hydroxymethyl-Norbornene 
aufgrund eines stabileren Übergangszustands etwa dreimal schneller mit Tetrazinen 
reagieren als ihre endosubstituierten Isomere. Um zu analysieren, ob dieses Verhalten 
auch auf Proteinebene beobachtet werden kann, wurden das endo-substituierte 
Norbornyllysin und zwei neue exo-substituierte Norbornen-Aminosäuren in 
Modellproteine eingebaut. Die Akzeptanz dieser neuen Norbornen-Aminosäuren durch 
das Pyl-System, das eine zuvor entwickelte PylRS-Dreifachmutante enthielt, wurde mit 
soliden analytischen Daten bewiesen. Der korrekte Einbau und die vollständige 
Markierung mit fluoreszierenden und PEGylierten Tetrazinen wurde durch SDS-PAGE-, 
Intakt-MS- und peptide mapping-Analysen der unmodifizierten und modifizierten 
Proteinspezies gezeigt. Eine schnellere Markierungsreaktion der exo-substituierten 
Norbornyl-Aminosäuren wurde bei diesen in vitro-Proteinmarkierungsstudien allerdings 
nicht beobachtet. In Zusammenarbeit mit der Arbeitsgruppe von Dr. Sabine Schneider 
konnte die Vielseitigkeit der in der Carell-Gruppe entwickelten PylRS Dreifachmutante in 
Kristallstrukturen mit gebundenen Pyl-Analoga gezeigt werden. 1 
Um die Auswahl an bioorthogonalen Modifikationsreaktionen zu erweitern, wurde die 
Aziridierung von Norbornenen mit elektronenarmen Sulfonylaziden, eine neuartige 
Klickreaktion, entwickelt. Die Reaktion wurde auf niedermolekularer, auf Peptid- und 
schließlich auf Proteinebene mit Norbornenen, Norbornen-Peptiden und Norbornen-
haltigen Modellproteinen charakterisiert. Die Geschwindigkeitskonstante zweiter 
Ordnung wurde mit k2 = 1,7×10 
-3 M-1s-1 bestimmt. Dieser Wert ist vergleichbar mit den 
Geschwindigkeitskonstanten der Ringspannungs-unterstützten Azid-Alkin-Cycloaddition 
der ersten Generation, die häufig für Biomolekül-Markierungen verwendet wird. 2,3 Die 
chemoselektive Proteinkonjugation mit Fluoreszenz- und Immuno-reagenzien am 
Norbornen-Rest wurde durch SDS-PAGE, Western Blot sowie durch peptide mapping und 
intakte massenspektrometrische Untersuchungen nachgewiesen. Die Reaktion verläuft 
effizient unter milden Bedingungen, erfordert keine Katalyse und ist orthogonal zu 
Zusammenfassung 
 
18 
funktionellen Gruppen von nativen Proteinen. Darüber hinaus sind Sulfonylazide leicht 
zugängliche Verbindungen, was die neu entwickelte Markierungsreaktion zu einer 
attraktiven Alternative zu den bestehenden Biokonjugationstechniken macht. 
Eine allgemeine Herausforderung beim Einbau von NCAAs in Proteine besteht darin, dass 
die Aminosäuren in großen Mengen chemisch synthetisiert werden müssen, um die 
erforderlichen millimolaren Konzentrationen während der Proteinexpression zu 
erreichen. Unsere Idee war es, diese aufwendigen Synthesen zu umgehen und die Arbeit 
an die biosynthetische Maschinerie der Wirtszelle zu übergeben. Dafür wurde in diesem 
Projekt ein Pyl-Biosynthese-"Entführungs"-System entwickelt, das die Biosynthese und 
den Einbau von unnatürlichem 3S-Ethinylpyrrolysin (ePyl), einer zweifach 
modifizierbaren Einheit, ermöglicht, indem E. coli-Zellen mit 3R-Ethinyl-D-Ornithin 
gefüttert werden. Die korrekte Synthese und die richtige Position des Einbaus der neuen 
NCAA in einem gereinigten Modellprotein wurde durch umfassende Analysen 
einschließlich massenspektrometrischer Untersuchungen auf intakter und Peptidebene 
nachgewiesen. Es konnte gezeigt werden, dass ortsspezifisch eingebautes ePyl durch zwei 
unterschiedliche orthogonale Klickreaktionen modifiziert werden kann, was den Zugang 
zu hochmodifizierten Proteinen ermöglicht. 
Um schließlich die Anwendbarkeit von NCAA-tragenden Proteinen als nützliche 
Werkzeuge in biomedizinischen Anwendungen zu beweisen, wurden ortsspezifisch 
modifizierte humane Carboanhydrase-Folsäure-Konjugate (HCA-FA) als zielgerichtete, 
pH-schaltbare Capping-Proteine für die Wirkstoffabgabe in mesoporösem Siliciumdioxid 
Nanoträgern (engl. abgekürzt MSNs) eingesetzt. Die Studien wurden in Zusammenarbeit 
mit den Gruppen von Prof. Bein und Prof. Bräuchle durchgeführt. Drei Schlüsselelemente 
des neu entwickelten Verschlusssystems ergeben sich aus dem ortsspezifisch 
modifizierten HCA-FA. Erstens ist das Protein groß genug, um die Poren der MSNs zu 
blockieren, um zu verhindern, dass die Ladung austritt. Zweitens bindet HCA 
Phenylsulfonamid (phSA) und daher Sulfonamid-funktionalisierte MSNs (MSN-phSA) 
pH-abhäng. Bei pH-Werten unter 7, die typischerweise während der Endozytose von 
MSNs vorliegen, lässt das Enzym MSN-phSA los und gewährleistet damit die Freisetzung 
der Fracht zum genau richtigen Zeitpunkt. Drittens steuert die ortsspezifische 
Funktionalisierung von HCA die Anbindung der MSNs an spezifische Zelltypen. 
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3 Abbreviations 
aaRS Aminoacyl-tRNA synthetase 
ADC Antibody-drug-conjugate 
AmpR Ampicilin resistance 
CHO Chinese hamster ovary cells 
CuAAC Cu(I)-catalyzed azide-alkyne 1,3-dipolar cycloaddition 
D-Orn D-ornithine 
DTT Dithiotreithol 
H3 Histone 3 
HRP Horse raddish peroxidase 
iEDDA Inverse electron demand Diels-Alder cycloaddition 
INN International nonproprietary name 
IPTG Isopropyl-�-thiogalactopyraniside 
MALDI Matrix assisted laser desorption/ionization 
MjTyrRS/MjtRNATyr Methanococcus jannaschii tRNA/tRNA-aminoacyl synthetase pair 
MMA Monomethylamine 
mRNA messenger ribonucleic acid 
MS mass spectrometry 
Abbreviations 
 
20 
MtbB Bimethylamine methyltransferase 
MtmB Monomethylamine methyltranferase 
MttB Trimethylamine methyltransferase 
NCAA Non canonical amino acid 
Norb Nobornene 
Orn Ornithine 
PAGE  Polyacrylamide gel electrophoresis 
PCR Polymerase chain reaction 
PLP Pyridoxal phosphate 
PTM Post translational modification 
Pyl Pyrrolysine 
PylRS  Pyrrolysyl-tRNA synthetase 
PylT  Pyrrolysine-tRNA 
rDA Reverse Diels-Alder reaction 
RF  Release factor 
RP-HPLC  Reverse phase high performance liquid chromatography 
SDS  Sodium dodecylsulfate 
Sec  Selenocystein 
SECIS  Selenocysteine insertion element 
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SerRS Serine-tRNA synthetase 
tRNAaa tRNA specific for amino acid aa 
tRNAPyl Pyrrolysine-tRNA 
TrxA Thioredoxin A 
UAA  Unnatural amino acid 
wt  Wild type 
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4 Introduction 
4.1 Natural expansions of the genetic code 
The set of 20 canonical amino acids has been seen as an unchangeable part of a universal 
genetic code. In contrast to this dogma, observed deviations of the genetic code and 
especially the discovery of a 21st and a 22nd proteinogenic amino acid have proven the 
mutability of the genetic code and have led to discussions about its origin.4 
4.1.1 The 20 canonical amino acids 
All organisms living on this planet share the same amino acid alphabet, even though their 
evolutional pathways may have diverged very early in the development of life. The 
bacterium Escherichia coli, a sunflower and the human species, for instance, share the same 
genetic code, which decodes the same set of protein building blocks. But why did exactly 
these amino acids develop and why exactly 20?  
A widely accepted hypothesis assumes that the first organisms were based entirely on 
ribonucleotides.5 The usage of only four building blocks enabled these ribo-organisms to 
form so called ribozymes. These are complex secondary structures which are able to 
catalyze specific chemical reactions. The following extension of the number of enzyme 
building blocks from four (ribo-organisms) to 20 (modern organisms) certainly increased 
the diversity of chemical functionality and therefore enabled more complex structures. 
Nevertheless, enlargement of versatility cannot be the only driving force in the evolutional 
development of amino acids.6,7 Several canonical amino acids show redundant functional 
properties as the acidic aspartate and glutamate, the amide containing asparagine and 
glutamine or the non-polar valine, leucine and isoleucine. A possible argument for the 
reduced complexity of the selected amino acid library could be their metabolic price.8,9 
Bulky, more complex amino acids, such as phenylalanine or tyrosine are found in lower 
amounts than easily accessible amino acids as valine or serine. Based on this economical 
principle, only small and metabolically cheap amino acids found their way into the set of 
protein building blocks by the cost of lower versatility. Although, when only arguing 
economically, the metabolic costs could be even more reduced, since it was shown, that 
most of the known protein folding structures are accessible with much smaller sets of 
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amino acids.10,11 Therefore, the question why exactly those 20 amino acids were selected 
early in the development of life cannot entirely be explained as a compromise between 
gained complexity and low metabolic costs. 
An explanation to this question is given by the so-called "frozen accident theory” first 
described by Francis Crick in 1968.12 This theory describes a situation in which many 
organisms with different sets of amino acids existed. One of these organisms developed an 
innovation (accident) that favored it in a way that no other organism could compete 
anymore. Every change of the amino acid set would have made this innovation impossible 
to realize. Therefore, the set of amino acids was frozen and not a target of evolution 
anymore. 
In contrast to this theory, natural genetic code variations such as stop-codon-read-through 
or the two additional amino acids selenocysteine (Sec) and pyrrolysine (Pyl) were found in 
natural proteins.13-16 Especially the discoveries of the additional amino acids Sec and later 
Pyl were stimulating the discussions about the origin of the canonical amino acids again.17 
4.1.2 Selenocysteine, the 21st proteinogenic amino acid 
Selenocysteine (Sec, U) was discovered in 1976 as the first proteinogenic amino acid which 
was not part of the standard set of 20 amino acids and is therefore often referred to as the 
"21st" proteinogenic amino acid.13 It was identified in all three domains of life but is most 
abundant in bacteria, where a quarter of all sequenced strains is synthesizing Sec.7,8 Even 
in the human genome, numerous Sec containing proteins, so called selenoproteins, were 
identified.18 
The structure of Sec can be formally described as a cysteine analog of which the thiol group 
is exchanged by a selenol group (Scheme 4.1).  
 
Scheme 4.1 Structure of selenocysteine (Sec) 
HO
O
NH2
SeH
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Sec was shown to be specifically introduced in response to the opal stop codon (UGA), first 
described for E. coli.19-21 As depicted in Figure 4.1, several factors have to exist in a bacterial 
genome to be able to encode Sec. First, a special tRNASec has to be present which recognizes 
the UGA codon. This tRNASec is charged by a standard SerRS with serine to yield Ser-
tRNASec and is afterwards converted to Sec-tRNASec by SelA, the selenocysteine 
synthase.22,23 SelA is a pyridoxal phosphate dependent enzyme which transfers selenium 
from selenium phosphate (provided by SelD) to tRNASec-coupled serine. The synthesis of 
Sec exclusively occurs on tRNASec-coupled serine, not on the free amino acid, which 
fundamentally differentiates the Sec incorporation pathway from the later discussed 
pyrrolysine incorporation pathway. SelB, a specific GTP dependent elongation factor 
binds the completed Sec-tRNASec and a crucial mRNA stem loop structure in a defined 
distance downstream of the gene of interest. This mRNA secondary structure element is 
called SECIS: Selenocysteine insertion sequence.24-27 The complex of SelB, SECIS and Sec-
tRNASec enables the ribosome to translate an opal codon (UGA) by binding the 
complementary anti-codon loop of Sec-tRNASec and inserting selenocysteine into the 
nascent protein chain. 
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Figure 4.1 Selenocysteine synthesis and incorporation into proteins in prokaryotic cells 
Analogs of SelB, SelD and SECIS have been identified in archaea and eukaryotes, where 
the principle incorporation of Sec works similarly, whereas the exact mechanisms of Sec 
biosynthesis differ slightly from the described bacterial pathway.28,29 
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4.1.3 Pyrrolysine, the 22nd proteinogenic amino acid 
The existence of pyrrolysine (Pyl, O) was first described in two independent reports in 2002 
by Chan et al.14 and Krzycki et al.15 Figure 4.2 shows the structure of pyrrolysine. Pyl 
contains a 4-methylated-(4R, 5R)-pyrroline-5-carboxylate, which is linked via an amide 
bond to the e-nitrogen of L-lysine. 30-32 
 
Figure 4.2 Structure of pyrrolysine (Pyl) 
4.1.3.1 Natural function and distribution  
The genetic ability to biosynthesize Pyl was discovered in more than 25 anaerobic archea 
and bacteria. pyrrolysine containing proteins have been identified mainly in 
methanogenic archea species of the family Methanosarcinaceae such as Methanosarcina 
mazei or Methanosarcina barkeri, but also in a few bacteria as in the bacteria 
Desulfitobacterium hafniense or Bilophila wadsworthia and in a symbiotic 
deltaproteobacterium of the gutless worm Olavius algarvensis. 15,33,34 
Pyl enables the methanogenic Methanosarcina species to metabolize monomethyl-, 
dimethyl- and trimethylamine since it is expressed in the active sites of the 
methyltransferases MtmB, MtbB and MttB.31,35 Although these three enzymes show little 
structural homologies, the function of Pyl in their active sites is similar.36-38 Figure 4.3 
exemplifies its function for the methyl transfer of monomethylamine by the 
methyltransferase MtmB: The first step of the methyl transfer is the addition of the 
methylamine to protonated Pyl, which activates the methyl group for transfer to MtmC, a 
cobalt-containing corrinoid cofactor bound enzyme. At the end of this enzymatic cascade, 
this methyl group is converted either to methane or to carbon dioxide or it enters pathways 
leading to carbon assimilation. Therefore, Pyl acts like a cofactor, with the difference, that 
it is incorporated cotranslationally as an amino acid. 
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Figure 4.3 Transfer of a methyl group (red) from monomethylamine to Pyl (orange) in the 
catalytic site of MtmB 
The function of bacterial Pyl containing methyltransferase homologues is not solved yet 
and their presence in the bacterial proteome probably is a result of horizontal gene 
transfer.39 
4.1.3.2 Biosynthesis 
The Pyl gene cluster contains five genes: pylT, pylS, pylB, pylC and pylD. A transfer of only 
these five genes together with the mtmB gene enabled E. coli to generate functional MtmB 
containing Pyl in its active site.40 These genes can therefore be considered as a genetic code 
expansion cassette.40,41 The genes pylT and pylS encode for an amber codon specific tRNA 
and its corresponding aminoacyl transferase PylRS which will be described in detail in the 
next chapter. The gene products of pylB, pylC and pylD are responsible for the biosynthesis 
of Pyl. The first attempts to identifying the underlying mechanisms suggested D-ornithine 
(D-Orn), Figure 4.4, as a possible precursor of Pyl, since it was shown, that the addition of 
this non-proteinogenic amino acid increased the yields of MtmB in the described 
heterologous E. coli expression system dramatically.42 
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Figure 4.4 Structure of D-ornithine (D-Orn) 
The exact mechanisms of the biosynthesis were revealed independently by the groups of 
Krzycki and Geierstanger in the year 2011, nine years after the discovery of Pyl. 15,43,44 Stable 
isotope-labeling experiments showed, that the only precursor of Pyl formation is the 
amino acid L-lysine.43 D-Ornithine was shown to take a shortcut in the biosynthetic 
pathway, which leads to the demethylated Pyl analog desmethylpyrrolysine (dmPyl), also 
called pyrroline-carboxy lysine (Pcl).44 Figure 4.5 shows the three steps from two lysine 
molecules to Pyl. 
The enzymes act in their genetical order from PylB to PylD. The formation of Pyl starts 
with the rearrangement of L-lysine to (3R)-3-methyl-D-ornithine. This impressive step is 
fulfilled in a radical reaction by PylB, a member of the iron-sulfur cluster containing 
radical SAM superfamily.45 The subsequent amide bond formation between the carboxyl 
group of methyl ornithine and the e-amino group of a second L-lysine is catalyzed by PylC, 
an ATP dependent ligase with structural similarities to ATP grasp superfamily enzymes.46 
The final step of the biosynthesis of Pyl is carried out by PylD, a dehydrogenase which 
harbors NAD+ as the coenzyme in its active site.47 The enzyme catalyzes an oxidation of the 
d-amino group of the fused ornithine moiety and a subsequent pyrroline ring formation. 
The elucidation of the Pyl biosynthesis also explained the observed higher MtmB titers of 
D-ornithine fed, Pyl-gene cluster and mtmB carrying E. coli, which was described above:42,44 
The first reaction step of the described biosynthesis (catalyzed by PylB) is the kinetic 
bottleneck of Pyl formation. This step can be circumvented by adding D-ornithine to the 
growth medium. D-ornithine is a homologue of the natural intermediate (3R)-3-methyl-D-
ornithine. The only difference is a missing methyl group in position 3. Both of the following 
biosynthetic enzymes (PylC and PylD) as well as the amino acyl synthetase PylRS accept 
the resulting intermediates with a missing methyl group.  
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Figure 4.5 Biosynthesis of pyrrolysine (Pyl) from two L-lysines and artificial shortcut of D-
ornithine to desmethylpyrrolysine (dmPyl) 
4.1.3.3 Translation of the UAG amber codon to pyrrolysine 
Adding Pyl to the amino acid set requires surprisingly few remarking adaptations of the 
conserved genetic code. 
Since every triplet-mRNA codon is already occupied by either an amino acid or a stop 
signal during translation, reprogramming of one codon is needed. In case of Pyl, the 
affected codon is the mRNA triplet UAG, the so-called amber stop codon. In Pyl-containing 
organisms, this codon is no longer recognized as a stop signal but as a specific codon for 
Pyl. Therefore, in these organisms the signal to stop protein synthesis is coded by one of 
the two remaining stop codons, namely UAA (ochre codon) or UGA (opal codon).  
Introduction 
 
30 
The actual recoding of UAG by Pyl-expressing organisms is enabled by only three 
components: The amino acid Pyl itself, an amber specific tRNA carrying the triplet 5’-CUA-
3’ in its anticodon loop (tRNAPyl) and the corresponding amino acyl-tRNA synthetase 
(PylRS) which charges the tRNAPyl with Pyl.15 As shown in Figure 4.6, the charged tRNAPyl 
can enter the A site of the ribosome during protein synthesis and introduce Pyl into the 
nascent protein chain in response to an amber codon.  
 
 
Figure 4.6 Charging of tRNAPyl by PylRS and incorporation of Pyl into a nascent protein in 
response to an amber codon during translation 
In contrast to the incorporation of selenocysteine, no specific mRNA secondary structure 
is required for Pyl incorporation. 48-51  
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4.2 Incorporation of NCAAs into proteins 
The incorporation of non-canonical amino acids (NCAAs) into proteins can add various 
new functionalities to the standard amino acid set. Examples for possible applications are 
given in section 4.2.1. Possible ways of introducing unnatural amino acids into proteins are 
described in the sections 4.2.2.1 and 4.2.2.2. 
4.2.1 Applications of unnatural amino acids in proteins 
4.2.1.1 Incorporation of new functionalities 
Unnatural amino acids can, without the need of further modification, directly introduce 
useful moieties into proteins.52 These moieties can e.g. simulate natural post translational 
modifications (PTMs) to enable the elucidation of their biological function which has been 
shown successfully for lysine methylations, acetylations, acylations or phosphorylations. 
53-59 The directly introduced functionalities are of course not limited to naturally occurring 
PTMs. Examples of NCAAs with new functionalities that have been introduced into 
proteins include also fluorescent, metal-chelating, redox-active, photo-active, spin-
labeling, stability increasing and backbone-extending properties.60-66 Novel NCAAs enable 
scientists e.g. to crosslink the protein of interest or create electron transfer pairs to study its 
interaction with binding partners. 67-70 Conformational changes in the protein structure can 
as well be analyzed e.g. by specifically introduced vibrational probes.71 Another application 
example is the specific design of artificial protein multimers which was facilitated by the 
introduction of metal-chelating NCAAs.72 Even the control of protein activity using a small 
molecule switch inside live cells was shown to be possible using a specifically designed 
NCAA.73 
The most versatile group of NCAAs introduces chemical handles, which can be specifically 
modified after protein expression allowing the fusion of biology and chemistry. 
4.2.1.2 Protein conjugation 
Examples of pharmaceutically applied protein conjugates 
Adding new functionalities to various biomolecules represent an area of extensive interest 
in the field of chemical biology. There are many reasons for adding new properties to 
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biomolecules via covalent attachment of small synthetic molecules. For example, such 
conjugates can facilitate investigations of protein function and structure, be used in call 
labeling studies, generate novel biomaterials or be useful in biomedical applications. 68,74-
77 
Protein conjugates already applied in biopharmaceuticals are e.g. conjugates of PEG and 
small proteins (below 70 kDa), which increase the half-life of the drug by increasing their 
size and preventing rapid renal clearance.78,79 The frequency of drug-injections can be 
decreased dramatically as e.g. in the case of N-terminally PEGylated granulocyte-colony 
stimulating factor (G-CSF, INN: Pegfilgrastim). The number of injections of this drug which 
stimulates the production of granulocytes and is frequently applied during chemotherapy 
can be reduced from a daily administration (Filgrastim) during therapy to a once-per-cycle 
treatment (Pegfilgrastim).80,81 
Another example for pharmaceutically relevant protein conjugates are antibody-drug-
conjugates (ADCs). This class of biopharmaceuticals contains highly potent toxins fused 
to malignant cell-targeting antibodies which deliver their poisonous payload directly into 
the target cell. 82-85 The ADC Trastuzumab emtansine for example directs the cytotoxic agent 
emtansine to HER2 positive breast cancer cells which destroys them by binding to 
tubulin.86-88 
Protein conjugation using natural amino acids 
One of the major goals in the production of protein conjugates is the generation of a 
homogenous product, preferably consisting of only one conjugation species. Principally, 
various methods exist for the attachment of synthetic molecules to proteins. Most applied 
methodologies used in commercialized biopharmaceuticals exploit functional groups 
present in the 20 proteinogenic amino acids. Among these, the ε-amino group of lysine, the 
thiol group of cysteine, or the N- or C-terminal groups are most commonly applied.75,89,90 If 
the addressed functional group is present several times on the surface of the protein of 
interest, as is usually the case for lysine amino groups, the synthetic molecule is added 
multiple times and non-site-specifically. The modification of the lower abundant 
cysteines, however, bears the danger of disrupting naturally occurring disulfide bonds and 
therefore influences the secondary structure of the protein. Depending on the protein, N-
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terminal attachments were shown to be relatively selective, even though cross reactions 
with e-amino groups of lysines are commonly observed. Additionally, again depending on 
the protein, terminal conjugations were shown to potentially influence the activity of the 
biomolecule. 89 
In order to increase the site specificity of the conjugation reaction, peptide tags with 
specific amino acid sequences can be used. Two examples of repeating amino acid tags are 
the tetracysteine tag which directly reacts with biarsenic compounds and the 
hexahistidine-tag which binds Ni(2+)-nitrilotriacetate (NTA) probes. 91,92 Another family of 
peptide/protein tags involves enzymes which specifically recognize and modify the fused 
peptide. Two examples of this growing family have to be mentioned. The SNAP and Clip 
tag are engineered transferases which transfer small molecules onto themselves and 
enable direct small molecule attachment and the aldehyde tag.93,94 The latter contains a 
cystein-thiol which is transformed into an aldehyde by FGE, the formylglycine-generating 
enzyme.95 The aldehyde can afterwards be specifically modified by hydroxyl amines or 
hydrazines. 
These peptide tags are easy to introduce and versatile tools for many applications. 
Nevertheless, they are big compared to single amino acids and usually introduced on one 
terminus which may disrupt the structure and function of the protein. 
Protein conjugation using NCAAs  
An uncompromising chemo- and site-specific protein conjugation technique takes 
advantage of unnatural, non-canonical amino acids (UAAs/NCAAs). These NCAAs can be 
incorporated into proteins by using various strategies. The first successful attempts to 
introduce unnatural amino acids into peptides were made by solid phase peptide 
synthesis, which is limited to shorter peptides consisting of up to around 100 amino 
acids.96,97 Semisynthetic strategies allow the combination of NCAA containing synthetic 
peptides with purified proteins by native chemical ligation.98-101 These (semi-)synthetic 
strategies result in specific products but are tedious especially for the generation of bigger 
proteins. 
Introduction 
 
34 
Another promising approach for the incorporation of NCAAs utilizes the natural 
translational machinery. The NCAAs are charged onto tRNAs which are recognized by the 
ribosome and incorporated in response to the respective mRNA-codon. This idea was first 
applied in in vitro translation systems.102 Transferring the idea of genetically encoded 
NCAA-incorporation to in vivo systems represents the major breakthrough in the field. 
This methodology is described in more detail in the following sections. 
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4.2.2 Site-specific, genetically encoded incorporation of NCAAs 
The genetic code does not contain blank codons that could be reassigned to new sense 
codons. Therefore, smart approaches had to be developed to fulfill the task of ribosomal 
and site specific incorporation of NCAAs into proteins.103 So far, there are three successful 
strategies for this task: Rare codon reassignment, amber stop codon suppression and the 
usage of quadruplet codons. All of these strategies share the introduction of an orthogonal 
tRNA/aminoacyl-tRNA synthetase (tRNAYYY(Y)/aaRS) pair into a host cell (see Figure 4.7). 
The tRNA is charged with the NCAA by the aaRS. Later on, the ribosome uses the NCAA-
charged tRNA to specifically translate the assigned complementary mRNA codon. 
Therefore, the strategies mainly differ in the assigned mRNA codon, at which the NCAA 
is incorporated into the protein of interest. 
 
Figure 4.7 Principle of site-specific, genetically encoded incorporation of NCAAs. Depending 
on the assigned mRNA codon (red) strategies can be divided into rare codon reassignment, amber 
stop codon reassignment or assignment of quadruplet codons. 
In rare codon reassignment, an uncommon natural amino acid codon as e.g. AGG, AGA 
(both arginine) or AUA (isoleucine) in E. coli is recoded to a NCAA by using orthogonal 
tRNA/aminoacyl-tRNA synthetase pairs.104-107 Principle and challenges are similar to the 
recoding of amber stop codons (described later). 
Instead of reprogramming an existing triplet-codon and disturbing its natural function, the 
use of artificial quadruplet codons allows, in theory, the generation of 44 = 256 new sense 
codons. In this technology, the genetic information of special tRNAs which contain four 
bases in the anticodon loop (e.g. tRNAAGAG) are introduced together with the respective 
aminoacyl synthetase gene into the genome of the host organism.108 Therefore, a 
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quadruplet codon in the mRNA (e.g. CUCU) does either result in a frame shift, or the 
translation to the NCAA (frame shift suppression). The principle could already be shown 
in E. coli, Xenopus oocytes and mammalian cells but is currently not competitive compared 
to triplet codon reassignment strategies.109-114 
Amber codon suppression is, so far, the most versatile and successful approach used for in 
vivo NCAA incorporation. This methodology was also the key technology of this thesis and 
is described in more detail in the following sections. 
4.2.2.1 Amber suppression via orthogonal tRNA/aminoacyl-tRNA synthetase pairs 
Three of the 64 triplet codons lead to the termination of ribosomal protein synthesis by 
recruiting release factors (e.g. RF1 or RF2 in E. coli) which results in the disassembly of the 
ribosome subunits. As described above, these stop codons are called ochre (UAA), opal 
(UGA) and amber (UAG). In E. coli, only 273 (7%) of all genes are terminated by the amber 
codon and essential genes are only in very few cases terminated by this stop codon. 115-117 
Several species do not employ the amber codon as a stop codon, but as a sense codon for a 
canonical amino acid. One example is Methanococcus jannaschii, a thermophilic 
methanogenic Archean, which uses the amber codon as a sense codon for tyrosine.118 The 
responsible tRNA / aminoacyl tRNA-synthetase pairs (MjTyrRS/MjtRNATyr) have been 
transferred to standard laboratory strains like E. coli or CHO cells and successfully used for 
the incorporation of NCAAs. Recent studies employed other aaRS/tRNA pairs as e.g. the 
E. coli pair of tryptophane.52,119 
To accomplish the incorporation of NCAAs, Schultz et al. developed a general approach 
which includes a series of selection steps.120 The major challenge here was to transform 
Methanococcus jannaschii tRNA and aminoacyl tRNA synthetase into an orthogonal pair by 
directed evolution. Orthogonality in this context means, that the tRNA exclusively 
recognizes amber codons and the synthetase only charges it with the intended NCAA. 
Therefore, a cross reaction with the endogenous E. coli expression system can be excluded. 
In brief, the directed evolution consists of two major steps. First, a tRNA library is created 
and suitable candidates which are not accepted by endogenous E. coli aminoacyl tRNA 
synthetases are selected. Second, an aminoacyl tRNA synthetase library is created and 
screened for candidates which are able to charge this tRNA with the desired amino acid. 
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For the selection process, Schultz et al. introduced the amber codon either into the toxic 
barnase gene for negative selection or into the b-lactamase ampicillin resistance gene for 
positive selection. The first genetically incorporated NCAA was the synthetic amino acid 
O-methyl-L-tyrosine (1), which was incorporated using the described evolved 
Methanococcus jannaschii tRNA and aminoacyl tRNA synthetase pair.120 This tyrosine 
derivative served as a proof-of-concept and was followed by more than 50 NCAAs up to 
now which were introduced into various proteins using this system. 60,121 Figure 4.8 
illustrates the variety of incorporated amino acids by showing some of the most 
remarkable examples. The ketone-bearing p- and m- acetylphenylalanines (2, 3) were the 
first ribosomaly incorporated NCAAs, enabling the bio-orthogonal modification of 
proteins by reaction with hydroxylamines.122,123 Especially p-acetylphenylalanine (2) was 
chosen for a variety of applications and was one of the first site-specifically incorporated 
NCAAs in eukaryotic and mammalian cells.124-126 Also other chemically interesting 
functionalities like e.g. b-diketone (4), alkene (5), alkyne (6) or azide (7) moieties were 
introduced using this technique.127-131 The alkyne and azide tyrosyl variants are able to react 
in copper mediated click reactions (see also section 4.3.4) and are therefore of special 
interest. Other impressive examples are the redox active 3,4-dihydroxy phenylalanine (8), 
the ferrocene containing cysteine variant 9, the bidentate metal chelating bipyridylalanine 
10, the popular photo-reactive p-benzoylphenylalanine 11 and the photoisomerizable 
fluorescent phenylalanine-4‘-azobenzene 12.132-138  
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Figure 4.8 Examples of incorporated NCAAs using evolved Methanococcus jannaschii tyrosyl 
tRNA and tRNA aminoacyl synthetase pairs 
These examples impressively illustrate the diversity of functional groups that have been 
incorporated using the MjTyrRS/MjtRNATyr pair but also show the structural limitations 
of this system. Even though the M. janaschii tyrosyl tRNA synthetase has been evolved 
extensively, the incorporated NCAAs all show high similarity to tyrosine. Therefore, other 
aaRS/tRNA pairs have been used as starting points for the creation of orthogonal pairs in 
E. coli such as Asp, Gln, Tyr or Phe aaRS/tRNA pairs from Saccharomyces cerevisiae or hybrid 
pairs where the aaRS and the tRNA originate from different organisms. 109,139-144 
All of these artificial systems have in common that especially bulkier moieties e.g. 
interesting bio-orthogonal reaction targets like norbornenes or strained alkenes and 
alkynes could not be incorporated due to structural restrictions in the aaRS active site. 
Therefore, amongst other interesting properties, the less restrictive pyrrolysine 
PylRS/tRNAPyl pair (see sections 4.1.3.3 and 4.2.2.2) was shown to be an interesting 
alternative and a useful addition for site-specific amino acid incorporations by amber 
suppression. 
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4.2.2.2 Amber suppression via the pyrrolysine system 
The discovery of the genetic incorporation of pyrrolysine in response to the amber codon 
immediately added a promising aaRS/tRNA pair to the already existing amber suppression 
tools. In its natural context in Methanosarcinae strains, but also in bacteria like 
Desulfitobacterium hafniense, the PylRS/tRNAPylCUA pair shows no cross reactivity with the 
endogenous protein synthesis machinery. Therefore, it was believed to show natural 
orthogonality without the need of further adaptations even in laboratory strains like E. coli, 
S. cervisiae, Caenorhabitis elegans, Drosophila melanogaster or mammalian cells and has 
proved true. 42,51,145,146 Even the transfer in live mouse brain cells was shown to be possible.147 
PylRS/tRNAPylCUA pairs of M. mazei, M. barkeri and D. hafniense have been successfully 
transferred into different species without losing orthogonality.145,148-150 Figure 4.9 depicts 
the incorporation of NCAAs via the pyrrolysine system in host cells. 
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Figure 4.9 Incorporation of NCAAs by introducing the pyrrolysine system into host cells. 
Orthogonality is symbolized by red x. Depending on the NCAA, wt or an adapted PylRS variant 
has to be introduced (see sections below). 
4.2.2.2.1 NCAA incorporation via the wt PylRS/tRNAPylCUA pair 
Besides the natural amino acid pyrrolysine, more than 20 analogues could be incorporated 
by transferring the wt PylRS/tRNAPyl pair to host cells like E. coli without the need for 
further modification of the system.53,148,150-163 Figure 4.10 shows selected Pyl analogs which 
are accepted by unmodified PylRS and illustrate the promiscuity of wt PylRS. Derivatives 
13 and 14 served as the first artificial substrates for studying PylRS since the total chemical 
synthesis of Pyl is tedious.151,164 The Boc-protected methyllysine 15 can be deprotected after 
site-specific incorporation to yield N-e-methyllysine, a common posttranslational 
modification (PTM). This allows the position-specific function determination of this 
regulatory element e.g. in histones.53,162 Lysine derivatives 16 - 21 carry handles for bio-
orthogonal conjugation reactions which will be described in section 4.3. 158-160,163,165 The 
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target protein expression yield strongly depends on the acceptance of the desired Pyl-
analog by the transferred Pyl-translation machinery. Amino acids 19 - 21 for instance can 
be incorporated using the wt PylRS/tRNAPyl pair but the obtained yields can be improved 
by adaptations of the system which will be described in the following sections. 
 
Figure 4.10 Examples of incorporated NCAAs using wt tRNAPyl/PylRS pairs 
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4.2.2.2.2 PylRS structure 
The key element for efficient incorporation of bulky NCAAs with high structural diversity 
is PylRS since it recognizes Pyl-analogues and loads them onto tRNAPyl (see section 4.1.3.3). 
Besides the low binding selectivity towards the tRNA anticodon, elucidation of the PylRS 
structure from M. mazei revealed a deep hydrophobic pocket as the main recognition site 
for Pyl.51,149,150,166-168 This pocket has high affinity for the pyrroline moiety of Pyl (Kd = 53 µM) 
but binds it mainly by relatively nonspecific hydrophobic interactions (see Figure 4.11). 
Additionally, PylRS does not contain an editing domain which could hydrolyze 
misacylated tRNAs like many other aaRSs do.169-171 Both findings explain the very unique 
substrate promiscuity for Pyl-related hydrophobic lysine variants. 
 
Figure 4.11 Structural details of M. mazei PylRS. A: Recognition site of Pyl-AMP. B: Substrate 
binding pocket of PylRS harboring Pyl-AMP. 
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4.2.2.2.3 NCAA incorporation via engineered PylRS/tRNAPylCUA pairs 
The detailed structural knowledge of PylRS paved the way for directed evolution of the 
recognition pocket similar to what was done before with MjTyrRS (section 4.2.2.1). 
Conveniently, modifications of the recognition site of PylRS have no noticeable effect on 
the actual activity of the enzyme since it is located relatively far away from the active site 
where the acylation of the amino acid takes place. Research groups who worked on the 
rational design or directed evolution of the recognition site independently identified five 
major residues of PylRS with high influence on the accepted Pyl analogs. In case of M. 
mazei PylRS these residues are Y306, L309, N346, C348 and Y384 (Figure 4.11A). An exchange 
of Y306 to a smaller amino acid like alanine or glycine for example enlarges the 
hydrophobic cavity and allows bulkier moieties to enter. Another example is the exchange 
of Y384 by a phenylalanine, which eliminates an hydroxy group and therefore results in 
even higher hydrophobicity of the recognition cavity and greater promiscuity of the 
enzyme. Recently, phage assisted continuous evolution (PACE), a novel directed evolution 
technique, was applied to PylRS, which increased the achieved NCAA containing protein 
yields.172 
At least 30 different mutants of PylRS were developed which have led to an impressively 
diverse selection of more than 80 incorporated NCAAs (examples are shown in Figure 
4.12).1,53-55,148,160-162,173-197 The engineered PylRS mutants show either higher incorporation 
activities than their wt equivalents or are required to make the incorporation of the desired 
NCAAs possible because the wt PylRS do not show any detectable activity on them.  
Amino acids incorporated by codon reassignment include posttranslationally modified 
lysines like acetyllysine 22, or the photocaged N-e-methyllysine 23.54,187  
The genetical incorporation of NCAA 22 greatly facilitated site specific functional studies 
of acetyllysine, the most abundant acyl-PTM in mammalian cells e.g. in the nucleosome or 
p53.55,198-201 
Furthermore, evolved PylRSs enabled the genetical incorporation of novel, bulkier 
conjugation groups like alkene 24, azide 25, protected native chemical ligation handle 26 or 
the furan containing protein-RNA crosslinker 27. Especially the strained trans-
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cyclooctene- (28 and 29), norbornene- (21 and 30) or cyclooctyne- (31 and 32) carrying lysine 
derivatives made unprecedented ultra-rapid protein conjugations possible (see section 
4.3).1,174-177  
Another example is the first incorporated radical NCAA 33 which contains a spin label and 
has been used to report intramolecular distance distributions of two sites in a model 
protein in vivo by double-electron electron resonance measurements.192 
A whole new family of phenylalanine derivatives including phenylalanine itself (34), m-
azide-phenylalanine 35 or terminal alkyne containing tyrosine derivative 36 was recently 
added to the set of NCAAs incorporated by the Pyl system. 194,195 These non-lysine 
derivatives were tested, since bacterial PheRS shows high structural similarities to 
PylRS.193,197,202-204 The mutagenesis of PylRS towards acceptance of Phe analogs was more 
successful than originally anticipated and it could be shown that the introduction of only 
two PylRS-mutations (N346A and C348A) is sufficient for the incorporation of more than 
40 Phe analogs.194-196,205 Although most of these phenylalanine derivatives can also be 
incorporated with the described MjTyrRS/tRNATyl pair (see section 4.2.2.1), their 
acceptance by evolved PylRS underlines the potential of this versatile genetic code 
expansion tool. 
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Figure 4.12 Examples of incorporated NCAAs using evolved PylRSs with wild type tRNAPyl 
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4.3 Bioorthogonal modifications of unnatural pyrrolysine homologs 
4.3.1 Bioorthogonality and practical aspects of protein labeling strategies 
The ability to label NCAAs site specifically and bioorthogonally opens new fields in 
protein sciences. The two major applications are the in vitro labeling of purified proteins 
for studying or extending their properties and the in vivo labeling of selected proteins e.g. 
for visualization of their distribution on the surface or inside a living cell. 
Depending on the purpose, different characteristics of the labeling chemistry become 
essential. When labeling a purified protein, the main focus lies on the generation of a 
specific modification product in high yield and therefore low amounts of side product. The 
kinetics of the reaction are less important in this case since the conjugation can be carried 
out usually with high excess of the modification reagent.206 In contrast, labeling of proteins 
in cells necessarily requires rapid reaction kinetics (k2 ³ 1 M
-1 s-1) because the probe must be 
applied in small amounts to prevent its possible toxicity and to exclude interference with 
the living system. In addition, the ligation reaction must efficiently proceed before the 
reagent gets metabolized or is cleared from the cell. 207-211 The labeling yield and 
homogeneity of the labeling product are usually less important in this case. 
Independently of the protein conjugation purpose, the most important property of protein 
labeling chemistry is bioorthogonality. This term sums up several characteristics and its 
evaluation defines whether a chemical reaction can be used for biomolecule labeling.212,213 
First of all, to be considered bioorthogonal, a reaction has to be applicable under biological 
conditions. This implies reaction conditions in aqueous solutions, pH values between 4 
and 10 and temperatures of maximum 40 °C. Secondly, the reaction has to be chemically 
and biologically inert which means, that the formed linkage has to be stable and none of 
the reaction reactants or products should unintentionally interfere with the native 
functionality of the protein or the studied organism. Furthermore, the reaction has to be 
selective only for the unnaturally incorporated functional group and not side react with 
other biological groups. In the case of purified protein conjugations, these competing 
groups only include the 20 proteinogenic amino acids, whereas in in vivo labeling also 
other functional groups e.g. aldehydes or alkenes in fatty acids are present which makes 
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selectivity more challenging. Therefore, a differentiation between truly bioorthogonal and 
chemoselective reactions can be made.212,213 
Finally, a rather practical aspect in the identification of the optimal protein labeling 
strategy and chemistry is the accessibility of the reagents. This includes the already 
described incorporation efficiency of the NCAA but also the chemical-synthetic effort that 
has to be made to obtain both the NCAA and the labeling reagent. Especially the NCAA, 
which is added in huge excess to the expression medium, should be easily accessible via 
high yielding synthetic routes. 
Unfortunately, a generally favorable bioorthogonal modification strategy does not exist 
since all of the described aspects have to be considered and evaluated according to the 
labeling purpose. Therefore, a set of different bioorthogonal reaction methods with their 
individual advantages and disadvantages has been developed. In the following 
subsections, the most widely used modification methods, which have been successfully 
applied on NCAAs introduced by the Pyl incorporation system will be discussed. 
4.3.2 Ketone-hydrazide/hydroxylamine reactions 
Aldehydes and ketones are small, synthetically accessible and versatile functional groups 
which have been used extensively as handles for biomolecule.214-217 While aldehydes were 
considered less suited for protein modification reactions due to possible amine additions, 
the less reactive ketones have been successfully introduced and modified in proteins. In 
fact, the first modification handles introduced in proteins were ketone containing amino 
acids and have since then been successfully applied in various protein modification 
studies.60  
Ketones can be modified under slightly acidic conditions (pH 4-6) by nucleophiles with 
strong a-effect like hydrazines or hydroxylamines to form hydrazones and oximes, 
respectively (Figure 4.13). The reaction can be catalyzed by the addition of aniline which 
activates the keto-group by formation of an intermediate Schiff-base and enables the use 
of neutral reaction conditions.218-220 The catalyzed reaction reaches second order rate 
constants of up to 170 M-1s-1.218 
Introduction 
 
48 
 
Figure 4.13 Reaction of aldehydes and ketones with hydrazines or hydroxylamines. A: Acid 
catalyzed, B: Aniline catalyzed under neutral conditions 
Owing to the small size of these functional groups but rather slow kinetics (second order 
rate constants between 10-4 and 10-3 M-1s-1 for uncatalyzed reaction) or the need of a catalyst, 
the reaction is perfectly suited for in vitro protein labeling but unfavorable for live-cell 
protein labeling because large excesses of labeling agents are needed.221,222 
4.3.3 Staudinger ligations 
One of the first bioorthogonal reactions developed utilizes azides as the reactive chemical 
group. The small size, absence in nature, synthetic accessibility and inertness toward 
natural functional groups make azides highly versatile and useful reagents in 
bioconjugations.3,60,148,206,223-232 Azides have been successfully incorporated into various 
biomolecules which include glycans, DNA, RNA, fatty acids and also proteins.233-237 
In analogy to the well-established Staudinger reduction (Figure 4.14 A), the group of C. 
Bertozzi developed in 2000 the so-called Staudinger ligation reaction.238-240 The original 
reduction reaction, first described in 1919, starts with the nucleophilic attack of 
triphenylphosphine and the formation of an Aza-ylide after loss of nitrogen from the azide. 
The Aza-ylide can afterwards be hydrolyzed to yield a primary amine as the reduction 
product and triphenylphosphine oxide as biproduct.241 In the Staudinger ligation reaction 
an internal ester group ortho to the phosphorous atom is introduced as electrophilic trap, 
which leads to intramolecular ring formation. After hydrolysis an amide bond is formed 
and connects the biomolecule with the intended substituted phosphine oxide (Figure 4.14 
B).240,242  
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Fusion of the intended label directly onto the carbonyl of the ester group even makes 
traceless Staudinger ligations possible which only result in an amide bond between the 
biomolecule and the marker (Figure 4.14 C).243 
 
Figure 4.14 A: Staudinger reduction B,C: Staudinger ligations 
Due to the rather slow reaction kinetics with second order rates of around 10-3 M-1s-1 and 
the oxidation sensitivity of phosphines, high concentrations of labeling reagent are 
required.241 Staudinger ligations are therefore mainly used for e.g. in vitro labeling of 
purified proteins or in vivo labeling of highly abundant biomolecules. 
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4.3.4 Azide-alkyne reactions 
In 1963, Rolf Huisgen studied the reaction of azides with terminal alkynes to yield stable 
triazoles.244 The reaction is interesting as bioorthogonal tool since it involves only small 
functional groups without cross reactivity to biomolecules. Although the reaction is highly 
exergonic (DG0 = -60 kcal/mol), it requires elevated temperature and pressure due to a high 
activation barrier which makes it not biocompatible in its original form.245 39 years later, 
Sharpless et al. and Meldal et al. reported independently, that copper(I) salts are able to 
catalyze the Huisgen reaction in water and increase the second order rate constant k2 by 
six to seven orders of magnitude.246,247 Moreover, the addition of Cu(I) was shown to 
influence the regioselectivity of the reaction yielding only the 1,4-substituted triazoles.248,249 
The initially proposed reaction mechanism of the Cu(I) catalyzed azide-alkyne 
cycloaddition (CuAAC) including one catalytic copper ion forming a six membered ring 
intermediate was revised by in-depth isotopic studies.250 The key difference found through 
these studies is the formation of a dinuclear copper intermediate as shown in Figure 4.15 B. 
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Figure 4.15 Azide-alkyne reactions 
Sharpless et al. used CuAAC as the prime example for "click chemistry", a biology-inspired 
concept of modular synthetic chemistry.251 CuAAC has also been proven very useful as 
biomolecule modification reaction in many biological studies including nucleic acid, 
protein or lipid functionalization. 60,131,231,237,252-256 The disadvantage of this reaction is the 
need of catalyzing copper salts which have been proven to have potentially toxic effects, 
shown on e.g. E. coli and mammalian cells.256-260 The toxic effect of Cu(I) can be reduced by 
the use of specific water soluble ligands which form activated complexes and therefore 
reduce the absolute amount of copper needed and further lead to acceleration of the 
reaction by stabilizing the active catalytic Cu(I) species.261-263 Even applications in living 
organisms like zebrafish have been shown.264-266 Ligand-assisted CuAAC reactions 
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typically reach second order rate constants of 10-200 M-1s-1 but need copper concentrations 
of 100 - 500 µM and therefore have limitations when labeling biomolecules in living 
cells.267-269 CuAAC reactions with lower copper concentrations down to 10 µM can be 
achieved by copper-chelating azides such as picolyl azides.270  
An azide-alkyne reaction without the need of a catalyst takes advantage of the intrinsic 
reactivity of ring strained alkynes (Figure 4.15 C). The reaction of cyclooctynes, the smallest 
stable and isolable cycloalkyne, has been described already more than 70 years ago before 
it was first applied in bioorthogonal labeling reactions.271-273 Strain-promoted-alkyne-azide 
cycloadditions (SPAAC) have been successfully applied in a series of biomolecule labeling 
studies including site-specific protein modifications. 2,3,225 The reaction is highly selective 
and non-toxic but shows rather low reaction kinetics with k2 ranging between 0.0012 M
-1s-1 
for unmodified cyclooctynes and 1 M-1s-1 for optimized cyclooctynes including e.g. 
difluorocyclooctynes (DIFO) or dibenzocyclooctynes (DIBO).274,275 
4.3.5 Inverse electron-demand Diels-Alder cycloadditions 
The cascade of an inverse electron demand Diels-Alder cycloaddition (iEDDA) followed 
by a retro-Diels-Alder (rDA) reaction between 1,2,4,5-tetrazines and strained alkenes like 
norbornenes or trans-cyclooctenes has been identified as a powerful and rapid ligation 
reaction in synthetic chemistry.276-278 The cycloaddition step of the reaction sequence is 
termed inverse electron demanding since, in the transition state of the reaction, the LUMO 
of the electron-poor tetrazine interacts with the HOMO of the electron rich dienophile. In 
classic Diels-Alder reactions the situation is opposite, the dienophile LUMO interacts with 
the HOMO of the diene.279 The iEDDA results in a strained bicyclic intermediate, which 
rapidly releases nitrogen in a subsequent rDA reaction (Figure 4.16 A). In protic solvents, 
the resulting 4,5-dihydropyridazine isomerizes to the final product 1,4-
dihydropyridazine.280  
The iEDDA reaction was shown to work under aqueous conditions for the first time by 
Hildebrand et al. using norbornene and Fox et al. using trans-cyclooctenes as 
dienophiles.281,282 (Figure 4.16B and C) The finding that aryl-substituted tetrazines are 
sufficiently stable in water was the key discovery for application of this chemistry on 
biomolecules.281,283 
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Figure 4.16 Inverse-electron-demand [4+2] Diels-Alder cycloadditions of tetrazines and 
strained alkenes. A: General mechanism. B: Norbornene as dienophile. C: Trans-cyclooctene as 
dienophile. 
 
Since then, the bioorthogonal modification of norbornenes has been successfully applied 
in a number of studies, including site-specific protein modifications by the Carell 
group.1,159,284 Norbornenes are synthetically accessible and their reaction with tetrazines 
was shown to be chemoselective within living cells and fast enough for in vivo experiments 
(k2 typically around 2 M
-1s-1). Faster reaction kinetics in inverse electron-demand reactions 
with second order rates of up to 104 M-1s-1 can be only achieved by trans-cyclooctenes, 
which have been site specifically introduced into proteins using the pyrrolysine 
incorporation system as well. 176,177,280,285-287 
In recent years, mainly because of the unprecedented reaction kinetics and no need for 
additional catalyst, the inverse electron-demand Diels-Alder cycloaddition became the 
most promising bioorthogonal labeling reaction for in vivo labeling and imaging 
studies.175,288-290 Another feature of these tetrazine-based reactions justifies their newly 
acquired supremacy in imaging studies: When bound to tetrazines, the fluorescence of 
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certain fluorophores is quenched through energy transfer. After the reaction of these 
functionalized tetrazines with alkenes or alkynes, the fluorescence is restored resulting 
into excellent signal-to-noise ratio, which is highly desirable and advantageous in various 
bioimaging studies.288 Newest developments by Vrabel et al. even make the attachment of 
fluorophores potentially obsolete since it could be shown, that the resulting 1,4-
dihydropyridazines of axially substituted trans-cyclooctenes show strong fluorescence 
themselves.291 
4.3.6 Desmethylpyrrolysine-aminobenzaldehyde ligations 
The genetic introduction of bioorthogonal reaction handles usually requires the addition 
of the desired amino acid to the expression medium in millimolar concentrations. 
Unfortunately, only 0.1% of the NCAA is incorporated into the protein of interest, the 
majority of the synthesized amino acid is disposed after the protein expression. In case of 
e.g. visualization studies and the low absolute amount of required labeled protein, the 
needed amount of NCAA is usually not a problem. In case of expression, purification and 
in vitro modification to gain e.g. antibody drug conjugates or PEGylated therapeutic 
proteins in big scale, synthetic effort and waste of resources have to be avoided wherever 
possible. Therefore, Geierstanger et al. utilized the reactivity of desmethylpyrrolysine 
(dmPyl) which can be biosynthesized by e.g. E. coli or mammalian cells when adding D-
ornithine to the expression medium and transfected with the needed genes (section 
4.1.3.2).292-294 Ornithine can be added as a racemic mixture and is a cheap resource without 
the need of chemical synthesis. 
Desmethylpyrrolysine can be modified chemoselectively using 2-amino-benzaldehydes (2-
ABAs) or 2-amino-acetophenones (2-AAPs), a reaction that has been described before for 
the Pyl-analog pyrroline-5-carboxylate.292 The first step of the conjugation reaction yields 
a pyrrolo-quinazoline ring which was shown to be stabilized through cyclization of the 2-
ABA/2-AAP carbonyl moiety with the e-amide group of dmPyl. This reaction is reversible. 
The linkage can be fixed by addition of reducing agents such as cyanoborohydride, leading 
to a stable addition product (Figure 4.17). 
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Figure 4.17 Modification of dmPyl containing proteins with 2-aminobenzalehydes (2-ABAs) 
 
4.3.7 Other ligation methods 
Other bioorthogonal reactions that have been applied on Pyl analogs include site-specific 
native chemical ligations, photoactivated click- and crosslinking-reactions or Sonogashira 
couplings. 120,181,295,296  
Since the development of bioorthogonal reactions is an area of extensive research, one 
could expect that new ligation reactions will appear and will be applied on NCAAs 
introduced by the Pyl incorporation system. Since the requirements of the coupling 
reaction are not universal but strongly depend on the purpose of the protein conjugate, 
scientists will benefit from every extension of the bioorthogonal chemistry toolbox. 
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6 Aims of the thesis 
The overall goal of this thesis was to extend the potential of the site-specific pyrrolysine 
incorporation system. We wanted to achieve this by developing new strategies for all 
involved steps: (Bio-) synthesis of non-canonical amino acids (NCAA), incorporation of 
novel NCAAs and their bioorthogonal conjugation. 
First of all, we wanted to incorporate novel, useful Pyl analogs into proteins such as newly 
discovered post-translational histone modifications. The possibility of introducing these 
modifications site-specifically into human histone should facilitate studies related to their 
natural function. 
As major part of this thesis, we planned to focus on the studies of Pyl analog-based 
bioorthogonal protein modification reactions. We were interested in studying the inverse 
electron demand Diels-Alder cycloaddition between norbornenes and tetrazines and the 
incorporation and modification of different norbornyl-Pyl-analogs in proteins in further 
detail. We wanted to develop a novel bioorthogonal norbonene modification reaction 
using sulfonyl azides and apply it on norbonyl containing peptides and proteins.  
As the major goal of this thesis we defined the utilization of the pyrrolysine biosynthetic 
machinery to generate an unnatural, double-modifiable Pyl variant which can be 
subsequently incorporated into a protein of interest. To achieve this, we planned to feed 
the Pyl precursor 3R-methyl-D-ornithine to E. coli transfected with the necessary Pyl 
biosynthesis and incorporation gene cluster. The resulting 3S-ethynylpyrrolysine 
containing protein should be modified and analyzed to prove the correct generation, 
incorporation and modification of this unnatural amino acid. 
Finally, we wanted to demonstrate the benefit of a site specifically incorporated NCAA and 
its specific modification by a pharmaceutically relevant application. Therefore, we 
intended to apply site-specifically modified human carbonic anhydrase-folic acid-conjugates 
as targeting, pH responsive capping proteins for drug delivery in mesoporous silica-based 
nanocarriers.  
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7 Original publications 
This thesis is based on the original publications, which are reproduced in the following 
subsections with the permission of the copyright holders. 
The contributions to each original publication are summarized in section 8.  
Relevant parts of the supplementary information to which I mainly contributed are shown 
in section 9. These supplementary information subsections are only shown for the three 
original publications in which I am listed as first author (original publications reprinted in 
sections 7.1, 7.4 and 7.5). 
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Synthesis of e-N-propionyl-, e-N-butyryl-, and
e-N-crotonyl-lysine containing histone H3 using
the pyrrolysine system†
Michael J. Gattner, Milan Vrabel and Thomas Carell*
Recently new lysine modifications were detected in histones and
other proteins. Using the pyrrolysine amber suppression system
we genetically inserted three of the new amino acids e-N-propionyl-,
e-N-butyryl-, and e-N-crotonyl-lysine site specifically into histone H3.
The lysine at position 9 (H3 K9), which is known to be highly
modified in chromatin, was replaced by these unnatural
amino acids.
The histone code is based on the post-translational modification
of critical amino acid residues in different histones. Among
these, lysine acetylations and methylations are the most abun-
dant and affect the transcriptional status of the genes associated
with the corresponding histones.1–3 The role of these modifica-
tions is sequence dependent. Typically acetylation is associated
with transcriptionally active genes, while methylation induces
transcriptional silencing.4,5 Recently Zhao and co-workers
discovered a number of new modified amino acids in histones.6–8
Some of these were also detected in proteins other than histones,
raising the possibility that they are of more widespread impor-
tance.9–11 The new post-translational modifications (PTMs) are
acylated derivatives of lysine at the e-amino position. The acylation
partners are propionic acid, butyric acid, malonic acid, succinic acid,
crotonic acid or fatty acids. A common characteristic of these
compounds is that they are key metabolic intermediates that
typically exist as CoA activated thioester species in the cell.12 It is
currently not clear how these newly discovered PTMs are biosynthe-
tically established within the histones and we do not fully under-
stand if and how they influence genetic processes.
So far no specific deacylases for e-N-propionyl- or e-N-
butyryl-lysine have been identified. However Sirt5, a member
of NAD-dependent sirtuins is able to specifically deacylate e-N-
malonyl- and e-N-succinyllysine.11 Recently it was discovered
that HDAC3 exhibits decrotonylase activity in vitro13 and it was
found that lysine crotonylation activates genes even in a
globally repressive environment.7,14
In order to enable investigation of the new lysine derivatives in
histones it is essential to generate histones that contain these
amino acids site specifically.15 In this direction semi-synthetic
chemical ligation based methods16,17 were utilized and chemical
methods were employed to generate acetyllysine (Kac) and methyl-
ated-lysines or derivatives thereof.18–21 Chin and co-workers
reported the introduction of Kac into H3 K5622 using the pyrro-
lysine system. This system was also employed for the synthesis of
monomethyl- and dimethyl-lysine containing histones.23,24 Schultz
et al. recently described the synthesis of histone H2B containing e-
N-crotonyllysine at position K11 using an evolved pyrrolysyl-tRNA
synthetase from Methanosarcina barkeri.25
Here we show that the pyrrolysine system can be used to
insert e-N-propionyl-(Kpr, 1), e-N-butyryl-(Kbu, 2), and e-N-
crotonyl-lysine (Kcr, 3) into histones at critical positions such
as H3 K9 using the wild type pyrrolysyl-tRNA synthetase. The
synthesis of the three modified amino acids 1–3 is shown in
Scheme 1. All three amino acids were obtained using the
depicted procedure in multi-gram quantities starting from
commercially available materials without the need for chroma-
tographic purification (for synthetic details see ESI†).
The amber suppression technology was used extensively for
the incorporation of various unnatural amino acids into
proteins.26 Recently we reported the development of an E. coli
based assay that allows examination of how efficiently the
pyrrolysine system from Methanosarcina mazei works.27 E. coli
cells containing a plasmid with an YFP reporter gene bearing
an amber stop codon at position K114 were generated. The
plasmid also contains the genes of the pyrrolysine tRNA (pylT)
and the corresponding synthetase (pylS) or of pylS mutants,
respectively, that were previously shown to improve the amber
suppression efficiency of bulkier pyrrolysine analogues.28,29
Upon addition of an unnatural amino acid to the expression
medium that is accepted by the tRNA–pyrrolysyl-tRNA synthetase
pair (tRNAPyl–PylRS), full-length fluorescent YFP is produced.
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Testing the three amino acids Kpr, Kbu and Kcr with this
reporter system, the best results were obtained in the presence
of wild type PylRS (see ESI†).
To further determine the efficiency of the incorporation we
transformed E. coli cells with a plasmid containing the gene of
thioredoxin A (trxA) with a C-terminal Strep-Tag and an amber
codon at position N56 as a model protein. A second plasmid
carrying the genes pylT and pylS was transformed. The cells
were grown in the presence of 5 mM Kcr and the protein
expression was induced by the addition of 1 mM IPTG at an
OD600 of 0.6. After an overnight expression at 30 1C the cells
were lysed and purified by Strep-Tag affinity chromatography.
We obtained 2 mg of the Kcr containing TrxA from 1 L cell
culture. The purified intact protein was analyzed by mass
spectrometry. The observed protein molecular weight of
13 014 Da (calculated: 13 016 Da) confirmed the presence of
the Kcr moiety in the protein. In addition tryptic digest was
performed followed by HPLC-MS/MS analysis, which further
showed that the modification was in the desired position
within the protein structure (see ESI†).
We next investigated if the system is able to provide histone
proteins containing one of the three modified lysine amino
acids. To this end we used a first plasmid containing pylS and
three copies of pylT under the control of a constitutive glutamine
promoter. A second plasmid was generated containing an
N-terminally His-tagged H3 gene with the amber stop codon at
position K9 under the control of an IPTG-inducible T7 promoter.
Both plasmids were transformed into E. coli BL21(DE3). We
individually added the three amino acids Kpr, Kbu, and Kcr to
the medium at concentrations of 5 mM for Kbu and Kcr and
10 mM for Kpr. The E. coli cells were grown until an OD600 of 0.6
and then gene expression was induced by the addition of 1 mM
IPTG. After 16 h at 30 1C we harvested and lysed the cells and
isolated the H3 proteins under denaturing conditions (7 M Urea)
using Ni–NTA column chromatography. The purified histones
containing the modifications in position 9 were refolded using
standard procedures (see ESI†). In all three cases we isolated
0.5–1.0 mg of modified histone H3 per L of cell culture (for
comparison we obtained 5 mg of unmodified histone H3).
In order to prove the presence of the unnatural lysine amino
acids and in particular to investigate potential deacylation
processes during protein expression and purification we
performed HPLC-MS/MS studies. When we analyzed the tryptic
digests of the H3 proteins by HPLC-MS/MS, peptides containing
K9 (or the corresponding modifications) were not detected due
to the position of this amino acid in a lysine rich sequence giving
rise to polar and in particular too short peptides for subsequent
analysis. We hence modified a method first described by Hunt
et al.30 The H3 proteins containing Kbu and Kcr were reacted
with propionic acid anhydride (4) directly in the gel. For H3
proteins containing the expected Kpr we used butyric acid
anhydride (5) instead. This chemical treatment blocks all free
lysine e-amino groups leading to longer and more hydrophobic
tryptic peptides (e.g. KSTGGKAPR instead of STGGK for the K9
containing peptide). After in-gel tryptic digest we repeated the
chemical treatment to cap also the N-terminal amino groups of
the generated peptides. The peptides were then eluted from the
gel and analyzed by HPLC-MS/MS. The obtained data are
depicted in Fig. 1 (for MS/MS data see ESI†). For wild type
histone H3, the positions K9 and K14 are either propionyl-
(K9Kpr K14Kpr, as shown in Fig. 1) or butyryl-capped. The MS
analyses of the corresponding modified histone H3 peptides
gave the correct mass spectra for K9Kpr K14Kbu, K9Kbu K14Kpr
and K9Kcr K14pr, respectively, showing the correct incorpora-
tion of the three lysine derivatives. We noted that the
MS-analyzed peptides were contaminated in all three cases with
Scheme 1 (A) Synthesis of the three amino acids e-N-propionyl-(Kpr, 1), e-N-
butyryl-(Kbu, 2), and e-N-crotonyl-lysine (Kcr, 3): (1) N
a
-Boc-Lys-OH, propionyl-,
butyryl or crotonyl chloride, 1 M NaOH/THF = 1/1, 0 1C to r.t., overnight; (2) DCM/
TFA = 5/1, r.t., 1.5 h. (B) Depiction of histone H3 and of the position K9 in the tail
where the modifications were incorporated (protein representation generated
from PDB 1KX5).
Fig. 1 (A) Schematic overview of the workflow: expression of the four histone H3
variants followed by in-gel capping of the purified proteins with propionic
anhydride (4) or butyric anhydride (5), tryptic digestion, repeated in-gel capping
and HPLC-MS/MS analysis. (B) MS spectra and illustrations of the capped K9
containing tryptic peptides (MS/MS spectra are shown in ESI†). The capping
modifications are shown in grey while the incorporated PTMs are shown in red.
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peptides in which the e-N-modified lysines were replaced by
lysine. These peptides gave MS-signals for all-propionylated or
all-buturylated peptides, showing that the acyl groups were
missing at H3 K9 already before the peptides were analyzed by
mass spectrometry. This discovery excludes the possibility that
the acyl groups were cleaved during MS-measurement.
We can also exclude that unmodified lysine was inserted
during amber suppression by potentially lysine-mischarged
tRNAPyl. When we performed the protein expressions in
medium lacking the unnatural amino acids, no YFP or histone
H3 was produced, showing that successful amber suppression
depends on the presence of these amino acid derivatives. We
consequently speculate that E. coli contains one or more
proteins (such as the bacterial sirtuin CobB) able to unspecifi-
cally deacylate Kpr- and Kbu-modified histone tails as
previously observed for Kac31 and Kcr.25 In order to test this
hypothesis we repeated the expression experiment in the
presence of 20 mM nicotine amide (NAM), a known inhibitor
of sirtuins.32 After careful MS analysis we indeed found a
strongly reduced amount of peptides containing natural lysine
before the capping. We could reduce the deacylation of Kpr,
Kbu and Kcr containing histones from about 20% to below 5%
after addition of NAM.
To further verify the presence of the incorporated PTMs
we performed a western blot analysis using polyclonal anti-
bodies (PTM BioLabs) against the three amino acids Kpr, Kbu
and Kcr. As shown in Fig. 2 the desired modifications were
selectively detected by the corresponding antibodies while the
unmodified histone H3 was not recognized. The antibodies
show compromised selectivities in cross labeling experiments
(see ESI†).
In summary, we show that by using the pyrrolysine system
the newly discovered lysine derivatives e-N-propionyl-, e-N-
butyryl-, and e-N-crotonyl-lysine can be inserted into histones
(here H3) at critical positions (here K9) using the wild type
pyrrolysyl-tRNA synthetase. The observed deacylation in E. coli
can be reduced by the addition of nicotine amide and thus
homogenous proteins bearing these PTMs are now available.
Histones containing defined lysine modifications will enable us
to further study the biochemistry behind the acylation and
deacylation processes in order to learn how the modification
chemistry influences gene activity.
This work was supported by the Excellence Cluster CIPSM,
the Volkswagen Foundation and the DFG SFB 1032. M.V.
thanks the LMU Munich for postdoctoral fellowship.
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Norbornenes in Inverse Electron-Demand Diels–Alder Reactions
Milan Vrabel,* Patrick Kçlle, Korbinian M. Brunner, Michael J. Gattner,
Ver!nica L!pez-Carrillo, Regina de Vivie-Riedle, and Thomas Carell*[a]
The development of methodologies that enable efficient
labeling of biomolecules is an important task in modern or-
ganic chemistry. The choice of ideal reaction partners for
such a reaction has to fulfil several basic criteria. Along
with high reaction rates and high selectivity under physio-
logical conditions that are compatible with the biomolecule,
it is also desirable to have good synthetic accessibility to the
starting materials. In the last couple of years, several groups
reported important developments along these lines that
have vastly expanded our ability to functionalize biomole-
cules.[1–9] Among the now available methods, the inverse
electron-demand Diels–Alder reaction (DARinv) of tetra-
zines with strained alkenes has emerged as one of the most
promising technologies.[10,11] The high chemoselectivity and
the advantage that the diverse set of functional groups in
bio ACHTUNGTRENNUNGmolecules have established the reaction as a truly bioor-
thogonal ligation methodology.[12–17] In particular the typical-
ly high bimolecular rate constants and high yields allow the
efficient labeling of fragile proteins given that either the di-
enophile or the tetrazine is embedded in the biomolecule.
However, the synthesis of the reaction partners is quite chal-
lenging, which has hindered broad applicability. It is there-
fore important to analyze the reactivity of different norbor-
nenes and derivatives thereof to develop better accessible
starting materials that might even have superior ligation
properties to meet the criteria of modern conjugation chem-
istry.
To optimize the reactivity of the reacting partners in
DARinv it was recently shown that electron-withdrawing sub-
stituents at the tetrazine[18] accelerate the reaction. In addi-
tion, the introduction of additional strain into the double- or
triple-bond reaction partner, for example, cyclopropane ring
fusion to a cyclooctyne or the use of trans-cyclooctene, sig-
nificantly enhance the reaction rate.[19–22] However, the ob-
served trans to cis isomerization of cyclooctenes[23] may lead
to partial deactivation of the reactive species and thus de-
creases the effective driving force of the reaction. Moreover,
cyclooctenes and cyclooctynes are relatively bulky function-
al groups and may perturb the structure of the target bio-
ACHTUNGTRENNUNGmol ACHTUNGTRENNUNGecule. In this regard, cyclopropenes were developed as
another type of highly reactive dienophiles, having the ad-
vantage of their small size.[23–25] However, here again the la-
borious synthesis of this class of compounds may hamper
their broader application in bio-labeling experiments.
Among other strained dienophiles, norbornenes stand out
because they are synthetically easily available, stable, and
comparatively small in size. Indeed, others and us used the
unusual reactivity of norbornene[26,27] to label nucleic
acids[28–30] and proteins.[31–34] We therefore reasoned that we
should investigate the parameters that determine the reac-
tivity of norbornenes and of heteroatom-containing norbor-
nene derivatives[35] with tetrazines to find the best reaction
partner in the DARinv for biomolecule labeling. Here we
show that the substitution pattern and in particular the pres-
ence of heteroatoms has a dramatic influence on the reactiv-
ity (Scheme 1). Our systematic study finally led to the iden-
tification of easily available and highly reactive derivatives
with significantly enhanced reaction rates and hence ligation
properties.
To study how different substituents influence the bimolec-
ACHTUNGTRENNUNGuACHTUNGTRENNUNGlar reaction rate of the DARinv, we first synthesized a series
of norbornene derivatives containing either a heteroatom
and/or different substituents (Table 1). Compounds 1–12
were synthesized by Diels–Alder or hetero Diels–Alder re-
actions using cyclopentadiene or furan as the diene, and the
corresponding acrylates or in situ formed imines as dieno-
philes (for details see the Supporting Information). To inves-
[a] Dr. M. Vrabel, M.Sc. P. Kçlle, M.Sc. K. M. Brunner,
Dipl.-Chem. M. J. Gattner, Dr. V. L!pez-Carrillo,
Prof. Dr. R. de Vivie-Riedle, Prof. Dr. T. Carell
Department of Chemistry
Ludwig-Maximilians-University
Butenandtstrasse 5-13, 81377 Munich (Germany)
Fax: (+49)89 2180 77756
E-mail : milan.vrabel@cup.uni-muenchen.de
thomas.carell@cup.uni-muenchen.de
Supporting information for this article is available on the WWW
under http://dx.doi.org/10.1002/chem.201301838.
Scheme 1. Schematic representation of the DARinv between dipyridyl ACHTUNGTRENNUNGtet-
ACHTUNGTRENNUNGrazine and norbornene derivatives 1–12 used in this study. The products
of the reaction are the corresponding isomers of dihydropyridazines. For
substituents R see Table 1.
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tigate the influence of the ge-
ometry on the reaction rates,
we also measured the kinetics
of the exo and endo norbor-
nenes separately. We used di-
pyridyltetrazine as the reaction
partner, because it is commer-
cially available and structurally
close to derivatives typically
used in bioconjugation experi-
ments. The rate constants were
determined under pseudo first-
order conditions using UV/Vis
spectroscopy following the
decay in the absorption of di-
pyridyltetrazine unit at 300 nm.
All reactions were conducted
at (21!0.1) 8C using a mixture of water/methanol
(95/5) as the solvent. The final concentration of di-
pyridyltetrazine was 50 mm. The final concentration
of norbornenes varied between 0.5 and 5 mm, cor-
responding to 10–100 equivalents with respect to
the tetrazine. The decay in the absorption of the
dipyridyltetrazine at 300 nm was monitored over
time (for details see the Supporting Information).
A typical diagram showing the profile of the ob-
served UV curves is shown in Figure 1. Pseudo
first-order rate constants were obtained by fitting
the data with a single exponential equation. The
observed rate constants were linearly dependent
on the concentration of the norbornene reaction
partner in all cases. The second-order rate con-
stants were calculated from the linear dependence
of the observed rate constants on the concentration
of the norbornene studied. The data are listed in
Table 1.
The data show that the introduction of a hetACHTUNGTRENNUNGero-
ACHTUNGTRENNUNGatom into the bicyclic structure of norbornene (de-
rivatives 7, 8, and 9) has in general a negative
effect on the reaction rate. The oxygen atom in po-
sition 7 shows a less dramatic influence compared
to the nitrogen atom present in azanorbornene 9.
In the case of oxanorbornenes (7 and 8) the reac-
tion was approximately three times slower than
that with compounds 1 and 3, which do not contain
a heteroatom in the bicyclic ring structure. This
slower reactivity of the oxanorbonenes may result
from the electron-withdrawing effect of the
oxygen, which reduces the electron density of the
bicyclic ring system. Evidently the shorter C"O
bond (143 pm versus 154 pm), which increases the
strain in the bicyclic ring structure is unable to
overcompensate the "I-effect. We next investigat-
ed the electronic effects in more detail studying
how substituents influence the reactivity. Indeed,
the presence of an electron-withdrawing substitu-
ent as in the derivatives 1, 2, 5, and 7 significantly
Table 1. Second-order rate constants for DARinv of norbornene derivatives 1–12 with
dipyridyltetrazine.
Norbornene k [m"1 s"1][a] Norbornene k [m"1 s"1][a]
1.3!0.02 0.49!0.004
0.56!0.005 1.78!0.007
5.2!0.13 0.12!0.001
1.76!0.013 0.05!0.002
0.29!0.033 0.43!0.007
1.43!0.02 4.55!0.087
[a] All reactions were performed in H2O/MeOH (95:5) at (21!0.1) 8C. The decay of
the absorption of dipyridyltetrazine was measured over time with various concentra-
tions of norbornene. The observed reaction rates were obtained by fitting the data
with a single exponential equation (y=a + be"kx). The linear dependence of the ob-
served rate constants k’ on the concentration of norbornene provided the second-
order rate constants k. The measurements were repeated three times for each deriva-
tive (for details see the Supporting Information).
Figure 1. Example of the UV data determined in a typical rate measurement using UV/Vis spectroscopy
(showed for derivative 1): a) graph showing the decrease in UV absorption of the dipyridyltetrazine at 300 nm
over time using 10, 25, 50, 75, and 100 equivalents of norbornene 1; b) plot showing the linear dependence of
the observed rate constants on the norbornene concentration. For plots of all norbornene derivatives see the
Supporting Information.
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reduces the reaction kinetics. In contrast, all derivatives with
electron-pushing substituents, such as the alcohols 3, 4, 6,
and 8 are 3–4 times faster. Interestingly, the rate accelera-
tion is very high in the exo-tricyclo[3.2.1.02,4]oct-6-ene-3-
methanol 12. In this case, the corresponding alcohol reacted
about 10 times faster than the ethyl ester 11. Because 11 is
significantly slower than the exo compounds 1 and 3, again
increased ring strain does not account for the higher reactiv-
ity of 12. These results show that additional strain does not
increase the reactivity, which is quite surprising. We noted,
however, a substantial reactivity difference between the exo
and the corresponding endo norbornene isomers. The large
reactivity difference was consistently observed in all exam-
ined compounds. The endo compounds all react significantly
less efficiently. This is particularly impressive for compound
10. The five-membered ring does not add strain and togeth-
er with the endo-configuration a compound is obtained,
which has a strongly reduced reactivity of only k= (0.05!
0.002)m"1 s"1. Comparing the rate constants of compound 1
with 2 and that of compound 3 with 4, an approximately 2.5
fold increase in favor of the exo isomer was observed. When
we performed the measurements of the two most reactive
derivatives 3 and 12 at 37 8C, the observed rate constants
were k= (8.0!0.46)m"1 s"1 and k= (6.1!0.17)m"1 s"1, re-
spectively, manifesting the potential of these derivatives.
Compound 12 has the additional advantage that it contains
a mirror symmetry element (Cs symmetry) so that upon re-
action only two defined products are formed. The high sym-
metry of compound 12 together with its superior reactivity
makes it the preferred choice for reverse electron-demand
Diels–Alder reactions (see Figure S1 in Supporting Informa-
tion).
To gain further insight into the observed reactivity differ-
ence between the exo and endo isomers, we next performed
transition-state calculations of the DARinv reaction of tetra-
zine with exo-norbornene 3 or endo-norbornene 4, respec-
tively, at the M06-2X/6-311+G ACHTUNGTRENNUNG(d,p) level of theory. A func-
tional of the M06 family already showed good performance
for the computation of barrier heights in other similar in-
verse electron-demand Diels–Alder reactions.[19,36,37] The in-
fluence of water as solvent was further determined with the
polarizable continuum model (PCM).[38]
The addition of tetrazine to norbornene derivatives 3 and
4 can proceed from the exo- or from the endo-side, respec-
tively. As a result, four different products can be formed via
four different transition states. In all cases the calculated en-
ergetic barrier for the endo-addition is much higher than for
the exo-addition (see the Supporting Information). The cor-
responding reaction leading to the exo-addition proceeds for
exo-norbornene 3 with a lower barrier (DG!=15.18 kcal
mol"1, Figure 2) than for endo-norbornene 4 (DG!=
15.83 kcalmol"1). These computations predict that the reac-
tion of tetrazine with 3 should be about three times faster
than the same reaction with 4.[39] This calculated increase in
the rate of the reaction is in excellent agreement with the
experimentally observed factor of 2.9 (see Table 1). The ex-
planation for the enhanced stabilization of the transition
state for 3 with respect to 4 is the stronger hydrogen bond
between H1 and the oxygen atom compared to the H2"O
hydrogen bond of 4[40] (Figure 2). This phenomenon was al-
ready observed in gas-phase calculations. Further stabiliza-
tion of the transition state towards 3 occurs due to the inter-
action of its stronger dipole moment with the solvent water
(see the Supporting Information).
In conclusion, we performed a short systematic kinetic
study about the reactivity of norbornene derivatives in in-
verse electron-demand Diels–Alder reactions with tetra-
zines. We experimentally evaluated the influence of various
substituents and of the whole geometry of the norbornene
on the reaction rates. The observed data clearly show that
norbornenes bearing non-electron-withdrawing substituents
in the exo position are most favored in the reaction. We per-
formed a computational analysis of the transition states of
the DARinv of tetrazine with exo and endo norbornene de-
rivatives to rationalize the observed rate difference. The cal-
culations show an excellent agreement with the experimen-
tal data and support the observed higher reactivity of the
exo isomers. We finally conclude that for biomolecular label-
ing studies one should consider compounds 3 and 12. The
former derivative is synthetically easily available in multi-
gram quantities, while the symmetry of compound 12 make
this compound the preferred dienophile in inverse electron-
demand Diels–Alder reactions with, for example, tetrazines,
particularly in cases where a high degree of stereocontrol is
important.
Experimental Section
Kinetic measurements : An equal volume of a 0.1 mm solution of dipyri-
dyltetrazine in H2O/MeOH (9:1) and a solution of norbornene (1, 2.5, 5,
Figure 2. M062X/6-311+G ACHTUNGTRENNUNG(d,p)-optimized transition-state structures for
the inverse electron-demand Diels–Alder reaction of tertrazine with exo-
norbornene 3 (a) and with endo-norbornene 4 (b), both leading to the
exo-addition of tertrazine. The barrier for the reaction of 3 with tetrazine
is 0.65 kcalmol"1 lower than the analogous reaction of 4. The indicated
H1"O hydrogen bond (2.66 !) of 3 is shorter than the corresponding
H2"O hydrogen bond (2.85 !) of 4.
Chem. Eur. J. 2013, 19, 13309 – 13312 " 2013 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim www.chemeurj.org 13311
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7.5 or 10 mm) in H2O were mixed in an UV-cuvette and immediately in-
serted into a UV spectrophotometer. The final concentration of tetrazine
was 0.05 mm and the final concentration of norbornene 0.5 to 5 mm, cor-
responding to 10 to 100 fold excess. The decay in the absorption of the
tetrazine was followed over 40–60 min in 0.5 or 1 min intervals. The data
were fit to a single exponential equation. Each measurement was repeat-
ed three times and the observed rate constants k! were plotted against
the concentration of norbornene. The second-order constants k were ob-
tained from the slope of the plot.
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The development of chemical tools that enable efficient and
selective labelling of proteins is of tremendous importance for
basic research and for biomedical and biotechnological appli-
cations.[1] One of the most popular techniques that allow pre-
cise control over the modification of proteins is based on the
incorporation of genetically encoded non-natural amino acids
by using bioorthogonal tRNA/tRNA-synthetase pairs. Crucial to
this is the incorporation of amino acids with unique side-chain
functionalities that can be selectively addressed by a bioorthog-
onal chemical reaction.[2] The pyrrolysine system, which in
nature is used to incorporate the amino acid pyrrolysine into
proteins, is one of the most popular systems for the incorpora-
tion of such noncanonical “clickable” amino acids.[3] In this
regard, amino acids containing alkyne,[4] trans-cyclooctene,[5]
cyclooctyne[5, 6] and norbornene[7] side chains have gained sig-
nificance, because they can be click-functionalised with azides
partially under CuI catalysis or with tetrazines in Diels–Alder re-
actions with inverse electron demand. Both wild-type and spe-
cifically mutated pyrrolysine synthetases (PylRSs) have been
used to load these noncanonical amino acids onto the cognate
pyrrolysine tRNA.[7c, 8]
Although crystal structures of wild-type PylRS have been re-
solved,[9] there has been no structural study to explain why
structurally demanding amino acids with side chains such as
norbornene are recognised. This hampers rational optimisation
of the pyrrolysine system. Previously we identified and charac-
terised a Methanosarcina mazei PylRS triple mutant (norb-
PylRS: Y306G, Y384F, I405R) that accepts the endo-norbornene-
containing Pyl analogue, 1.[7c] Here we show that this protein
also loads the more reactive[10] exo-norbornene (2) and cyclo-
propyl-norbornene (3) derivatives (Figure 1A) onto the cog-
nate tRNA, for subsequent incorporation into the growing pep-
tide chain at the ribosome. We report click chemistry with
these novel norbornene derivatives and provide a crystal struc-
ture of norb-PylRS in complex with the nonhydrolysable ATP
analogue AMP-PNP, and with the norbornene amino acid 1.
The three amino acids (1–3) were synthesised by using the cor- responding norbornene chloroformates and commercially
available N-a-Boc-protected lysine (see the Supporting Infor-
mation). Using the pyrrolysine system with norb-PylRS, we in-
corporated these derivatives into human carbonic anhydrase II
(HCA) as a model protein. For protein expression, Escherichia
coli BL21 (DE3) cells were transformed with two plasmids: one
contained the HCA gene with an amber codon at position 131,
and a second carried genes coding for pylT and norb-pylRS. The
cells were grown in the presence of 2 mm norbornene amino
acid (1, 2 or 3), and protein expression was induced by addi-
tion of isopropyl-b-d-thiogalactopyranoside (IPTG; 1 mm) at
OD600=0.9. After 10 h expression at 37 8C, the cells were lysed
Figure 1. A) Norbornene-containing pyrrolysine analogues 1–3 and tetra-
zines 4 and 5 (dansyl fluorophore and PEG moiety, respectively). B) SDS-
PAGE gel of HCA containing either cysteine or Pyl analogue 1, 2 or 3 at posi-
tion 131. All variants were treated with 4 : only HCA samples containing nor-
bornene showed fluorescence. The complete shift of the modified HCA var-
iants compared to the Cys-containing HCA indicates a quantitative modifica-
tion reaction. C) Intact MS spectra of HCA containing Pyl analogues 2 (HCA-
2, left) or 3 (HCA-3, right) at position 131. The deconvoluted MS spectra
show unmodified (green) and modified (brown) HCA.
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and purified by sulfonamide af-
finity chromatography. From a
litre of cell culture, we obtained
9 mg of HCA containing exo-
norbornene amino acid 2 or
3 mg HCA containing 3. For
comparison, we obtained 9 mg
of the protein when using the
endo-norbornene Pyl analogue
1. The presence of the nonca-
nonical amino acids at posi-
tion 131 was confirmed by ESI-
MS/MS (see the Supporting In-
formation). The successful incor-
poration of norbornene deriva-
tives 2 and 3 proves the high
promiscuity of the triple mutant
norb-PylRS with norbornene
substrates.
In order to demonstrate that
the norbornene functionalities
can be used for site-specific pro-
tein modification we next syn-
thesised the tetrazine deriva-
tives 4, which contains a dansyl
fluorophore, and 5, which can
be used for protein PEGylation
(for HCA PEGylation see the
Supporting Information). We in-
cubated 10 mm modified HCA
(containing 1, 2 or 3) in PBS
buffer with 5 equivalents of 4 or 5. After overnight incubation
at room temperature, SDS-PAGE gel analysis of the reaction
mixtures showed quantitative reactions (Figure 1B). We next
confirmed the presence of the expected click products by
mass spectrometric analysis of the modified proteins (Fig-
ure 1C). In all three cases successful product formation was de-
tected, thus underlining the high efficiency of the norbornene-
based protein modification procedure. Most importantly, the
cyclopropyl-norbornene (3) provides in principle (because of
its higher symmetry) only one exo and one endo product, in-
stead of two of each. This is important because more-complex
product mixtures (as obtained with 1 and 2) can hamper bio-
technological applications.
To investigate the molecular basis for the substrate tolerance
we determined X-ray crystal structures for the mutant enzyme.
Norb-PylRS was crystallised in complex with the ATP analogue
AMP-PNP as well as in complex with the adenylated norbor-
nene amino acid (obtained by incubation of the enzyme with
1 and ATP). The structures were solved at 2.35 and 2.45 !, re-
spectively. (For data processing statistics see Table S1 in the
Supporting Information). Norb-PylRS in complex with AMP-PNP
superimposes well with the wild-type PylRS structure (PDB ID:
2Q7E), with an RMSD of 0.66 !. No large structural rearrange-
ments are evident (Figure 2A). In both proteins AMP-PNP bind-
ing is the same, with two magnesium ions coordinated by the
a/b- and b/g-phosphates (Figure 2C). In the structure of the
mutant PylRS with AMP-PNP we observed that the Y306G
mutation (base of the hydrophobic substrate binding pocket)
enlarges the binding site, but does not perturb the backbone
structure. The position of Tyr384 in the loop that closes the
active side (b7–b8 hairpin) is occupied by Phe384. The third
mutation (exchange of Ile405 by an arginine) causes a small
shift of the b7–b8 hairpin as a result of hydrogen-bond forma-
tion between Arg405 and the backbone carbonyl of Phe384
and Asp386 (Figure 2B). This loop plays a pivotal role in deter-
mining the substrate specificity.[11] All other parts of the protein
backbone are unchanged. We also noticed that in the norb-
PylRS:AMP-PNP complex a PEG molecule from the crystallisa-
tion solution had entered the active side (Figure S1). In the co-
crystals of norb-PylRS with the adenylated norbornene amino
acid (1), the adenylated norbornene is clearly defined in the
electron density (Figure 3D). The norbornene moiety is deeply
buried in the enlarged hydrophobic binding pocket (Figure S1).
In the wild-type complex, the space occupied by the norbor-
nene head group is taken by the Tyr306 side chain (Figure 3A
and B), thus explaining why the Y306G mutation is essential
for efficient recognition of the norbornene unit of 1.[7c] This
mutation enlarges the binding pocket such that the exo- and
cyclopropyl norbornene units (2 and 3) also can be recognised
(for 3 see Figure S1). In the wild-type synthetase complex with
Pyl, two important interactions can be identified. These are es-
sential for determining the substrate specificity : first, a bifurcat-
Figure 2. Norb-PylRS triple-mutant structure. A) Overall structure of norb-PylRS in complex with the ATP analogue
AMP-PNP (gold) superimposed with the wild-type synthetase (PDB ID: 2Q7E, grey). AMP-PNP shown as a stick
model ; mutated residues Y306G, Y384F and I405R are in red. B) Ribbon-and-stick representation of the changes
in the b7–b8 hairpin caused by the I405R mutation. C) and D) Simulated-annealing omit Fo!DFc electron density
map of AMP-PNP (C) and the adenylated norbornene 1 (D) contoured at 3s. The surrounding amino acid residues
are drawn as sticks. Mg2+ ions and water are shown as green and red spheres, respectively.
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ed hydrogen bond from the tyrosyl residue (Tyr384) to the pyr-
roline nitrogen as well as to the a-amino group of the sub-
strate (Figure 3C); second, an important H bond between the
side chain of Asn346 and the substrate carbonyl-amide link-
age.[8g,9a] In contrast to the crystal structure of the native sub-
strate and N-e-[(cyclopentyloxy)carbonyl-l-lysine] bound to
wild-type PylRS, the carbamate linkage of the adenylated
endo-norbornene (1) in complex with the triple mutant norb-
PylRS does not form a hydrogen bond with Asn346 (distance
3.45 !). Instead Cys348 adopts a rotameric conformation in
which the cystein sulfur atom is shifted into an H-bond-donat-
ing position (distance ~2.6 !) to the carbamate oxygen (Fig-
ure 3D). Such !SH donor-containing H bonds have been ob-
served to be important for establishing intermolecular interac-
tions;[12] however, they are generally weaker compared to !NH
and !OH donors. The b7–b8 hairpin carrying Phe384 is disor-
dered in all structures.[9a] It was previously proposed that the
hairpin functions to protect the unstable pyrrolysyladenylate
intermediate when the specific tRNA-Pyl species is in short
supply.[8h,13]
In summary, we present the crystal structure of the pyrroly-
syl tRNA synthetase mutant norb-PylRS. The structure unravels
the principles that establish the substrate specificity of the
norb-PylRS/PylT system for the incorporation of noncanonical
amino acids into proteins. Important is the observation that
the replacement of Tyr306 by Gly increases the size of the
binding pocket significantly, and therefore enables efficient
binding of the sterically demanding norbornene moiety. An
unusual H bond between Cys348 and the carbamate oxygen
of the amino acid was found to be involved in correct sub-
strate recognition. Additionally, two novel exo-norbornene
amino acids were successfully incorporated into HCA, thus
demonstrating the broad promiscuity of the evolved triple-
mutant norb-PylRS. These moieties can be used for quantita-
tive and site-specific fluorescent labelling and PEGylation of
proteins, and thus suggests great potential for the norbornene
functionality in modern bioorthogonal chemistry.
Experimental Section
General: Chemicals were purchased from Sigma–Aldrich, Fluka,
ABCR (Karlsruhe, Germany) or Acros Organics (Fisher Scientific, Nid-
derau, Germany) and used without further purification. Solvents for
silica-gel column chromatography were distilled prior to use. Reac-
tions were monitored on Silica 60 F254 TLC plates (Merck Milli-
pore). Detection was achieved by UV irradiation (254 or 366 nm)
and staining with p-anisaldehyde in ethanol, CAM or KMnO4 solu-
tions. Flash column chromatography was performed on Silica 60
(230–400 mesh; Merck Millipore). NMR spectra were recorded on
the following spectrometers: Varian Oxford 200 (Agilent Technolo-
gies), AC 300 (Bruker), Varian XL 400 and AMX 600 (Bruker). The
spectrometers were calibrated by using residual undeuterated sol-
vents as an internal reference. The structures of norbornenes were
solved by using 2D NMR techniques. Mass spectra were recorded
on the following machines: MAT 95 (EI ; Thermo Finnigan), LTQ-FT
(ESI-ICR; Thermo Finnigan) and LTQ-Orbitrap XL (Thermo Scientific).
Proteins were purified on an "KTA purifier system (GE Life Scien-
ces).
Cloning, expression and purification of HCA containing 1, 2 or 3
at position 131: The expression vector pACA_HCA G131C (HCA
under control of the T7 promoter; ampicillin resistance gene) was
a kind donation from Prof. Trauner (Ludwig Maximilians University,
Munich). The amber codon (boldface in the following sequence)
was introduced to substitute G131 in a site-directed (blunt end)
mutagenesis with the 5’-phosphorylated primers 5’-TAG AAA GCT
GTG CAG CAA CCT GAT GGA CTG-3’ and 5’-AAA ATC CCC ATA TTT
GGT GTT CCA GTG AAC CAA G-3’ to generate plasmid pACA_HCA
G131amber. This plasmid was transformed together with pACyc_
pylRS Norb,[7c] 3#pylT (genes of the triple mutant of PylRS and
three copies of pylT)[7c] into E. coli BL21(DE3) cells (NEB, Norwich,
MA). LB medium (1 L) containing chloramphenicol (34 mgL!1), car-
benicillin (100 mgL!1) and norbornene amino acid (1, 2 or 3 ;
2 mm) was inoculated with overnight culture (10 mL). The cells
were stirred at 37 8C until OD600=0.9, then ZnSO4 (1 mm) and IPTG
(0.1 mm) were added to induce the expression of the HCA
G131amber gene. After further incubation (10 h, 37 8C) the cells
were harvested and stored at !20 8C until further use. The harvest-
ed cells were resuspended in wash buffer (Tris (25 mm, pH 8.8),
Na2SO4 (50 mm), NaClO4 (50 mm)) and disrupted in a French Press.
The supernatant of the centrifuged lysate was subjected to sulfo-
namide affinity protein purification in an "KTA purifier system. A
3 mL column was loaded with p-aminomethylbenzenesulfonamide-
agarose resin (A0796; Sigma–Aldrich) and equilibrated with wash
buffer. After binding (0.75 mLmin!1) of the protein solution, the
column was washed with seven column volumes of wash buffer.
HCA was eluted by low pH (elution buffer: NaOAc (100 mm),
NaClO4 (200 mm, pH 5.6)). The protein-containing fractions were
Figure 3. Structural recognition of norbornene amino acid 1 and comparison
with the wild-type (wt) enzyme complex. A) Active site with superimposed
Pyl and norbornene head groups. The side chain of Tyr306 in the wt enzyme
occludes the space occupied by the norbornene functional group in the
triple mutant. B) Mutation Y306G does not affect the peptide backbone of
the residues at the binding pocket, as shown by the superposition of the
PylRS-Norb (gold) and wt (grey) AMP-PNP complexes. C) Closed b7–b8 hair-
pin and Tyr384–Pyl interaction in the wt enzyme and position of Arg405 in
the norb-PylRS:norbornene complex. D) Hydrogen bond between the carba-
mate moiety and Cys348. Cartoon and stick representation of the wt
enzyme (grey) and norb-PylRS (gold).
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combined, analysed by SDS-PAGE, dialysed against water and
lyophilised. Typical yields of pure HCA protein were 9 mg per L ex-
pression medium (for 1 and 2) and 3 mg per L expression medium
(for 3).
Click of norbornene-containing HCA: Purified HCA containing 1,
2 or 3 was used for modification with tetrazine derivatives (4 :
dansyl moiety; 5 : PEG moiety). HCA G131C was used as a negative
control. The final concentration of the protein was 10 mm in PBS
buffer, and tetrazine derivative (50 mm) was added. After overnight
incubation at room temperature the samples were analysed by
SDS-PAGE or intact mass spectrometry. The SDS-PAGE gel was ana-
lysed with an LAS-3000 image reader (Fujifilm) to identify modifica-
tion of HCA with the fluorophore 4 (excitation 312 nm; Figures S2
and S3).
Intact MS: Purified intact HCA variants were analysed by nano-
HPLC-ESI MS. After reaction with tetrazine 4 or 5, the protein was
used directly for HPLC-MS analysis. A self-packed C4 nano-column
(ReproSil Gold 300 C4, 3 mm) was used for HPLC separation, and
mass spectrometry was performed by an LTQ-Orbitrap XL. Raw
mass spectra and deconvoluted spectra are depicted in Fig-
ures S7–S12 for all variants.
Norb-PylRS expression, purification and crystallisation: The se-
quence encoding the catalytic domain (residues 185–454) of the
PylRS triple mutant (Y306G, Y384F, I405R; norb-PylRS) from
M. mazei was PCR amplified with primers 5’-GCG CAT ATG GCA
AGT GCC CCC GCA CTT AC-3’ and 5’-TTA TGC GGC CGC TTA CAG
GTT GGT AG-3’ from a plasmid containing the full-length syntheta-
se.[7c] The fragment was cloned into the expression plasmid pET28a
(Novagen/EMD Millipore) in-frame with an N-terminal His6 tag.
Norb-PylRS was expressed in E. coli Rosetta DE3 cells (EMD Milli-
pore). As a first purification step the cleared lysate was incubated
with Perfect-pro Ni-NTA Superflow resin (5 PRIME, Hamburg, Ger-
many), and eluted with a step-wise imidazole gradient. The eluted
protein was concentrated and loaded onto a HiLoad Superdex 200
(16/60) size-exclusion column (GE Healthcare), equilibrated with
HEPES (10 mm, pH 7.4), NaCl (300mm), MgCl2 (5 mm) and dithio-
threitol (1 mm). Fractions containing norb-PylRS were concentrated
to 15 mgmL!1. Aliquots were flash-frozen in liquid nitrogen and
stored at !80 8C. Crystallisation of norb-PylRS in complex with
AMP-PNP was carried out as previously described for the wild-type
protein.[9a] In order to co-crystallise norb-PylRS with the endo-nor-
bornene amino acid, the protein was diluted (1 mgmL!1) and incu-
bated for 2 h with endo-norbornene sodium salt (2 mm) and ATP
(1 mm; Sigma–Aldrich) in protein storage buffer [HEPES (10 mm,
pH 7.4), NaCl (300 mm), MgCl2 (5 mm), dithiothreitol (1 mm)] . The
protein was concentrated to 10 mgmL!1 prior to crystallisation.
Crystals appeared overnight in sodium acetate (100 mm) and
PEG3350 (15–18%). All crystals were cryoprotected with well solu-
tion supplemented with ethylene glycol (30%, w/v) before flash-
freezing, and then stored in liquid nitrogen until data collection.
Data collection and structure determination: Diffraction data
were collected at the synchrotron beam lines PXI (Swiss Light
Source, Villigen, Switzerland) and ID23-2 (European Synchrotron
Radiation Facility, Grenoble, France). The crystals diffracted X-rays
to 2.35 ! (norb-PylRS:AMP-PNP) and 2.45 ! (norb-PylRS:AMP-Norb)
spacing, respectively. The data were processed with XDS[14] and
SCALA,[15] ensuring consistent indexing and choosing the same set
of free reflections. The Crystals belong to the same space group as
reported previously for the wild type synthetase[9] (P64, unit cell di-
mensions: a=b=105 !, c=70 !, a=b=908, g=1208). The struc-
ture was solved by molecular replacement by using the norb-PylRS
AMP-PNP wild-type complex (PDB ID:1Q7E) in PHASER.[16] For the
norb-PylRS AMP-Norb the coordinates of the norb-PylRS AMP-PNP
were used in a difference Fourier method followed by rigid body
refinement in REFMAC.[17] In order to reduce model bias, all non-
protein atoms as well as the loop region around Phe384 were re-
moved from the model prior to molecular replacement, and the
temperature factors were reset, followed by simulated annealing in
PHENIX.[18] Clear peaks for AMP-PNP and AMP-Norb were visible in
the simulated-annealing omit Fo!DFc map (Figure 1). Rounds of
model building and refinement were carried out in COOT,[19]
PHENIX and REFMAC. The refinement parameter file for AMP-Norb
was generated with prodrg2[20] and TLSMD server[21] was used for
TLS refinement. Diffraction data and refinement statistics are sum-
marised in Table S1. All structural figures were prepared with
PyMol (Delano Scientific, San Carlos, CA). Atomic coordinates were
submitted to the Protein Data Bank (http://www.ebi.ac.uk/pdbe/)
with the PDB IDs 4BW9 (Pyl-Norb:AMP-PNP) and 4BWA (Pyl-Norb:
adenylated norbornene).
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Sulfonyl azide-mediated norbornene aziridination
for orthogonal peptide and protein labeling†
Michael J. Gattner, Michael Ehrlich and Milan Vrabel*‡
We describe a new bioconjugation reaction based on the aziridination
of norbornenes using electron-deficient sulfonyl azides. The reaction
enables to attach various useful tags to peptides and proteins under
mild conditions.
Bioconjugation reactions substantially extend our ability to
chemically manipulate proteins. Numerous chemical strategies
for the attachment of synthetic molecules to proteins have been
developed.1 Early approaches focused on native functional
groups present on endogenous amino acids.2 The main draw-
back of this approach is the lack of specificity since multiple
copies of each amino acid are present in the primary protein
structure. Unique recognition elements can be introduced into
the protein structure to improve the selectivity of the ligation.
One possibility is to add a specific amino acid sequence to the
target protein that can be recognized by either an appropriate
protein modifying enzyme3 or by specific chemical probes.4
Another approach uses the biosynthetic machinery of the cell
for incorporation of unnatural amino acids containing artificial
functional groups.5 We and others have used this approach for
the incorporation of unnatural amino acids into proteins and
have shown that the introduced functionality can be efficiently
tagged by orthogonal chemical reactions.6 The right choice of
the reacting functional groups and the proper ligation technique
plays a crucial role here.7 Among other suitable functional
groups that enable efficient protein labeling various derivatives
of cyclooctyne, cyclooctene and cyclopropene have gained special
attention in the field.8 An extraordinary fast kinetic was observed
especially in combination with tetrazines in inverse electron-
demand Diels–Alder reactions or in dipolar cycloadditions with
nitrile imines.8a,b,e Unfortunately, the high reactivity of such systems
is often accompanied by reduced stability and an increased tendency
toward side reactions.9 Moreover, synthetic access to these reagents
often represents a considerable challenge. It is therefore desirable to
develop a methodology that not only enables robust protein labeling
but also utilizes easily available starting materials.
Based on our experience using norbornenes as highly reactive
compounds in combination with nitrile oxides, nitrile imines and
tetrazines10we searched for reagents that do react with norbornenes,
but also meet the criteria for better synthetic accessibility. Here we
show that aziridination of norbornenes using electron-deficient
sulfonyl azides represents an excellent balance between reactivity,
stability and availability of the starting materials. We demonstrate
that this reaction can be used for efficient labeling of norbornene-
containing peptides and proteins.
Inspired by the pioneering studies on norbornene aziridination
by Franz et al.,11 we decided to investigate whether this reaction
can proceed in an aqueous environment and can be used for
biomolecule labeling. Sulfonyl azides have been previously
successfully applied as reagents for detecting thiocarboxylates in
bacterial proteomes12 and as ligation agents for thioacid-containing
peptides and proteins.13 These studies clearly indicate that sulfonyl
azides are compatible with natural systems. To investigate the
reactivity of sulfonyl azides with norbornene under aqueous
conditions we first performed a model reaction. We reacted
sulfonyl azide 1 with norbornene in water/acetonitrile (1 : 1) at
moderate temperature overnight (Scheme 1 and Scheme S1, ESI†).
After purification using semipreparative HPLC we obtained the
desired aziridine 2 in 78% yield. We also isolated the corresponding
sulfonamide 3 (18%) as a by-product formed by the nucleophilic
attack of a water molecule on the aziridine and subsequent ring
opening. 2D-NMR analysis of 2 showed that only the exo-aziridine
product was formed in the reaction (see ESI†). The reaction mecha-
nism leading to the formation of the desired aziridine can involve
the initial formation of a triazole intermediate followed by the
extrusion of nitrogen. Alternatively, the aziridine formation parallels
that of epoxidation involving a concerted addition of the azide to the
double bond with a concomitant loss of nitrogen.11a No direct
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experimental evidence that would support or disprove any of
these mechanisms was observed during our experiments. A more
detailed study is required to address this issue.
To gain more insight into the reaction kinetics we measured
the bimolecular rate constant of the reaction in water/acetonitrile
(9 :1) to simulate more relevant conditions required for its use on
biomolecules. To ensure sufficient water solubility of the norbornene
substrate we used endo-5-norbornene-2-methanol in these experi-
ments. Themeasurements were performed under pseudo first order
conditions using an excess of norbornene and were performed in
triplicate (for details see ESI†). The second order rate constant was
determined to be k = 1.7 ! 10"3 # 0.21 ! 10"3 M"1 s"1. This value
is comparable to the rate constants of the strain-promoted azide–
alkyne cycloaddition reaction of the first generation cyclooctyne
derivatives that are commonly used for biomolecule labeling
applications.14 These promising results prompted us to further
examine the reaction as a potentially new methodology for
modification of biomolecules.
To investigate the stability of sulfonyl azides and products
formed in their reaction with norbornenes, we first incubated 1
and the isolated products 2 and 3 in a 50 mM MES buffer at
pH 5.5 (MES = 2-(N-morpholino)ethanesulfonic acid) and in
50 mM TRIS buffer at pH 8.5 (TRIS = 2-amino-2-hydroxymethyl-
propane-1,3-diol). HPLC analysis of the mixtures did not show
any reaction or decomposition even after a prolonged incubation
time (Fig. S6, ESI†). Only slow hydrolysis of aziridine 2 to the
corresponding sulfonamide 3 was detected. The observed slow
hydrolysis of the originally formed aziridine in water is in fact
not an obstacle for biomolecule labeling since the desired tag
will stay attached to its target.
Although sulfonyl azides have been previously used in the
biological context,12,13 to exclude possible side reactions with
endogenous amino acids we performed additional experiments.
The electron deficient sulfonyl azides could react with nucleophilic
groups on proteins (e.g. cysteines or lysines). Our stability study
showed that sulfonyl azides were not affected by amino groups
since the incubation of compound 1 in TRIS buffer that contains a
primary amino group did not show any reaction even at pH 8.5.
When we incubated 1 (0.5 mM) with cysteine (50 mM or 2.5 mM)
the corresponding sulfonamide was formed as a result of azide
reduction (Fig. 1, Fig. S6 and S7, ESI†). No nucleophilic substitution
reaction was detected. This reaction again will not interfere with
protein labeling itself. However, considering the relatively high
concentrations of cysteine and glutathione in cells, this side
reactivity may hinder the use of this chemistry for in vivo
applications. To examine a possible reactivity of the aziridine
product with other nucleophiles such as amines or thiols we
incubated 2 in 50 mM TRIS or in 50 mM cysteine solution. We
again observed only slow hydrolysis to form the corresponding
sulfonamide 3. These experiments demonstrate that the aziridine
moiety is stable toward these nucleophiles. Also, sulfonyl azides can
react with nucleophilic double bonds including indole andN-methyl
indole.15 To investigate whether this reaction takes place in
tryptophan residues (Trp) we incubated compound 1 (0.5 mM)
with Trp (0.5 mM). We did not observe any detectable reaction
after two days (Fig. S8, ESI†). These additional experiments
indicate that sulfonyl azides can be used for peptide and protein
labeling in the presence of these native functional groups.
To evaluate the reaction on biomolecules we next synthesized a
norbornene-containing peptide: AFDXKDKPAA, where X = endo
norbornene-containing amino acid 4. The peptide was incubated
at 50 mM final concentration with sulfonyl azide 1 (2.5 mM) in water/
acetonitrile (9 :1) and the reaction was followed by MALDI-TOF
spectrometry. The analysis of the reaction mixture showed complete
conversion of the starting peptide to the aziridinated product within
35 hours (Fig. 2 and Fig. S3, ESI†). The hydrolysis of the aziridine to
the corresponding sulfonamide was in this case observed only after
prolonged incubation time (72 hours, see Fig. S4, ESI†).
Encouraged by these results we next moved to proteins. Using
the pyrrolysine amber suppression system we introduced the endo
norbornene amino acid 4 into E. coli thioredoxin (Trx) and human
carbonic anhydrase (HCA) as model proteins.10c,16 The norbornene
functionality was incorporated at positions Asn65 of Trx (Trx N65X)
and His36 of HCA (HCA H36X) (for expression and purification
details see the ESI†). We next synthesized sulfonyl azide derivatives
5 and 6 bearing a biotin tag or a dansyl fluorophore to examine the
norbornene aziridination on proteins (Fig. 3). We first incubated a
40 mM solution of Trx N65X with 50 equivalents of 5 overnight at
37 1C in 50 mM Tris (pH 7.5). The successful, almost quantitative
labeling of Trx N65X with 5 was indicated by a gel shift of the
protein band after SDS-PAGE and further confirmed by intact mass
spectrometry (Fig. 3A, estimated yield 95%).
In addition, after tryptic digestion and MS analysis we found
the expected mass of the peptide LNIDHXPGTAPK containing
Scheme 1 Model reaction of norbornene with sulfonyl azide 1. Yields:
78% of 2 and 18% of 3.
Fig. 1 Reduction of the sulfonyl azide 1 in the presence of cysteine. The
new peak (10.3 min) was identified as the corresponding sulfonamide by
LC-MS (calc. for C10H11N2O5S [M " H]
": 271.0389, found: 271.0393).
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the desired biotin modification at position X ([M + 2H]2+calc. =
1188.0978, [M + 2H]2+obs. = 1188.0919, DM = 4 ppm). To further
evaluate the chemistry on proteins we used the wild type HCA
(HCA wt) and norbornene containing HCA H36X respectively.
The proteins (40 mM final concentration) were incubated with
the fluorescent sulfonyl azide 6 (2 mM, 50 equiv.) in 50 mM
MES buffer, pH 5.5 at 37 1C overnight (Fig. 3B). SDS-PAGE and
subsequent fluorescence detection showed selective labeling of
the norbornene containing HCA H36X. Only after prolonged
incubation time (four days) we observed a weak fluorescent
signal in the reaction of the HCA wt protein, which could be
due to non-specific labeling. The origin of the non-specific
reaction was not clear since our investigations regarding possible
side reactions with endogenous amino acids did not show any
reaction. Moreover, the sulfonyl azides were stable under the
labeling conditions used (50 mM MES, pH 5.5). Similar non-
specific reaction was previously described in the literature, where
fluorescent sulfonyl azides were used for visualization of thiocar-
boxylates in bacterial proteome.12 However, in this case also the
side reactivity could not be appropriately explained. Nevertheless,
the specific reaction with norbornene is much faster and there-
fore the side reaction can be eliminated by simply removing the
excess reagent after the reaction. To verify the presence of the
desired fluorescent dansyl tag we digested the protein and
analyzed the peptide mixture using HPLC-MS. These data
demonstrated that the modification was present in the correct
position within the protein structure (peptide QSPVDIDTXTAK,
X = norbornene amino acid 4 aziridinated by 6: [M + 2H]2+calc. =
1079.5082, [M + 2H]2+obs. = 1079.5039, DM = 4 ppm).
In summary, we show that norbornene aziridination using
electron-deficient sulfonyl azides can be used for orthogonal
peptide and protein labeling. The reaction proceeds efficiently
under mild conditions, does not require any catalysis and
is orthogonal to functional groups of native proteins. Since
norbornenes, sulfonyl azides and derivatives thereof are easily
accessible compounds the presented technology constitutes an
attractive alternative to currently used bioconjugation techniques
especially for in vitro applications. Further optimization and evalua-
tion of this chemistry toward its use for in vivo peptide and protein
labeling is ongoing.
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Orchestrating the Biosynthesis of an Unnatural Pyrrolysine Amino
Acid for Its Direct Incorporation into Proteins Inside Living Cells
Michael Ehrlich,[a] Michael J. Gattner,[a] Bastien Viverge,[a] Johanna Bretzler,[a] David Eisen,[a]
Michael Stadlmeier,[a] Milan Vrabel,[b] and Thomas Carell*[a]
Abstract: We here report the construction of an E. coli ex-
pression system able to manufacture an unnatural amino
acid by artificial biosynthesis. This can be orchestrated
with incorporation into protein by amber stop codon sup-
pression inside a living cell. In our case an alkyne-bearing
pyrrolysine amino acid was biosynthesized and incorporat-
ed site-specifically allowing orthogonal double protein la-
beling.
The incorporation of unnatural amino acids into proteins is
a highly topical research field as it allows one to modulate the
properties of proteins by chemical means.[1] Practically, the in-
corporation of amino acids that are amenable to further chem-
ical modification by orthogonal “click” reaction are interesting
for the addition of, for example, polyethylene glycols, toxoph-
ores, and fluorophores to proteins for diagnostic or medical
applications.[2] A recently introduced technology in this direc-
tion is based on the 22nd genetically encoded amino acid pyr-
rolysine (Pyl), which is biosynthesized from two l-lysine amino
acids by the enzymes PylB, PylC, and PylD (Figure 1 and
Figure 1 in the Supporting Information).[3] The biosynthetic
pathway was elucidated by feeding experiments[4] and struc-
tural characterization of the involved enzymes.[5] Pyl is subse-
quently loaded onto a special Pyl-tRNA (PylT) with the assis-
tance of a specific aminoacyl-tRNA synthetase (PylRS). PylT de-
livers Pyl to the ribosome for incorporation into the nascent
polypeptide chain in response to the presence of the amber
stop codon (UAG) in the mRNA. Therefore the pyrrolysine
system reprograms this stop codon for Pyl insertion.
As PylRS is rather promiscuous and can be adopted to bind
unnatural amino acids using bio-engineering, the PylRS/pylT
pair has enabled the incorporation of a large variety of Pyl de-
rivatives featuring additional functional groups, for example,
for click modification.[6] One problem associated with this tech-
nology is, however, that the unnatural Pyl amino acids need to
be synthesized in rather large quantities to reach the required
millimolar concentrations in the culture medium necessary for
efficient incorporation. These laborious syntheses can be cir-
cumvented with a host organism (E. coli) that produces the
modified unnatural amino acid by itself.[7] This in consequence
requires the insertion and modulation of the Pyl biosynthetic
machinery in the E. coli host system.[4b, c] Thus we planned to
study if the Pyl biosynthesis pathway allows in vivo construc-
tion and finally incorporation of the unnatural 3S-ethynylpyrro-
lysine (ePyl) amino acid, which may be amenable to subse-
quent click modification (Figure 1).
Since Pyl is derived from the PylB product 3R-methyl-d-orni-
thine and one l-lysine via the action of the enzymes PylC and
PylD (see Figure 1 in the Supporting Information), we cloned
the genes of both enzymes into a first plasmid (1) (Figure 2). A
second plasmid (2) was prepared containing one gene copy of
the PylRS aminoacyl-tRNA synthetase gene pylS and three
Figure 1. Developed methodology for biosynthesis and incorporation of the
novel ethynylpyrrolysine (ePyl). The new amino acid 3S-ethynyl-d-ornithine
1 was converted to ePyl by hijacking the pyrrolysine biosynthesis machinery
analogous to the biosynthesis of pyrrolysine (Pyl) via biosynthesis enzymes
PylC and PylD. A site-specific incorporation into the protein human carbonic
anhydrase 2 (hCA, PDB: 1BCD) by translation with an aminoacyl-tRNA syn-
thetase (PylRS)/Pyl-tRNA (PylT) pair at the amber stop codon was possible.
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copies of the pylT gene. A third plasmid (3) was used with the
gene for the human carbonic anhydrase 2 (hCA).[8] This manip-
ulated hCA gene contains an amber stop codon (GGG!TAG)
at the amino acid position G131.[9] All three plasmids were co-
transformed into E. coli cells. Plasmid 3 was selected on a car-
benicillin-containing medium, while plasmid 2 was equipped
with a chloramphenicol acetyltransferase (CAT) gene bearing
an amber stop codon at either position A69 or D111 upstream
of the active site. This plasmid represents the master reporter
as it allows growth of E. coli cells in the presence of chloram-
phenicol only if a Pyl derivative is biosynthesized and incorpo-
rated in CAT efficiently by stop codon suppression.
For selection of successfully transformed E. coli cells we
added carbenicillin, chloramphenicol, and initially d-ornithine.
This system allowed us to test if d-ornithine is converted to
desmethylpyrrolysine (dmPyl) by the action of PylC and PylD
followed by final incorporation into proteins via amber sup-
pression.[4b] Indeed, we observed growing E. coli showing that
the biosynthesis operates and thus dmPyl is successfully incor-
porated into CAT.
We next used 3’-substituted d-ornithine derivatives and fi-
nally found growing E. coli cells in the presence of carbenicillin,
chloramphenicol, and 3S-ethynyl-d-ornithine 1. This demon-
strates that 3S-ethynyl-d-ornithine 1 is able to serve as a d-or-
nithine surrogate during biosynthesis.
The synthesis of the starting material 3S-ethynyl-d-ornithine
1 is conveniently possible as depicted in Scheme 1. We started
with Carboxybenzyl (Cbz) protected 3-amino-propionaldehyde
2, which was allowed to react with ethynyl bromide in
a Grignard reaction. The formed alcohol 3 was converted into
the bromide 4 via an Appel reaction.[10] Subsequent substitu-
tion of the bromide 4 with the deprotonated S-configured
Schçllkopf reagent provided the two pyrazine derivatives with
the corresponding SR (5) and RR (6) configuration in a diasteroi-
someric mixture which could be separated using silica column
chromatography. We were unable to detect the SS and RS
products, showing the high stereocontrol provided by the
Schçllkopf auxiliar.[11] Sequential deprotection of both diaste-
reoisomers to the methoxyesters 7 and 8 and subsequent hy-
drolysis provided the 3S,2R- and 3R,2R-configured ethynylorni-
thines 1 and 9, respectively. The absolute configuration was
verified by a crystal structure of the 3S,2R-ethynylornithine
1 (Scheme 1b).
To investigate how efficiently 3S-ethynyl-d-ornithine 1 serves
as a biosynthetic precursor for Pyl derivatives we performed
time-dependent growth studies. Growth was observed in the
presence of d-ornithine and 3S-ethynyl-d-ornithine 1 but inter-
estingly not with 3R-ethynyl-d-ornithine 9 (see Figure 2 in the
Supporting Information). We explain this result with the fact
that PylC has a hydrophobic pocket to bind the methyl group
of its natural 3R-methyl-d-ornithine substrate that is large
enough to accommodate the 3S-ethynyl unit.[5b] Interestingly,
E. coli cells show faster growth in the presence of 3S-ethynyl-
d-ornithine compared to d-ornithine, indicating that filling of
the hydrophobic pocket enhances substrate affinity and hence
the efficiency of the biosynthesis (Figure 3 in the Supporting
Information).
To prove that the designed E. coli cells are indeed able to
manufacture 3S-ethynylpyrrolysine (ePyl) for subsequent incor-
poration into proteins, we next isolated the hCA protein from
the E. coli cultures (see Figure 4 in the Supporting Information).
The protein was conveniently purified in a single chromato-
graphic step using a p-aminomethylbenzene-sulfonamide
column exploiting the binding affinity to the ZnII ion in the
active site of hCA.[12] When we added d-ornithine in our con-
trol experiments to the medium we typically isolated around
6 mg of hCA per L of culture. Upon addition of 3S-ethynyl-d-
ornithine 1, the yield increased dramatically to 75 mg per L in-
dicating, in combination with the results from the growth
curves, that the speed of the biosynthesis of ePyl is the deter-
mining factor.
Subsequently, the incorporation of ePyl into the hCA
enzyme was proven by intact protein mass spectrometric stud-
Figure 2. Biosynthetic conversion of 3S-ethynyl-d-ornthine 1 to ethynylpyr-
rolysine (ePyl) and incorporation into the amber codon bearing proteins
chloramphenicol acetyltransferase (CAT) and human carbonic anhydrase 2
(hCA) using an E. coli expression system. E. coli cells were transformed with
following coding plasmids: plasmid 1: pylC, pylD ; plasmid 2: pylS, 3x pylT
and CAT-A69amber or CAT-D111amber ; plasmid 3: hCA131amber and an ampi-
cillin resistance gene (PDBs: 1BCD, 1Q23).
Scheme 1. a) Synthesis of 3S-ethynyl-d-ornithine 1 and 3R-ethynyl-d-orni-
thine 9. Reagents and conditions: a) HC⌘CMgBr, THF, ˇ78 8C to RT, 2 h;
b) PPh3, CBr4, DCM, 0 8C to RT, 5 h; 50% over 2 steps; c) (S)-2,5-dihydro-3,6-
dimethoxy-2-isopropylpyrazine, nBuLi, THF, ˇ78 8C, 30 min, 72% (SR/RR : 2/
5); d) 3m HCl, MeOH, H2O, RT, 2 d, 78%; e) 12m HCl, H2O, 80 8C, 15 h, 91%;
f) 3m HCl, MeOH, H2O, RT, 2 d, 86%; g) 12m HCl, H2O, 80 8C, 15 h, 11%;. h) X-
ray structure of 1.
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ies using a high-resolution FT-ICR mass spectrometer. Indeed,
the isolated hCA protein showed the correct molecular weight
for the ePyl-containing hCA-ePyl131 (Figure 3a; see also
Figure 5 in the Supporting Information). The position of ePyl
incorporation was verified by the mass spectrometric analysis
after tryptic digestion on an Orbitrap XL system (LC-MS/MS).
This experiment demonstrates that the incorporation proceed-
ed at the desired position (G131!ePyl131, Figure 3b, see also
Figure 6 in the Supporting Information). In addition we verified
the correct incorporation in CAT-ePyl111 (see Figure 7 in the
Supporting Information). As a further control we analyzed the
isolated hCA-dmPyl131 protein that was generated in the pres-
ence of d-ornithine and observed the correct molecular weight
for dmPyl incorporation (G131!dmPyl131; see Figure 8 in the
Supporting Information). In summary the data show that our
Pyl biosynthesis cluster containing E. coli cells produced an
hCA protein variant with a G131!ePyl131 mutation.
To demonstrate that the ePyl amino acid can be further ma-
nipulated inside a protein we next employed two orthogonal
chemical modification reactions. We first used the chemistry
developed by Geierstanger and co-workers[13] to form a tertiary
amine adduct by site-specific reaction at the pyrroline ring
structure of Pyl with 2-aminobenzaldehyde (ABA) derivatives.
We treated to this end the ePyl-containing hCA with a biotiny-
lated 2-aminobenzaldehyde derivative 10 shown in Figure 3c.
The reagent was added to the hCA-ePyl131 protein solution
and the protein was analyzed after 16 h reaction at room tem-
perature by gel electrophoresis. Full conversion of the hCA-
ePyl131 protein was observed based on migration differences
of the labeled protein. The biotinylation of hCA-ePyl131 was
verified in a Western blot using an anti-biotin antibody (Fig-
ure 3d).
Next, we studied the ability to click-react the alkyne unit by
CuI-catalyzed reaction (CuAAC) with 7-hydroxycoumarin azide
(11), which turns fluorescent after cycloaddition.[14] Indeed,
after treating the protein at room temperature for 16 h at
pH 7.4 the product protein showed the expected blue fluores-
cence (Figure 3d). Tryptic digestion and LC-MS/MS analysis al-
Figure 3. Site-specific incorporation of ePyl in hCA and orthogonal double labeling. a) Deconvoluted intact mass spectrum of hCA-ePyl131. Detected protein
species: [M]: 29272.05 Da (calcd. : 29272.03 Da; relative abundance 20%), [MˇH2O]: 29254.00 (calcd. : 29254.02 Da; relative abundance 100%). b) Identification
of ePyl peptide fragment after tryptic digestion: hCA sequence coverage of 88.03%. MS/MS spectra of peptide fragment YGDFXK: (X=ePyl). Identified a- and
b-ions are marked in red, identified x- and y-ions are marked in blue. Parent ion: [M+2H]2+obs.=438.71616 (DM=ˇ0.01 ppm). c) Scheme of the single and/or
double ePyl modification reaction with either azide 11 or the 2-aminobenzaldehyde reagent 10 or using both. d) Labeling of hCA-ePyl131. Protein bands
were visualized for all samples after SDS-PAGE by fluorescence measurement. After transfer to a nitrocellulose membrane a PonceauS staining followed by
Western Blot using an anti-biotin-HRP conjugate and chemiluminescent readout was performed.
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lowed us to unambiguously identify the coumarin-labeled pro-
tein (see Figure 9 in the Supporting Information).
Finally, we investigated if the ePyl amino acid can be used
for double labeling. To this end the hCA-ePyl131 protein was
first treated with azide 11 (2 h, RT, pH 7.4) and subsequently re-
acted with the biotinylated 2-aminobenzaldehyde 10 (14 h, RT,
pH 7.4). The obtained product protein showed blue fluores-
cence and presence of the inserted biotin label was proven by
immunostaining with the anti-biotin antibody. Further LC-MS/
MS analysis provided additional support for the successful
double labeling of the hCA protein (Figure 3d, see Figure 10 in
the Supporting Information).
In summary we generated an E. coli expressions system
which is able to biosynthesize an unnatural amino acid. This
biosynthesis can be orchestrated with methods that allow the
incorporation of the resulting unnatural amino acid into pro-
teins by amber suppression. In this particular case we inserted
an alkyne-modified pyrrolysine amino acid which is amenable
to two different orthogonal click reactions at one amino acid
providing access to highly modified proteins.
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Genetically designed biomolecular capping
system for mesoporous silica nanoparticles
enables receptor-mediated cell uptake and
controlled drug release†
Stefan Datz,a Christian Argyo,a Michael Gattner,a Veronika Weiss,a
Korbinian Brunner,a Johanna Bretzler,a Constantin von Schirnding,a
Adriano A. Torrano,a Fabio Spada,a Milan Vrabel,b Hanna Engelke,a
Christoph Bräuchle,a Thomas Carella and Thomas Bein*a
Eﬀective and controlled drug delivery systems with on-demand release and targeting abilities have
received enormous attention for biomedical applications. Here, we describe a novel enzyme-based cap
system for mesoporous silica nanoparticles (MSNs) that is directly combined with a targeting ligand via
bio-orthogonal click chemistry. The capping system is based on the pH-responsive binding of an aryl-
sulfonamide-functionalized MSN and the enzyme carbonic anhydrase (CA). An unnatural amino acid (UAA)
containing a norbornene moiety was genetically incorporated into CA. This UAA allowed for the site-
speciﬁc bio-orthogonal attachment of even very sensitive targeting ligands such as folic acid and anand-
amide. This leads to speciﬁc receptor-mediated cell and stem cell uptake. We demonstrate the successful
delivery and release of the chemotherapeutic agent Actinomycin D to KB cells. This novel nanocarrier
concept provides a promising platform for the development of precisely controllable and highly modular
theranostic systems.
Introduction
The development of eﬀective systems for targeted drug delivery
combined with on demand release behavior can be considered
one of the grand challenges in nanoscience. In particular,
porous nanocarriers with high drug loading capacity, immuno-
logical stealth behavior and tunable surface properties are
promising candidates for biomedical applications such as
cancer therapy and bioimaging.1–5 Specifically, multifunc-
tional mesoporous silica nanoparticles (MSNs) have great
potential in drug delivery applications due to their attractive
porosity parameters and the possibility to conjugate release
mechanisms for diverse cargos6,7 including gold nano-
particles,8,9 iron oxide nanocrystals,10 bio-macromolecules,11,12
enzymes,13 and polymers.14 Control over a stimuli-responsive
cargo release can be achieved via diﬀerent trigger mechanisms
such as redox reactions,15 pH changes,16 light-activation,6,17 or
change in temperature.7 Drug delivery vehicles equipped with
acid-sensitive capping mechanisms are highly desirable for
acidified target environments such as the transition from early
to late endosomes, tumors, or inflammatory tissues.
Here, we present genetically designed enzyme-capped
MSNs that combine two important prerequisites for advances
in drug delivery, namely stimuli-responsive drug release and
specific cell targeting (Scheme 1). Specifically, these pH-
responsive MSNs consist of a capping structure based on
carbonic anhydrase (CA). CA is a model enzyme abundant in
humans and animals and generally catalyzes the hydration of
carbon dioxide and the dehydration of bicarbonate.18 It is
attached to the silica nanoparticle surface via aryl sulfonamide
groups. Acting as inhibitors, sulfonamide groups strongly
bind to the active site of the CA. This enzyme-sulfonamide
binding is reversible depending on the pH, where an acidic
medium causes protonation of the sulfonamide, resulting in
cleavage of the coordination bond and access to the porous
system.19 The CA gatekeepers were used to exploit the
†Electronic supplementary information (ESI) available: Experimental details,
further characterization of functionalized MSNs, synthesis of anandamide–
tetrazine, results of additional cell studies, dose-dependent MTT assay. See DOI:
10.1039/c5nr08163g
aDepartment of Chemistry, Nanosystems Initiative Munich (NIM), Center for Nano
Science (CeNS), and Center for Integrated Protein Science Munich (CIPSM),
University of Munich (LMU), Butenandtstr. 5-13, 81377 Munich, Germany.
E-mail: bein@lmu.de
bInstitute of Organic Chemistry and Biochemistry, Academy of Sciences of the
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endosomal pH change as an internal cellular trigger and to
gain control over the release of cargo molecules from the
mesoporous system.
This stimuli-responsive capping system on MSNs was com-
bined with cell targeting specificity via a bio-orthogonal click
chemistry approach. Targeting ligands provide specific
binding to certain cell membrane receptors allowing for an
enhanced and distinctive cellular uptake of such modified
nanocarriers. For example, various cell receptors are over-
expressed on cancer cells, which can lead to a preferential
receptor-mediated endocytosis of modified MSNs. For the
attachment of such targeting ligands exclusively to the outer
periphery of the enzyme gatekeepers, we exploited a recently
developed method that takes advantage of the pyrrolysine
amber suppression system followed by bio-orthogonal copper-
free click chemistry.20–22 This system has already been utilized
in applications such as optical gene control.23 To the best of
our knowledge, this is the first time the pyrrolysine amber sup-
pression system is used in a combination with porous nano-
carriers for specific cell recognition and drug delivery. The
incorporation of an unnatural amino acid (UAA) containing a
norbornene moiety into CA provides a bio-orthogonal reaction
pathway by covalently attaching tetrazine-modified targeting
ligands.24,25 It has recently been demonstrated that norborn-
ene–tetrazine click chemistry is a favorable synthesis strategy
over various other methods including thiol–maleimide reac-
tion and amide formation due to extremely mild and bio-
compatible reaction conditions and higher selectivity.26 Here,
copper-free click chemistry of norbornene-modified human
carbonic anhydrase II with targeting ligands was performed to
prepare folate- and anandamide-modified multifunctional
mesoporous silica nanocarriers.27 The anandamide is, due to
the cis-configured double bonds, a particularly sensitive recep-
tor ligand that requires extremely mild coupling conditions.
The targeting system based on folate-modified silica nano-
carriers was studied on KB cancer cells, which are known to
overexpress the folate receptor FR-α.6,28 The targeting system
based on anandamide-modified particles was tested on neural
stem cells and A431 cells. The combination of on-demand
release and specific receptor-mediated cell uptake properties
within one multifunctional mesoporous silica nanocarrier
system, containing biomolecular valves based on carbonic
anhydrase, is anticipated to oﬀer promising potential for con-
trolled drug delivery applications including cancer therapy.
Experimental part
Synthesis of thiol-functionalized MSNs (MSN-SH)
A mixture of TEOS (1.92 g, 9.22 mol) and TEA (14.3 g,
95.6 mmol) was heated to 90 °C for 20 min under static con-
ditions in a polypropylene reactor. Then, a preheated (60 °C)
mixture of CTAC (2.41 mL, 1.83 mmol, 25% in H2O) and NH4F
(100 mg, 0.37 mmol) in bidistilled H2O (21.7 g, 1.21 mol) was
added and the resulting reaction mixture was stirred vigorously
(700 rpm) for 30 min while cooling down to room temperature.
Afterwards, TEOS (18.2 mg, 92 µmol) and MPTES (18.1 mg,
92 µmol) were premixed briefly before addition to the reaction
mixture. The final reaction mixture was stirred over night at
room temperature. After dilution with absolute ethanol
Scheme 1 Schematic illustration of the genetically designed biomolecular pore gating system providing a pH-responsive drug release from meso-
porous silica nanoparticles (MSNs). Aryl sulfonamide functionalized MSNs oﬀer pH-dependent reversible attachment of the bulky enzyme carbonic
anhydrase, which eﬃciently blocks the pore entrances to prevent premature cargo release. Furthermore, speciﬁc cancer cell targeting can be
achieved via site-speciﬁc modiﬁcation of a genetically incorporated norbornene amino acid in the biomolecular gatekeepers.
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(100 mL), the nanoparticles were collected by centrifugation
(19 000 rpm, 43 146 rcf, 20 min) and redispersed in absolute
ethanol. Template extraction was performed in an ethanolic
solution of MSNs (100 mL) containing NH4NO3 (2 g) which
was heated at reflux conditions (90 °C oil bath) for 45 min.
This was followed by a second extraction step (90 mL absolute
ethanol and 10 mL hydrochloric acid (37%)) under reflux con-
ditions for 45 min (the material was washed with absolute
ethanol after each extraction step and collected by centrifu-
gation); finally the particles were redispersed in absolute
ethanol and stored as colloidal suspension.
Synthesis of sulfonamide-functionalized MSNs (MSN-phSA)
For the covalent attachment of a sulfonamide derivative to the
external particle surface, a thiol-reactive linker was syn-
thesized. 6-Maleimidohexanoic acid N-hydroxysuccinimide
ester (mal-C6-NHS, 10 mg, 33 µmol) was dissolved in DMF
(500 µL, dry) and was added to an ethanolic solution (15 mL)
containing 4-(2-aminoethyl)benzene sulfonamide (6.7 mg,
33 µmol). The resulting reaction mixture was stirred for 1 h at
room temperature. Afterwards, thiol-functionalized silica
nanoparticles (MSN-SH, 100 mg) in absolute ethanol (10 mL)
were added and the mixture was stirred over night at room
temperature. Subsequently, the particles were collected by cen-
trifugation (19 000 rpm, 41 146 rcf, 20 min), washed twice with
absolute ethanol and were finally redispersed in ethanol
(15 mL) to obtain a colloidal suspension.
Cargo loading and particle capping
MSNs (MSN-phSA, 1 mg) were immersed in an aqueous solu-
tion of fluorescein (1 mL, 1 mM), DAPI (500 µL, 14.3 mM) or
Actinomycin D (500 µL [14 v% DMSO], 140 µM) and stirred
over night or for 1 h, respectively. After collection by centrifu-
gation (14 000 rpm, 16 837 rcf, 4 min), the loaded particles
were redispersed in a HBSS buﬀer solution (1 mL) containing
carbonic anhydrase (1 mg) and the resulting mixture was
allowed to react for 1 h at room temperature under static con-
ditions. The particles were thoroughly washed with HBSS
buﬀer (4 times), collected by centrifugation (5000 rpm, 2200
rcf, 4 min, 15 °C), and finally redispersed in HBSS buﬀered
solution.
Click chemistry of norbornene-containing hCA
MSNs (MSN-phSA, 0.5 mg) were immersed in 500 µL HBSS
buﬀer solution and 0.5 mg norbornene-containing hCA was
added. In the meantime, 2.5 µg tetrazine p-benzylamine
(DMSO stock solution, 0.92 mg mL−1) and 0.41 mg
NHS-PEG2000-FA were mixed in 100 µL HBSS and stirred over-
night in the dark at room temperature. The solutions were
mixed afterwards and stirred for two hours, washed several
times and redispersed in 1 mL HBSS buﬀer. Subsequently,
1 µL Atto633mal (DMF stock solution, 0.5 mg mL−1) was
added and the mixture was stirred for 1 hour. The particles
were thoroughly washed with HBSS buﬀer (4 times), collected
by centrifugation (5000 rpm, 2200 rcf, 4 min, 15 °C), and
finally redispersed in HBSS buﬀered solution.
Synthesis of Knorb
The norbornene containing amino acid Knorb was synthesized
as described in ref. 29.
Mutagenesis of pACA_HCA H36amber
Adapted from ref. 30 with permission from The Royal Society
of Chemistry. The amber codon (TAG) was introduced into the
expression vector pACA_HCA31 at position His36 of the human
carbonic anhydrase II gene by blunt end site directed muta-
genesis using the primers forward HCA H36amber and reverse
HCA H36amber (see Table 1).
Expression of norbornene-containing HCA
Adapted from ref. 30 with permission from The Royal Society
of Chemistry. The expression vector pACA_HCA H36amber
was transformed together with pACyc_pylRS Norb, 3xpylT29
which contains the genes of the triple mutant of PylRS and
three copies of pylT in E. coli BL21(DE3) cells (NEB). 1 L of LB
medium containing 34 mg L−1 chloramphenicol, 100 mg L−1
carbenicillin and 2 mM norbornene amino acid Knorb was
inoculated with 10 mL of an overnight culture. The cells were
stirred at 37 °C until an OD600 of 0.9. At this optical density
1 mM ZnSO4 and 0.1 mM IPTG were added to induce the
expression of the HCA H36amber gene. After further 10 h at
37 °C the cells were harvested and stored at −20 °C until
further use. The harvested cells were resuspended in washing
buﬀer (25 mM tris; 50 mM Na2SO4; 50 mM NaClO4; pH 8.8)
and disrupted by French Press procedure. The supernatant of
the centrifuged lysate was used for sulfonamide aﬃnity
protein purification using an ÄKTA purifier system. The self-
packed 3 mL column of p-aminomethylbenzenesulfonamide–
agarose resin (Sigma-Aldrich, A0796) was equilibrated with
washing buﬀer. After binding (0.75 mL min−1) of the protein
solution, the column was washed with 7 column volumes of
washing buﬀer. HCA was eluted by lowering the pH by elution
buﬀer (100 mM NaOAc; 200 mM NaClO4; pH 5.6). The protein
containing fractions were combined, analyzed by SDS-PAGE,
dialyzed against water and lyophilized. Typical yields of the
pure norbornene amino acid Knorb containing protein HCA
H36Knorb were 20 mg L−1 expression medium.
Tryptic digestion and MS/MS of norbornene-containing HCA
Adapted from ref. 30 with permission from The Royal Society
of Chemistry. The sequence of HCA II is shown in Table 2.
Table 1 Sequences of the used primers for the generation of
expression vector pACA_HCA H36amber. The introduced Amber codon
is shown in bold
Name Sequence
Forward HCA H36amber 5′phosph GTT GAC ATC GAC ACT
TAG ACA GCC AAG TAT GAC
Reverse HCA H36amber 5′phosph AGG GGA CTG GCG CTC
TCC CTT GG
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Position His36, which was chosen for the incorporation of
amino acid Knorb, is shown in red. The peptide generated
after tryptic digestion is emphasized in bold letters. Fig. 1
shows the corresponding MS/MS spectrum. Table 3 shows the
expected and identified MS/MS fragments of the relevant
tryptic peptide.
Cell culture
HeLa and A431 cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) : F12 (1 : 1) (lifeTechnologies) with
Glutamax I medium and KB cells in folic acid deficient Roswell
Park Memorial Institute 1640 medium (RPMI 1640, lifeTechnol-
ogies), both supplemented with 10% fetal bovine serum
(FBS) at 37 °C in a 5% CO2 humidified atmosphere. The cells
were seeded on collagen A-coated LabTek chambered cover
glass (Nunc). For live cell imaging the cells were seeded 24 or
48 h before measuring, at a cell density of 2 × 104 or 1 × 104
cells per cm2.
The FGF-2 and EGF dependant neural stem cell line ENC1
was derived from E14 mouse embryonic stem cells and cul-
tured as described.32 ENC1 cells were maintained in gelatine
coated flasks and propagated in a 1 : 1 mixture of Knockout-
DMEM (Life Technologies) and Ham’s F-12 (Sigma) sup-
plemented with 2 mM GlutaMAX-I (Life Technologies), 100 U ml−1
penicillin (Sigma), 100 μg ml−1 streptomycin (Sigma) 1%
N2 and 20 ng ml−1 each of mouse recombinant FGF-2 and
EGF (Peprotech). N2 supplement was produced in house as
described, with the exception that insulin was of human origin
(Sigma I9278) instead of bovine. Stem cells and A431 cells were
seeded on ibidi 8-well µ-slides.
In vitro cargo release
Cells were incubated 7–24 h prior to the measurements at
37 °C under a 5% CO2 humidified atmosphere. Shortly before
imaging, the medium was replaced by CO2-independent
medium (Invitrogen). During the measurements all cells were
kept on a heated microscope stage at 37 °C. The subsequent
imaging was performed as described in the spinning disk con-
focal microscopy section.
Table 2 Amino acid sequence of HCA II
Fig. 1 MS/MS spectrum of the tryptic peptide QSPVDIDTXTAK (X = 4). Parent ion: [M + 2H]2+calc. = 726.8829, [M + 2H]
2+
obs. = 726.8807 (ΔM =
3 ppm).
Table 3 Expected and identiﬁed MS/MS fragments of the tryptic
peptide QSPVDIDTXTAK (X = Knorb). Identiﬁed fragments are shown in
red for b ions and blue for y ions
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Endosomal compartment staining
To stain the early/late endosome or the lysosome with GFP,
commercially available CellLight© staining from lifeTechnolo-
gies was used. The cells were simultaneously incubated with
MSNs and the BacMam 2.0 reagent. The concentration of the
labeling reagent was 25 particles per cell (PCP) of the BacMam
2.0 reagent (cf. staining protocol33). For incubation, the cells
stayed at 37 °C under 5% CO2 humidified atmosphere for
21–24 h before the measurement.
Caspase-3/7 staining
For apoptosis detection commercially available CellEvent™
caspase-3/7 Green Detection Reagent was used. A final concen-
tration of 2.5 µM caspase-3/7 reagent and 0.5 µg mL−1 Hoechst
33342 were added to the cells for 30 min and imaging was per-
formed without further washing steps.
Uptake studies
The functionality of the folic acid targeting ligand was evalu-
ated in a receptor competition experiment. For this purpose,
one part of the KB cells was pre-incubated with 3 mM folic
acid, to block the receptors, for 2 h at 37 °C under a 5% CO2
humidified atmosphere. Then the KB cells were incubated
with particles for 2/5/8 h at 37 °C under a 5% CO2 humidified
atmosphere. For staining the cell membrane, the cells were
incubated with a final concentration of 10 μg mL−1 wheat
germ agglutinin Alexa Fluor 488 conjugate for one minute.
The cells were washed once with CO2-independent medium
and imaged. For stem cell uptake studies cells were seeded the
day prior to incubation. They were incubated for 2 h with free
anandamide–tetrazine at a final concentration of 10 µg ml−1.
After 2 h 15 µg of particles were added and incubated for
another 2 h. Then, the cells were washed 3× with medium con-
taining growth factors and if preincubated free anandamide–
tetrazine and incubated until imaging. Immediately before
imaging, cell membranes were stained using cell mask deep
red (lifetechnologies) and washed with medium.
Spinning disc confocal microscopy
Confocal microscopy for live-cell imaging was performed on a
setup based on the Zeiss Cell Observer SD utilizing a Yokogawa
spinning disk unit CSU-X1. The system was equipped with a
1.40 NA 100× Plan apochromat oil immersion objective or a
0.45 NA 10× air objective from Zeiss. For all experiments the
exposure time was 0.1 s and z-stacks were recorded. DAPI and
Hoechst 33342 were imaged with approximately 0.16 W mm−2
of 405 nm light, GFP and the caspase-3/7 reagent were imaged
with approximately 0.48 W mm−2 of 488 nm excitation light.
Atto 633 was excited with 11 mW mm−2 of 639 nm light. In the
excitation path a quad-edge dichroic beamsplitter (FF410/504/
582/669-Di01-25 × 36, Semrock) was used. For two color detec-
tion of GFP/caspase-3/7 reagent or DAPI/Hoechst 33342 and
Atto 633, a dichroic mirror (560 nm, Semrock) and band-pass
filters 525/50 and 690/60 (both Semrock) were used in the
detection path. Separate images for each fluorescence channel
were acquired using two separate electron multiplier charge
coupled device (EMCCD) cameras (PhotometricsEvolve™).
Results and discussion
pH-Responsive MSNs with an average particle size of 150 nm
(average pore diameter: 3.8 nm) containing biomolecular
valves based on the enzyme carbonic anhydrase (CA, hydro-
dynamic diameter: 5.5 nm) were synthesized via a delayed co-
condensation approach.34 An outer functional shell consisting of
benzene sulfonamide groups (pHSA) acts as an anchor point
for the enzymatic gatekeepers. The formation of the inhibitor–
enzyme complex (phSA-CA) leads to a dense coating at the
external particle surface (MSN-phSA-CA). The characterization
of the particle system by dynamic light scattering (DLS), zeta
potential measurements, transmission electron microscopy
(TEM), nitrogen sorption isotherms, infrared and Raman spectro-
scopy confirms the successful synthesis of carbonic anhydrase-
coated MSNs. In vial release experiments demonstrate
eﬃcient sealing of the pores with carbonic anhydrase acting as
a bulky gatekeeper, preventing premature cargo release and
allowing for release upon acid-induced detachment of the
capping system (for detailed information about synthesis and
characterization see ESI†).
In order to investigate the pH-responsive removal of the
bulky gatekeepers from the particles, in vial cargo release experi-
ments were performed. We used a custom-made two-compart-
ment system to analyze the time-based release of the
fluorescent model cargo fluorescein.12 After incorporation of
fluorescein molecules into the mesoporous system, carbonic
anhydrase was added to block the pore entrances. An eﬃcient
sealing of the pores and no premature release of the cargo was
observed for the sample MSN-phSA-CA dispersed in HBSS
buﬀer (pH 7.4) at 37 °C (Fig. 2a, closed state, black curve). After
3 h the solution was exchanged and the particles were dispersed
in citric-acid phosphate buﬀer (CAP buﬀer, pH 5.5). The change
to acidic milieu, which simulates the acidification of endo-
somes, causes a significant increase in fluorescence intensity
over time (open state, red curve). Furthermore, we could show
the long-term stability of the capping system for more than
16 hours in HBSS buﬀer and cell medium at pH 7.4 (Fig. 2b).
These in vial release experiments demonstrate eﬃcient sealing
of the pores with carbonic anhydrase acting as a bulky gate-
keeper, preventing premature cargo release and allowing for
release upon acid-induced detachment of the capping system.
For eﬃcient receptor-mediated cancer cell uptake and selec-
tive drug delivery a targeting ligand needs to be implemented.
Since the particle surface is covered with bulky enzymes (CA),
we aimed for the attachment of the targeting moieties directly
to the outer periphery of the enzyme, in order to be accessible
for cell receptors. For this approach to be successful, the site
of targeting ligand attachment on the enzyme is of key impor-
tance. Ideally it should be positioned opposite of the binding
site of the enzyme, to prevent blocking of the active site and
thus leakage of the capping system. However, site-specific
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chemical modifications of proteins are highly challenging.
Several methods, such as the reaction of thiol groups with male-
imide or of lysine chains with activated esters, lack specificity.
A more specific method is the incorporation of unnatural
amino acids into the protein.20,35,36 Among others, the genetic
incorporation of UAAs bearing side chains with alkyne,37,38
trans-cyclooctene,39 cyclooctyne40 or norbornene20,24 function-
alities has been reported previously. Subsequently these resi-
dues can be modified specifically and bio-orthogonally, for
example by reverse electron-demanding Diels–Alder reactions
with tetrazines.25,26,39 The natural PylRS/tRNAPyl pair is
perfectly suitable to genetically incorporate UAAs due to its
orthogonality to common expression strains. Recently, a
norbornene-containing Pyl analogue (Knorb) has been deve-
loped by some of us.20,21 Here, the synthesis of norbornene-
functionalized human carbonic anhydrase II (HCA) was
accomplished similar to a previously described procedure
yielding HCA H36Knorb.41 The correct position of the UAA was
confirmed by tryptic digestion of the protein followed by
HPLC-MS/MS analysis (see ESI†). HCA H36Knorb carrying nor-
bornene on the opposite face of its phSA-binding site was
bound to phSA-MSN and then treated with an excess of folate–
PEG2000–tetrazine (Fig. 3) or anandamide–tetrazine. The excess
of the tetrazine reagent could be easily removed by centrifu-
gation of the nanoparticles followed by washing. The eﬃciency
of the folate-targeting system was examined on KB-cells pre-
senting either free or blocked FA-receptors (Fig. 3). For visual-
ization, the cell membrane of the KB cells was stained with
WGA488 (green), and the particles were labeled with Atto633
(red). In Fig. 3c–e we present the folic acid receptor blocked
cells that were incubated with particles between 2 and 8 h.
With increasing incubation time, only a few particles were
internalized and unspecific cell uptake was observed only to a
minor degree. In contrast, the cells with available folic acid
receptor on their surface (Fig. 3f–h) exhibit a significant and
increasing uptake behavior and a considerably higher degree
of internalized particles. Thus we could confirm the successful
application of bioorthogonal modification of a capping
enzyme to act as targeting ligand. We also proved that the
genetically modified enzyme capping strategy described here
can be used to attach even sensitive ligands like arachidonic
acid via mild click-chemistry conditions, e.g. for the site-
specific targeting of neural stem cells and diﬀerent cancer
cells.32 We tested the anandamide-targeting system on neural
stem cells and A431 cells. Neural stem cells have anandamide
receptors and successfully internalize the anandamide-
particles (see ESI, Fig. S9†). A431 cells (epidermoid carcinoma)
are also known to over-express the G-protein coupled cannabi-
noid-based receptor CB2. These receptors can interact with
anandamide-functionalized MSNs. Similar to the folate-based
targeting experiment, the cannabinoid receptors on the A431
cells were either blocked or free. After 3 h of incubation the
receptor-blocked cells internalized just a few anandamide-
functionalized MSNs. In contrast, the amount of intracellular
particles is clearly much larger in the case of non-blocked can-
nabinoid receptors (Fig. S10†). The successful experiments
with diﬀerent cell lines and targeting ligands show that the
investigated bio-orthogonal attachment concept could be
expanded to a variety of enzymes and ligands.
Employing fluorescent live-cell imaging, we investigated the
in vitro release behavior of encapsulated 4′,6-diamidino-2-
phenylindole (DAPI) in HeLa cancer cells. The molecular size
of DAPI is similar to fluorescein. It was therefore expected to
eﬃciently enter the mesoporous system of the silica nano-
particle. Due to its eﬀective turn-on fluorescence upon inter-
calation into DNA double strands, DAPI is commonly used as
Fig. 2 In vial release kinetics of ﬂuorescein molecules from the enzyme-coated MSNs at diﬀerent pH values. (a) Sample MSN-pSA-CA features no
premature release of the ﬂuorescent cargo molecules in HBSS buﬀer solution at pH 7.4 (closed state, black curve). After 3 h the medium was
changed to slightly acidic milieu (CAP buﬀer, pH 5.5, red curve) resulting in a signiﬁcant increase in ﬂuorescence intensity. The gatekeepers are
detached from the particle surface upon acidiﬁcation, causing an eﬃcient and precisely controllable release of ﬂuorescein from the mesoporous
system. (b) Long-term stability of the capping system was investigated in HBSS buﬀer (pH 7.4, black curve) and cell medium (blue curve). No un-
intended cargo release was observed within about 16 h.
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nuclei counterstain in cell imaging (about 20 fold enhance-
ment in fluorescence intensity).42 Since DAPI is cell membrane
permeable, free fluorescent dye molecules are able to stain the
nucleus within very short time periods (1–5 min), as described
in several staining protocols.43 After incorporation of DAPI
into the mesoporous system of the silica nanocarriers, the
pores were sealed by addition of carbonic anhydrase. The
HeLa cells were incubated for a total time period of 24 h with
the loaded particles, which were additionally labeled with Atto
633 dye (red), as depicted in Fig. 4. After 7 h of incubation,
MSNs were eﬃciently taken up by the cells and were found to
be located in endosomes. Importantly, almost no staining of
the nuclei with DAPI (blue) could be observed at this time
point. Only after 15 h, blue fluorescence (even more intensive
after 24 h) provided evidence of eﬃciently released DAPI from
the MSNs. Control experiments in which the sample super-
Fig. 3 (a) Norbornene-functionalized carbonic anhydrase (HCA H36Norb) with indicated functionalization site (red) and active site (blue) is able to
react in a reversed-electron-demand Diels–Alder reaction with a folate–PEG2000–tetrazine derivative to give HCA-FA. (b) Schematic receptor-
mediated uptake of folate-functionalized MSN-CA nanoparticles. (c–e) Nonspeciﬁc and (f–h) receptor-mediated endocytosis of MSN-phSA-CA-FA
(red) by KB cells (WGA488 membrane staining, green). A speciﬁc receptor-mediated cell uptake was observed for MSN-phSA-CA-FA with KB cells
(not pre-incubated with FA) after 5 and 8 h incubation at 37 °C (g/h). Incubation of MSN-phSA-CA-FA with FA-pre-incubated KB cells for 2, 5, 8 h at
37 °C showed only minor unspeciﬁc cellular uptake over all incubation times (c–e). The scale bar represents 10 μm.
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natant after particle separation (centrifugation) was added to
the HeLa cells showed no significant nuclei staining even
after 24 h (Fig. 4d). These cell experiments prove a substantial
time-dependent release of DAPI from the mesopores of our
nanocarrier system and also show that no free dye molecules
were present in the solution. We suggest that the observed
delayed nuclei staining results from a cascaded release mecha-
nism. First, acidification throughout the endosomal pathway
Fig. 4 Fluorescence microscopy of HeLa cells incubated with MSN-phSA-CA nanoparticles loaded with DAPI and labeled with Atto 633 (red) after (a) 7 h, (b)
12 h and (c) 24 h of incubation. The delayed nuclei staining with DAPI (blue) is caused by a time-dependent release of DAPI based on the need for an acidic
environment. (d) In a control experiment, the incubation with the supernatant solution (without MSNs) showed no staining of the nuclei with DAPI after 24 h,
suggesting that no free DAPI molecules were present in the particle solution. The nuclei are indicated with dashed circles. The scale bar represents 10 µm.
Fig. 5 Representative ﬂuorescence microscopy images of HeLa cells incubated with MSN-phSA-CA nanoparticles loaded with Actinomycin D
(AmD; a–d) or DMSO (e–h) and labeled with Atto 633 (red) after 24 h of incubation. As a control, the supernatant of AmD loaded particles after par-
ticle separation was incubated with the cells (i–l). Cell nuclei were stained with Hoechst 33342 (blue). For live/dead discrimination CellEvent caspase
3/7 (green) was used. Due to activation of caspase-3/7 in apoptotic cells, DNA can be stained after cleavage of the DNA-binding dye from a binding-
inhibiting peptide. MSNs were eﬃciently taken up by cells (c/d and g/h). Cell death can only be observed for cells treated with AmD loaded MSN-
phSA-CA after 24 h of incubation (increased DNA staining in green) (b). In contrast, nanoparticles loaded with DMSO or the sample supernatant do
not induce signiﬁcant apoptosis (almost no DNA-staining) (f and j). The scale bars represent 50 µm.
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to late endosomes or endolysosomes is of key importance.
Only the pH change to mildly acidic values (about 5.5) makes
the detachment of the bulky gatekeepers from the MSN hosts
possible. Subsequent opening of the pores leads to an eﬃcient
cargo release.
Additional co-localization experiments showed the localiz-
ation of CA-capped nanoparticles in acidic cell compartments
after endocytosis (Fig. S8†). To examine the ability of our newly
developed MSN drug delivery system to transport chemothera-
peutics and to aﬀect cells with their cargo, we incorporated
Actinomycin D (AmD), a cytostatic antibiotic, dissolved in
DMSO. Free AmD is membrane permeable and induces an
uncontrolled cell death within a few hours. MSN-phSA-CA pro-
vided intracellular AmD release and caused eﬃcient cell death
after 24 h. The delayed reaction demonstrates that AmD was
delivered in a controlled manner via the particles and released
only after acidification of the endosome and subsequent de-
capping of the gate-keeper CA. In Fig. 5 cell death is visualized
by a caspase 3/7 stain – a marker for apoptotic/dead cells.
Control particles loaded with pure DMSO did not induce sig-
nificant cell death at all, nor did the supernatant solution after
particle separation via centrifugation (Fig. 5i–l). The results are
in good accordance with dose-dependent cell viability studies
(Fig. S11†) where the AmD-loaded particles killed HeLa cells
eﬀectively after 24 h of incubation (IC50,rel = 8.3 µg mL
−1). This
experiment shows the great potential of the MSN-phSA-CA
system to eﬃciently deliver chemotherapeutics to cancer cells.
The pH-responsive genetically modified capping system pro-
vides the ability to act as a general platform for diﬀerent tar-
geting ligands and cargos.
Conclusions
We conclude that the novel capping system concept based on
pH-responsive detachment of carbonic anhydrase combined
with folic acid as targeting ligand allows for highly controllable
drug release from porous nanocarriers. Our drug delivery
system provides an on-demand release mechanism shown by
in vial and in vitro cargo release experiments. The multifunc-
tional MSNs were eﬃciently endocytosed in cancer cells and
could be located in acidic cell compartments where they
released their cargo. Furthermore, the system has an on-board
targeting mechanism as demonstrated in additional in vitro
experiments. The targeting mechanism is attached at a specific
site of the capping enzyme preventing interference with the
closure mechanism. Our newly developed pH-responsive gate-
keepers with genetically designed targeting functions provide
a promising platform for the design of versatile and modular
drug delivery systems.
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9.1 Selected supplementary information corresponding to section 7.1 
 
Synthesis of ε-N-propionyl-, ε-N-butyryl-, and ε-N-crotonyl-lysine 
containing histone H3 using the pyrrolysine system 
 
Pages 8-26 and 30 of the supplementary information of the corresponding original 
publication are shown since they contain methods and data generated by the author of 
this thesis. 
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3 Cloning and mutagenesis 
 
3.1 pETDuet_yfpTAG, pylS,T 
 
The cloning procedure of pETDuet_yfpTAG is described in the supporting information of an 
earlier publication of our group
[1]
. In brief, M. mazei pylS and pylT were inserted into the first 
multiple cloning site using the restriction sites BamHI/NotI and NotI/AflII, respectively. The 
gene encoding for the C-terminally StrepII-tagged eYFP Lys114Amber was inserted into the 
second multiple cloning site using the restriction sites NdeI/KpnI. In contrast to the 
previously published construct, the first T7-promoter was not replaced by a Trp-promoter 
and three copies of the pylT gene were inserted instead of one. 
 
3.2 pACyc_3xpylT, pylS 
 
The Methanosarcina mazei pylS gene was digested using the restriction enzymes ApaLI and 
NotI. The 2.2 kb fragment was inserted into pACYC-Duet1 (Novagen) using the same sites. 
The following custom designed DNA-fragment (GeneArt) encoding for the E.coli pGLN-
promoter and a Shine Dalgarno sequence was inserted into this plasmid using the restriction 
sites ClaI/NcoI: 5’-TCATCAATCATCCCCATAATCCTTGTTAGATT 
ATCAATTTTAAAAAACTAACAGTTGTCAGCCTGTCCCGCTTATAATATCATACGCCGTTATACGTTGTT
TACGCTTTGAGGAAGCC-3’. The resulting construct pACYC-pGLN was subsequently digested 
with NotI and PacI to insert a custom designed DNA-fragment (GeneArt) encoding for three 
copies of pylT, which are flanked by the E.coli proK promoter and terminator, respectively. 
Sequence of this fragment is as follows, with the proK-promoter and -terminator highlighted 
in bold letters, and pylT being underlined: 5’-
GCGGCCTGCTGACTTTCTCGCCGATCAAAAGGCATTTTGCTATTAAGGGATTGACGAGGGCGTATCT
GCGCAGTAAGATGCGCCCCGCATTGGAAACCTGATCATGTAGATCGAATGGACTCTAAATCCGTTCA
GCCGGGTTAGATTCCCGGGGTTTCCGCCATACATGTTATGGAAACCTGATCATGTAGATCGAATGGA
CTCTAAATCCGTTCAGCCGGGTTAGATTCCCGGGGTTTCCGCCATACATGTTATGGAAACCTGATCAT
GTAGATCGAATGGACTCTAAATCCGTTCAGCCGGGTTAGATTCCCGGGGTTTCCGCCAAATTCGAAA
AGCCTGCTCAACGAGCAGGCTTTTTTGCCTTAAG-3’.  
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3.3 pPSG IBA3_trxA N65amber 
 
The modified E. coli gene trxA was cloned by using the IBA Stargate System into pPSG IBA3. 
The gene was amplified from the vector pBAD202 (Invitrogen) by using the following 
primers: 
Forward: AGCGGCTCTTC AATG GGA TCT GAT AAA ATT ATT CAT CTG ACT GAT G 
Reverse: AGCGGCTCTTC TCCC CAG GTT AGC GTC GAG GAA CTC TTT C 
The PCR-product was inserted into the entry vector IBA51 following the manual of IBA. A 
second cloning step transferred the gene into the destination vector pPSG IBA3. This vector 
contains an IPTG inducible T7 promotor and a C-terminal Strep-Tag. 
The amber codon at position N65 was inserted by blunt-eŶd ŵutageŶesis, usiŶg the 5’-
phosphorylated primers: 
Forward: CCG GGC ACT GCG CCG AAA TAT G 
Reverse: CTA GTG ATC GAT GTT CAG TTT TGC AAC GG 
 
3.4 pPSG IBA35_h3 K9amber 
 
The human synthetic gene h3, coding for the histone H3.3 was delivered by GeneArt, codon 
optimized for expression in E. coli. The gene was amplified by using the following primers: 
Forward: AGCGGCTCTTC AATG GCA CGT ACC AAA CAG ACC GCA CGT AAA AG 
Forward (+TAG): AGCGGCTCTTC AATG GCA CGT ACC AAA CAG ACC GCA CGT TAG AGC ACC G 
Reverse: AGCGGCTCTTC TCCC TGC ACG TTC ACC ACG AAT ACG ACG TGC 
The PCR-product was inserted into the entry vector IBA51 following the manual of IBA. A 
second cloning step transferred the gene into the destination vector pPSG IBA35. This vector 
contains an IPTG inducible T7 promotor and a N-terminal His6-Tag. 
The amber codon at position K9 was inserted by using a modified Forward primer for the 
entry vector generation: 
Forward (+TAG): AGCGGCTCTTC AATG GCA CGT ACC AAA CAG ACC GCA CGT TAG AGC ACC G 
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4 Testing the incorporation of Kpr, Kbu and Kcr into YFP 
 
Four different M. mazei PylRS synthetase variants were tested for their acceptance of the 
modified lysine amino acids: - wt  
- Y306A V401K 
- Y306G Y384F I405R 
- Y306A Y384F 
 
4.1 Expression of YFP K144Kpr, K144Kbu and K144Kcr 
 
E. coli strain BL21(DE3) (NEB) (fhuA2 lacZ::T7 gene1 [lon] ompT gal sulA11 R(mcr-
73::miniTn10--Tet
S
)2 [dcm] R(zgb-210::Tn10--Tet
S
) endA1 Δ(mcrC-mrr)114::IS10) was used 
for the production of Kpr, Kbu or Kcr containing YFP. Cells were grown in 50 mL LB-medium 
containing 5 mM of Kbu or Kcr or 10 mM Kpr (37°C, 220 rpm) and 50 mg/L carbenicillin and 
34 mg/L Chloramphenicol. When OD600=0.6 was reached, expression of yfpTAG was induced 
by addition of 1 mM IPTG. After further 16 h at 30 °C YFP expression was analyzed by 
fluorescence microscopy.  
 
4.2 Detection of YFP K144Kpr, K144Kbu and K144Kcr 
 
The YFP fluorescence was analyzed by microscopy on a TCS SPE spectral confocal microscope 
(Leica) with an inverse stand and the HCX FL APO 63x/140-0.60 oil objective (excitation: 488 
nm). As shown in Fig. S4.1 the best YFP-read through results for all three acylated lysine 
derivatives were obtained with the wt-PylRS. Therefore this variant was used for the 
incorporation of the amino acids into H3. 
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Fig. S4.1. Fluorescence microscopy of E. coli transformed with the pETDuet_YFPK114amber reporter system and addition of 
the three different lysine derivatives Kpr, Kbu and Kcr 
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5 Incorporation of Kcr into TrxA 
5.1 Expression of TrxA N65Kcr 
E. coli strain BL21(DE3) were transformed with pACyc_pylTTT, pylS and 
pPSG IBA3_trxA N65amber. An overnight culture was used for inoculation (to OD600 of 0.1) of 
2L LB medium containing 5mM Kcr, 50 mg/L carbenicillin and 34 mg/L chloramphenicol. Cells 
were grown at 37 °C until an OD600 of 0.6. Expression of trxA N65Kcr was induced by addition 
1 mM IPTG. The cells were shaked for further 16 h at 30 °C. After centrifugation (10.000 x g, 
10 min, 4°C) the cells were stored at -20°C or directly purified.  
 
5.2 Purification of TrxA N65Kcr 
All purification steps were carried out at 4°C. Cells were resuspended in StrepA buffer (10 
mM Tris-HCl pH 8, 1 mM EDTA, 150 mM NaCl) and supplemented with protease inhibitor mix 
(Roche). The cells were lysed using a French press (Thermo Scientific). Cell debris was 
removed by centrifugation (38 000 x g, 30 min, 4 °C) and the supernatant was applied to a 5 
mL Strep-Tactin column (IBA), equilibrated with StrepA buffer. Proteins were eluted from the 
column using the same buffer containing 2.5 mM desthiobiotin. The eluted fractions were 
pooled and concentrated. Typical protein yields of 2 mg per liter expression medium Kcr 
containing TrxA were achieved. Purified TrxA was equilibrated with StrepA buffer, 
concentrated and stored at -80°C.  
 
5.3 Intact MS of TrxA N65Kcr 
The purified intact protein TrxA N65Kcr was analyzed by HPLC-MS. A self-packed nano C4 
column was used for HPLC and mass spectrometry was performed on a LTQ-Orbitrap XL 
mass spectrometer (Thermo). Fig. S5.1 shows the raw mass spectrum. Fig. S5.2 depicts the 
deconvoluted spectrum. The calculated mass of the protein is 13015.9 Da, the observed 
mass is 13013.8 Da. Unspecific deacylation of Kcr was not observed at the intact protein 
level. 
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Fig. S5.1. Raw intact mass spectrum of TrxA N65Kcr. 
 
 
Fig. S5.2. Deconvoluted mass spectrum of TrxA N65Kcr. 
 
5.4 In-Gel chymotryptic digestion of TrxA N65Kcr 
The Coomassie Blue stained SDS-gel was washed twice for 10 min with water (bidest.). 
Protein bands were excised from the gel, cut in small cubes (ca. 1mm
3
) and transferred to 
Eppendorf tubes. The gel slices were washed ďy iŶĐuďatioŶ iŶ ǁateƌ ;ϭϬϬ μLͿ foƌ ϭϱ ŵiŶ at 
RT. Then 50 mM NH4HCO3/aĐetoŶitƌile ;eaĐh ϭϬϬ μL) was added and incubated for additional 
ϭϱ ŵiŶ. All liƋuids ǁeƌe ƌeŵoǀed aŶd the gel Đuďes Đoǀeƌed ǁith aĐetoŶitƌile ;ϭϬϬ μLͿ. Afteƌ 
removal of acetonitrile the gel particles were rehydrated with 50 mM NH4HCO3 ;ϭϬϬ μLͿ foƌ 
ϱ ŵiŶ. This ǁas folloǁed ďy fuƌtheƌ additioŶ of ϭϬϬ μL aĐetoŶitƌile aŶd iŶĐuďatioŶ foƌ ϭϱ ŵiŶ. 
The liƋuids ǁeƌe ƌeŵoǀed aŶd agaiŶ ϭϬϬ μL aĐetoŶitƌile were added to shrink the particles. 
After 5 min all acetonitrile was removed. The gel cubes were dried at RT for 10 min. Protein 
denaturation and reduction were carried out by adding DTT (10 mM in 50 mM NH4HCO3, 100 
μLͿ aŶd iŶĐuďatioŶ foƌ ϰϱ ŵiŶ at ϱϲ °C. The tubes were cooled to RT, all liquids were 
ƌeŵoǀed aŶd alkylatioŶ ǁas peƌfoƌŵed ďy additioŶ of ϭϬϬ μL iodoaĐetaŵide (55 mM in 50 
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mM NH4HCO3) and incubation for 30 min at RT (in the dark). Further washing steps (15 min 
at RT with 50 mM NH4HCO3/aĐetoŶitƌile, eaĐh ϭϬϬ μL, tǁiĐeͿ aŶd additioŶ of acetonitrile 
;ϭϬϬ μLͿ ƌesulted iŶ shƌiŶkage of the gel Đuďes ǁhiĐh ǁas Đoŵpleted ďǇ ƌeŵoǀal of all liƋuids 
and drying in a vacuum centrifuge (10 min). In-gel digestion was carried out by rehydration 
of the gel paƌtiĐles iŶ ϭϬϬ μL Ϯ5 ŵM NH4HCO3 containing 0.5 μg chymotrypsin (Promega) 
and incubation at 37 °C overnight. The supernatant was removed and stored separately. For 
the eǆtƌaĐtioŶ of the peptides the gel paƌtiĐles ǁeƌe ƌesuspeŶded iŶ ϭϬϬ μL Ϯ5 ŵM NH4HCO3 
and sonicated for 15 min before addition of ϭϬϬ μL aĐetoŶitƌile aŶd fuƌtheƌ soŶiĐatioŶ foƌ ϭ5 
min. The supernatant was again removed and stored separately. For quantitative peptide 
extraction the gel slices were further sonicated with 5% formic acid and acetonitrile (each 
ϭϬϬ μL foƌ ϭ5 ŵiŶͿ. FiŶallǇ all peptide solutions were combined and concentrated in a 
vacuum centrifuge. The samples were used for peptide mass analysis after an extended 
centrifugation step (10 min, 13000 rpm). 
 
5.5 HPLC-MS/MS of chymotryptic digestion of TrxA N65Kcr 
For the nano-HPLC ESI mass spectrometry analysis the tryptic digested peptides were loaded 
onto a Dionex C18 Nano Trap Column (100 µm), subsequently eluted and separated by a self 
packed C18-AQ, 3 µm, 120 Å column. The peptide fragments were analyzed by tandem MS 
followed by HR-MS using a coupled Dionex Ultimate 3000 LTQ-Orbitrap XL MS system 
(Thermo). 
The obtained peptide fragment data were analyzed with the SEQUEST algorithm 
iŵpleŵeŶted iŶ the softǁaƌe ͞Proteome discoverer 1.10.263͟ (Thermo) against a peptide 
library of E. coli containing the TrxA variant. The search was limited to chymotryptic 
peptides, two missed cleavage sites, +2 charged monoisotopic precursor ions and a peptide 
tolerance of <10 ppm. Sequence coverage and probability values of the chymotryptic TrxA 
N65Kcr digestion sample is shown in Table S5.1.  
 
Table S5.1. Sequence coverage and probability values of the chymotryptic TrxA N65Kcr digestion. 
Sample Sequence coverage score 
TrxA N65Kcr 69.2% 362.3 
 
Table S5.2 sums up the MS/MS evaluation data of the chymotryptic peptide NIDHXPGTAPKY 
containing either Kcr or K at position X. The amount of deacylation was calculated from the 
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integrals of the mass signals based on the fact that the ionization properties of the peptides 
are almost similar. 
 
Table S5.2. MS/MS evaluation data of the chymotryptic peptide NIDHXPGTAPKY of the TrxA N65Kcr digestion. 
Sample [M+2H]
2+
 ΔM Probability Ions found 
TrxA N65Kcr 704.8649 + 1.24 ppm 25.78 14/22 
TrxA N65K 
(deacylated) 
670.8529 + 2.06 ppm 32.52 16/22 
 
The MS/MS spectrum of the described [M+2H]
2+
 ions is depicted in Figure S5.3. Sequencing 
data (MS/MS data) of the relevant peptide fragment NIDHXPGTAPKY of Kcr containing TrxA 
(X=Kcr, Table S5.3) proof the insertion of the amino acid Kcr at the correct position (N65Kcr). 
Fig. S5.4 and table S5.4 show the relevant peptide fragments of deacylated Trx N65Kcr (Trx 
N65K). As fragmentation of the peptide can occur starting either with the N-terminus (b ion 
series) or the C-terminus (y ion series) both ion series can always be found. 
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TrxA N65Kcr 
 
 
Fig. S5.3. MS/MS spectrum of the chymotryptic peptide NIDHXPGTAPKY (X = Kcr) of the TrxA N65Kcr digestion. 
 
 
Table S5.3. Assigned MS/MS fragments resulting from fragmentation of the chymotryptic peptide NIDHXPGTAPKY (X = Kcr) 
of the TrxA N65Kcr digestion. 
#1 b(1+) b(2+) Seq. y(1+) y(2+) #2 
1 115.05021 58.02874 N     12 
2 228.13428 114.57078 I 1294.67900 647.84314 11 
3 343.16123 172.08425 D 1181.59493 591.30110 10 
4 480.22014 240.61371 H 1066.56798 533.78763 9 
5 676.34127 338.67427 N-KCr 929.50907 465.25817 8 
6 773.39404 387.20066 P 733.38794 367.19761 7 
7 830.41551 415.71139 G 636.33517 318.67122 6 
8 931.46319 466.23523 T 579.31370 290.16049 5 
9 1002.50031 501.75379 A 478.26602 239.63665 4 
10 1099.55308 550.28018 P 407.22890 204.11809 3 
11 1227.64805 614.32766 K 310.17613 155.59170 2 
12     Y 182.08116 91.54422 1 
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TrxA N65K (deacylated Kcr) 
 
 
Fig. S5.4. MS/MS spectrum of the deacylated chymotryptic peptide NIDHXPGTAPKY (X = K) of the TrxA N65Kcr digestion. 
 
 
Table S5.4. Assigned MS/MS fragments resulting from fragmentation of the deacylated chymotryptic peptide 
NIDHXPGTAPKY (X = K) of the TrxA N65Kcr digestion. 
#1 b(1+) b(2+) Seq. y(1+) y(2+) #2 
1 115.05021 58.02874 N     12 
2 228.13428 114.57078 I 1226.65284 613.83006 11 
3 343.16123 172.08425 D 1113.56877 557.28802 10 
4 480.22014 240.61371 H 998.54182 499.77455 9 
5 608.31510 304.66119 N-Asn->Lys 861.48291 431.24509 8 
6 705.36787 353.18757 P 733.38794 367.19761 7 
7 762.38934 381.69831 G 636.33517 318.67122 6 
8 863.43702 432.22215 T 579.31370 290.16049 5 
9 934.47414 467.74071 A 478.26602 239.63665 4 
10 1031.52691 516.26709 P 407.22890 204.11809 3 
11 1159.62188 580.31458 K 310.17613 155.59170 2 
12     Y 182.08116 91.54422 1 
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6 Incorporation of Kpr, Kbu and Kcr into H3  
6.1 Expression of H3 wt, K9Kpr, K9Kbu, K9Kcr 
E. coli strain BL21(DE3) was transformed with pACyc_pylTTT, pylS and 
pPSG IBA35_h3 K9amber. An overnight culture was used for inoculation (to OD600 of 0.1) of 
0.5 L LB medium containing 5 mM Kcr or Kbu or 10 mM Kpr, 50 mg/L carbenicillin and 
34 mg/L chloramphenicol. Cells were grown at 37 °C until an OD600 of 0.6. Expression of 
h3 K9Kmod was induced by addition 1 mM IPTG. Optionally 20 mM nicotinamide (NAM) 
were added at this point to inhibit a possible deacylation of the incorporated modified 
amino acids. The cells were shaked for further 16 h at 30 °C. After centrifugation (10.000 x g, 
10 min, 4°C) the cells were stored at -20°C or directly purified.  
 
6.2 Purification of H3 wt, K9Kpr, K9Kbu, K9Kcr 
All purification steps were carried out at room temperature. Cells were resuspended in HisA 
buffer (50 mM Tris-HCl, 500 mM NaCl, 20 mM imidazol, pH 7.5) supplemented with 7 M 
urea. The cells were lysed using a French press (Thermo Scientific). Cell debris was removed 
by centrifugation (38 000 x g, 30 min, rt) and the supernatant was applied to a 1 mL HisTrap 
FF column (GE), equilibrated with HisA buffer. Proteins were eluted from the column using 
the same buffer containing 250 mM imidazol. The eluted fractions were pooled and 
concentrated. Typical protein yields of 1 mg per liter expression medium Kcr or Kbu 
containing H3 were achieved. The yield of Kpr containing H3 was typically lower at 0.5 mg/L 
expression medium. H3 wt protein yield was at 4-5 mg/L. Purified H3 was optionally dialyzed 
twice (2 h, than over night) against 2 L StrepA buffer (10 mM Tris-HCl pH 8, 1 mM EDTA, 150 
mM NaCl) supplemented with 5 mM DTT at 4 °C. concentrated and stored at -80°C.  
 
6.3 In-Gel Propionylation and butyrylation and tryptic digestion of H3 
variants H3 wt, K9Kpr, K9Kbu, K9Kcr 
The first washing steps of this procedure were performed in the same way as for the 
chymotryptic digestion described in 5.5. 
Instead of the reduction and alkylation, the capping of unmodified lysine residues was 
carried out
[2]
. After this procedure trypsin cleaves exclusively after arginine residues. 
Consequently longer peptides are generated from the digestion which can be analyzed. 
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6 Incorporation of Kpr, Kbu and Kcr into H3  
6.1 Expression of H3 wt, K9Kpr, K9Kbu, K9Kcr 
E. coli strain BL21(DE3) was transformed with pACyc_pylTTT, pylS and 
pPSG IBA35_h3 K9amber. An overnight culture was used for inoculation (to OD600 of 0.1) of 
0.5 L LB medium containing 5 mM Kcr or Kbu or 10 mM Kpr, 50 mg/L carbenicillin and 
34 mg/L chloramphenicol. Cells were grown at 37 °C until an OD600 of 0.6. Expression of 
h3 K9Kmod was induced by addition 1 mM IPTG. Optionally 20 mM nicotinamide (NAM) 
were added at this point to inhibit a possible deacylation of the incorporated modified 
amino acids. The cells were shaked for further 16 h at 30 °C. After centrifugation (10.000 x g, 
10 min, 4°C) the cells were stored at -20°C or directly purified.  
 
6.2 Purification of H3 wt, K9Kpr, K9Kbu, K9Kcr 
All purification steps were carried out at room temperature. Cells were resuspended in HisA 
buffer (50 mM Tris-HCl, 500 mM NaCl, 20 mM imidazol, pH 7.5) supplemented with 7 M 
urea. The cells were lysed using a French press (Thermo Scientific). Cell debris was removed 
by centrifugation (38 000 x g, 30 min, rt) and the supernatant was applied to a 1 mL HisTrap 
FF column (GE), equilibrated with HisA buffer. Proteins were eluted from the column using 
the same buffer containing 250 mM imidazol. The eluted fractions were pooled and 
concentrated. Typical protein yields of 1 mg per liter expression medium Kcr or Kbu 
containing H3 were achieved. The yield of Kpr containing H3 was typically lower at 0.5 mg/L 
expression medium. H3 wt protein yield was at 4-5 mg/L. Purified H3 was optionally dialyzed 
twice (2 h, than over night) against 2 L StrepA buffer (10 mM Tris-HCl pH 8, 1 mM EDTA, 150 
mM NaCl) supplemented with 5 mM DTT at 4 °C. concentrated and stored at -80°C.  
 
6.3 In-Gel Propionylation and butyrylation and tryptic digestion of H3 
variants H3 wt, K9Kpr, K9Kbu, K9Kcr 
The first washing steps of this procedure were performed in the same way as for the 
chymotryptic digestion described in 5.5. 
Instead of the reduction and alkylation, the capping of unmodified lysine residues was 
carried out
[2]
. After this procedure trypsin cleaves exclusively after arginine residues. 
Consequently longer peptides are generated from the digestion which can be analyzed. 
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Another advantage is the possible comparison of originally modified with deacylated 
peptides.  
The dried gel pieces were incubated with 20 µL of propionic or butyric anhydride and 40 µL 
of 2 M ammonium hydroxide for 30 min at 51 °C. This step was repeated once. Afterwards 
the gel pieces were washed as described in 5.5. The tryptic digestion was performed by 
adding 100 µL of a 5 ng/µL trypsin (Promega) solution in 25 mM ammonium 
hydrogencarbonate. The digestion solution was incubated over night at 37 °C. Afterwards 
the capping procedure was repeated twice as described after the digestion to also cap the N-
termini generated during digestion. 
The peptides were extracted from the gel pieces and analyzed by HPLC-MS/MS in the same 
way as described for the chymotryptic peptides in 5.5. 
 
6.4 HPLC-MS/MS of propionylated or butyrylated tryptic peptides of H3 
variants H3 wt, K9Kpr, K9Kbu, K9Kcr 
For the nano-HPLC ESI mass spectrometry analysis the tryptic digested peptides were loaded 
onto a Dionex C18 Nano Trap Column (100 µm), subsequently eluted and separated by a self 
packed C18-AQ, 3 µm, 120 Å column. The peptide fragments were analyzed by HR-MS 
followed by tandem MS using a coupled Dionex Ultimate 3000 LTQ-Orbitrap XL MS system 
(Thermo). 
The obtained peptide fragment data were analyzed with the SEQUEST algorithm 
iŵpleŵeŶted iŶ the software ͞Proteome discoverer 1.1.0.263͟ (Thermo) against a peptide 
library of E. coli containing the protein sequence of human histone H3.3. The search was 
limited to tryptic peptides, two missed cleavage sites, +2 charged monoisotopic precursor 
ions and a peptide tolerance of <10 ppm. The sequence coverage and probability values of 
the capped tryptic H3 wt, H3 K9Kpr, Kbu and Kcr digestion samples are shown in Table S6.1.  
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Table S6.1. Sequence coverage and probability values of the capped tryptic H3 K9Kpr, Kbu and Kcr digestion samples. 
Sample capping Sequence coverage score 
H3 wt propionylation 62.05% 73.51 
H3 wt butyrylation 61.03% 52.72 
H3 K9Kpr butyrylation 54.41% 105.58 
H3 K9Kbu propionylation 60.29% 47.37 
H3 K9Kcr propionylation 48.53% 21.44 
 
Table S6.2 sums up the MS/MS evaluation data of the tryptic peptide XSTGGKAPR containing 
either K (capped), Kpr, Kbu or Kcr at position X. The amount of deacylation mentioned in the 
main paper was calculated from the integrals of the mass signals based on the fact that the 
ionization properties of the peptides are almost similar. 
 
Table S6.2. MS/MS evaluation data of the tryptic peptide XSTGGKAPR (X = K, Kpr, Kbu or Kcr) of the capped H3 digestion. 
Sample capping [M+2H]
2+
 ΔM Probability Ions found 
H3 wt propionylation 535.3057 3.86 ppm 45.19 14/16 
H3 wt butyrylation 556.3284 2.09 ppm 24.71 14/16 
H3 K9Kpr butyrylation 549.3199 1.07 ppm 10.75 13/16 
H3 K9Kbu propionylation 542.3140 4.65 ppm 17.23 13/16 
H3 K9Kcr propionylation 541.3046 1.79 ppm 21.44 12/16 
 
MS Spectra of the described [M+2H]
2+
 ions are depicted in Figures S6.1-S6.5. Sequencing 
data (MS/MS data) of the relevant peptide fragment XSTGGKAPR of modified lysine 
containing H3 (X = Kpr, Kbu or Kcr, Table S6.3-S6.7) proof the insertion of the modified 
amino acids at the correct position in H3 (K9). As fragmentation of the peptide can occur 
starting either with the N-terminus (b ion series) or the C-terminus (y ion series) both ion 
series can always be found.  
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H3 wt propionylated 
 
 
Fig. S6.1. MS/MS spectrum of the propionyl capped tryptic peptide XSTGGKAPR (X = K, capped by propionylation) of the H3 
wt digestion. 
 
Table S6.3. Assigned MS/MS fragments resulting from fragmentation of the propionyl capped tryptic peptide XSTGGKAPR 
(X = K, capped by propionylation) of the H3 wt digestion. 
 
#1 b(1+) b(2+) Seq. y(1+) y(2+) #2 
1 241.15465 121.08096 K-Propionyl  
N-term-Propionyl 
    9 
2 328.18668 164.59698 S 829.45267 415.22997 8 
3 429.23436 215.12082 T 742.42064 371.71396 7 
4 486.25583 243.63155 G 641.37296 321.19012 6 
5 543.27730 272.14229 G 584.35149 292.67938 5 
6 727.39847 364.20287 K-Propionyl 527.33002 264.16865 4 
7 798.43559 399.72143 A 343.20885 172.10806 3 
8 895.48836 448.24782 P 272.17173 136.58950 2 
9     R 175.11896 88.06312 1 
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H3 wt butyrylated 
 
 
Fig. S6.2. MS/MS spectrum of the butyryl capped tryptic peptide XSTGGKAPR (X = K, capped by butyrylation) of the H3 wt 
digestion. 
 
Table S6.4. Assigned MS/MS fragments resulting from fragmentation of the butyryl capped tryptic peptide XSTGGKAPR (X = 
K, capped by butyrylation) of the H3 wt digestion. 
 
#1 b(1+) b(2+) Seq. y(1+) y(2+) #2 
1 269.18605 135.09666 K-Butyryl 
N-term-Butyryl  
    9 
2 356.21808 178.61268 S 843.46837 422.23782 8 
3 457.26576 229.13652 T 756.43634 378.72181 7 
4 514.28723 257.64725 G 655.38866 328.19797 6 
5 571.30870 286.15799 G 598.36719 299.68723 5 
6 769.44557 385.22642 K-Butyryl 541.34572 271.17650 4 
7 840.48269 420.74498 A 343.20885 172.10806 3 
8 937.53546 469.27137 P 272.17173 136.58950 2 
9     R 175.11896 88.06312 1 
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H3 K9Kpr butyrylated 
 
Fig. S6.3. MS/MS spectrum of the butyryl capped tryptic peptide XSTGGKAPR (X = Kpr) of the H3 K9Kpr digestion. 
 
Table S6.5. Assigned MS/MS fragments resulting from fragmentation of the butyryl capped tryptic peptide XSTGGKAPR (X = 
Kpr) of the H3 K9Kpr digestion. 
#1 b(1+) b(2+) Seq. y(1+) y(2+) #2 
1 255.17035 128.08881 K-Butyryl  
N-term-Propionyl 
    9 
2 342.20238 171.60483 S 843.46837 422.23782 8 
3 443.25006 222.12867 T 756.43634 378.72181 7 
4 500.27153 250.63940 G 655.38866 328.19797 6 
5 557.29300 279.15014 G 598.36719 299.68723 5 
6 755.42987 378.21857 K-Butyryl 541.34572 271.17650 4 
7 826.46699 413.73713 A 343.20885 172.10806 3 
8 923.51976 462.26352 P 272.17173 136.58950 2 
9     R 175.11896 88.06312 1 
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H3 K9Kbu propionylated 
 
 
Fig. S6.4. MS/MS spectrum of the propionyl capped tryptic peptide XSTGGKAPR (X = Kbu) of the H3 K9Kbu digestion. 
 
Table S6.6. Assigned MS/MS fragments resulting from fragmentation of the propionyl capped tryptic peptide XSTGGKAPR 
(X = Kbu) of the H3 K9Kbu digestion. 
#1 b(1+) b(2+) Seq. y(1+) y(2+) #2 
1 255.17035 128.08881 K- Butyryl  
N-term- Propionyl  
    9 
2 342.20238 171.60483 S 829.45267 415.22997 8 
3 443.25006 222.12867 T 742.42064 371.71396 7 
4 500.27153 250.63940 G 641.37296 321.19012 6 
5 557.29300 279.15014 G 584.35149 292.67938 5 
6 741.41417 371.21072 K-Propionyl 527.33002 264.16865 4 
7 812.45129 406.72928 A 343.20885 172.10806 3 
8 909.50406 455.25567 P 272.17173 136.58950 2 
9     R 175.11896 88.06312 1 
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H3 K9Kcr propionylated 
 
 
Fig. S6.5. MS/MS spectrum of the propionyl capped tryptic peptide XSTGGKAPR (X = Kcr) of the H3 K9Kcr digestion. 
 
Table S6.7. Assigned MS/MS fragments resulting from fragmentation of the propionyl capped tryptic peptide XSTGGKAPR 
(X = Kcr) of the H3 K9Kcr digestion. 
#1 b(1+) b(2+) Seq. y(1+) y(2+) #2 
1 253.15465 127.08096 K-Crotonyl 
N-term-Propionyl 
    9 
2 340.18668 170.59698 S 829.45267 415.22997 8 
3 441.23436 221.12082 T 742.42064 371.71396 7 
4 498.25583 249.63155 G 641.37296 321.19012 6 
5 555.27730 278.14229 G 584.35149 292.67938 5 
6 739.39847 370.20287 K-Propionyl 527.33002 264.16865 4 
7 810.43559 405.72143 A 343.20885 172.10806 3 
8 907.48836 454.24782 P 272.17173 136.58950 2 
9     R 175.11896 88.06312 1 
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7 Western Blot 
 
The antibodies against Kpr, Kbu and Kcr were purchased from PTM biolabs. The western blot 
was performed following the procedures recommended by PTM biolabs. As shown in Figure 
S7.1 the H3 K9Kpr, H3 K9Kbu and H3 K9Kcr histone modifications can be selectively 
labeled.using the corresponding antibodies when compared to the wild type histone (H3 K9). 
In a cross experiment every antibody was tested against every histone modification (H3 
K9Kpr, H3 K9Kbu and H3 K9Kcr). This experiment revealed that the antibodies also recognize 
the related modifications (e.g. H3 K9Kpr is recognized also by anti Kbu antibody). This cross 
labeling activity could be a result of the high concentrations of purified histones used for the 
western blot. The results are summed up in Fig. S7.2. 
 
 
Fig. S7.1. Western Blot of the three different antibodies against different modifications 
 
 
 
Fig. S7.2. Western Blot of the three different antibodies against different modifications  
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9.2 Selected supplementary information corresponding to section 7.4 
 
Sulfonyl azide-mediated norbornene aziridination for orthogonal 
peptide and protein labeling 
 
Pages S11-S13 and S17-S22 of the supplementary information of the corresponding original 
publication are shown since they contain methods and data generated by the author of this 
thesis. 
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5. Peptide labeling experiments 
The experiments were performed as follows:  
50 µM of the peptide solution was incubated at 37 °C with 2.5 mM 4-((4-
(azidosulfonyl)phenyl)amino)-4-oxobutanoic acid 1 in H2O/CH3CN (9:1) mixture and the progress of 
the reaction was monitored using MALDI mass spectrometry. Probes of the reaction mixture were 
spotted onto MALDI target using sinapic acid solution as a matrix (SA in 50/50 H2O/CH3CN + 
0.1%TFA) and the spectra were recorded in negative mode.  
Calculated masses:  
Norbornene–containing peptide: [M-H]¯: 1279.7 Da 
Labeled peptide: [M-H]
¯
: 1549.7 Da 
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Figure S3: Peptide labeling experiments using 50 µM peptide and 2.5 mM sulfonyl azide 1. MALDI-
TOF spectra showing the progress of the peptide labeling reaction in time. Starting peptide calc. mass: 
1279.7 Da and the product mass: 1549.7 Da; observed: 1278.4 Da and 1548.5 Da respectively. 
ΔMcalc.= 270.0 Da; ΔMfound = 270.1 Da.  
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Figure S4: Peptide labeling experiments using 50 µM peptide and 2.5 mM sulfonyl azide 1. MALDI-
TOF spectra showing the formation of the hydrolyzed sulfonamide product after prolonged incubation 
time (calc. mass [M-H]
¯
: 1567.7 Da; observed: 1566.6 Da). The observed mass peak at 1580.1 could 
not be assigned.  Desired aziridine product mass: 1549.7 Da; observed: 1548.5 Da.  
Additional experiment using 50 µM peptide and 5 mM (100 equiv.) 4-((4-
(azidosulfonyl)phenyl)amino)-4-oxobutanoic acid 1 in H2O/CH3CN (9:1) mixture showed full 
conversion of the starting peptide to the aziridinated product within 24 hours (Figure S5). 
 
Figure S5: Peptide labeling experiments using 50 µM peptide and 5 mM sulfonyl azide 1. MALDI-
TOF showed full conversion within 24 hours in this case. Starting peptide calc. mass: 1279.7 Da and 
the product mass: 1549.7 Da; observed: 1278.4 Da and 1548.5 Da respectively. ΔMcalc.= 270.0 Da; 
ΔMfound = 270.1 Da. 
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8. Cloning, expression and purification of norbornene–containing 
proteins 
8.1. Cloning and mutagenesis of IBA3_Trx N65amber 
The expression vector pPSG_IBA3_trx was created following the Stargate cloning protocol (IBA, 
Göttingen) using the primers forward trxA pENTRY_IBA51 and reverse trxA pENTRY_IBA51 
(Table S1). The commercial vector pBAD202 (Life Technologies) was used as template for trxA gene 
amplification. The amber codon (TAG) at position Asn65 was introduced by blunt end site directed 
mutagenesis using primers forward trxA N65amber and reverse trxA N65amber. 
Table S1: Sequences of the used primers for generation of expression vector IBA trx N65amber. 
Name Sequence 
forward trxA pENTRY_IBA51 AGCGGCTCTTC AATG GGA TCT GAT AAA ATT ATT CAT CTG ACT GAT G 
reverse trxA pENTRY_IBA51 AGCGGCTCTTC TCCC CAG GTT AGC GTC GAG GAA CTC TTT C 
forward trxA N65amber 5’phosph CCG GGC ACT GCG CCG AAA TAT G 
reverse trxA N65amber 5’phosph CTA GTG ATC GAT GTT CAG TTT TGC AAC GG 
 
8.2. Expression of norbornene–containing Trx 
E. coli strain BL21(DE3) was transformed with pACyc_pylRS Norb, 3xpylT
1
 and 
pPSG_IBA3_trxA N65amber. An overnight culture was used for inoculation (to OD600 of 0.1) of 2 L 
LB medium containing 2 mM 4, 50 mg/L carbenicillin and 34 mg/L chloramphenicol. Cells were 
grown at 37 °C until an OD600 of 0.6. Expression of trxA N65X was induced by addition 1 mM IPTG. 
The cells were shaken for further 16 h at 30 °C. After centrifugation (10.000 x g, 10 min, 4°C) the 
cells were stored at -20°C or directly purified.  
All purification steps were carried out at 4°C. Cells were resuspended in StrepA buffer (10 mM Tris-
HCl pH 8, 1 mM EDTA, 150 mM NaCl) and supplemented with protease inhibitor mix (Roche). The 
cells were lysed using a French press (Thermo Scientific). Cell debris was removed by centrifugation 
(38 000 x g, 30 min, 4 °C) and the supernatant was applied to a 5 mL Strep-Tactin column (IBA), 
equilibrated with StrepA buffer. Proteins were eluted from the column using the same buffer 
containing 2.5 mM desthiobiotin. The eluted fractions were pooled and concentrated. Typical protein 
yields of 25 mg per liter expression medium of 4 containing Trx were achieved. Purified Trx N65X 
was equilibrated with StrepA buffer, concentrated and stored at -80 °C. A raw intact MS spectrum of 
Trx N65X (X = norbornene amino acid 4) is shown in Figure S9. The deconvoluted spectrum is shown 
in red in Figure 3A of the main text. 
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Figure S9: Raw intact MS spectrum of Trx N65X (X = norbornene amino acid 4) 
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8.3. Tryptic digestion and MS/MS of norbornene–containing Trx 
The sequence of Trx is shown in Table S2. Position Asn65 which was chosen for the incorporation of 
amino acid 4 is shown in red. The peptide generated after tryptic digestion is emphasized in bold 
letters. Figure S10 shows the corresponding MS/MS spectrum. Table S3 shows the expected and 
identified MS/MS fragments of the relevant tryptic peptide. 
Table S2: Amino acid sequence of Trx 
.  
        10         20         30         40         50         60  
MGSDKIIHLT DDSFDTDVLK ADGAILVDFW AHWCGPCKMI APILDEIADE YQGKLTVAKL  
 
        70         80         90        100        110        120  
NIDHNPGTAP KYGIRGIPTL LLFKNGEVAA TKVGALSKGQ LKEFLDANLG SAWSHPQFEK 
 
 
Figure S10: MS/MS spectrum of the tryptic peptide LNIDHXPGTARK (X = 4). Parent ion: 
[M+2H]
2+
calc. = 720.8961, [M+2H]
2+
obs. = 720.8932 (ΔM = 4 ppm). 
 
Table S3: Expected and identified MS/MS fragments of the tryptic peptide LNIDHXPGTARK (X = 
4). Identified fragments are shown in red for b ions and blue for y ions. 
#1 b⁺ Seq. y⁺ y²⁺ #2 
1 114.09135 L 
  
12 
2 228.13428 N 1327.70051 664.35389 11 
3 341.21835 I 1213.65758 607.33243 10 
4 456.24530 D 1100.57351 550.79039 9 
5 593.30421 H 985.54656 493.27692 8 
6 871.46724 X 848.48765 424.74746 7 
7 968.52001 P 570.32462 285.66595 6 
8 1025.54148 G 473.27185 237.13956 5 
9 1126.58916 T 416.25038 208.62883 4 
10 1197.62628 A 315.20270 158.10499 3 
11 1294.67905 P 244.16558 122.58643 2 
12 
 
K 147.11281 74.06004 1 
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8.4. Mutagenesis of pACA_HCA H36amber 
The amber codon (TAG) was introduced into the expression vector pACA_HCA 
11
 at position His36 
of the human carbonic anhydrase II gene by blunt end site directed mutagenesis using the primers 
forward HCA H36amber and reverse HCA H36amber. 
 
Table S4: Sequences of the used primers for the generation of expression vector pACA_HCA 
H36amber. 
Name Sequence 
forward HCA H36amber 5’phosph GTT GAC ATC GAC ACT TAG ACA GCC AAG TAT GAC 
reverse HCA H36amber 5’phosph AGG GGA CTG GCG CTC TCC CTT GG 
 
8.5. Expression of norbornene containing HCA 
The expression vector pACA_HCA G131amber was transformed together with pACyc_pylRS Norb, 
3xpylT
1
 which contains the genes of the triple mutant of PylRS and three copies of pylT in E. coli 
BL21(DE3) cells (NEB). 1 L of LB medium containing 34 mg/L chloramphenicol, 100 mg/L 
carbenicillin and 2 mM norbornene amino acid 4 was inoculated with 10 mL of an overnight culture. 
The cells were stirred at 37 °C until an OD600 of 0.9. At this optical density 1 mM ZnSO4 and 0.1 mM 
IPTG were added to induce the expression of the HCA H36amber gene. After further 10 h at 37 °C the 
cells were harvested and stored at -20 °C until further use. The harvested cells were resuspended in 
washing buffer (25 mM Tris; 50 mM Na2SO4; 50 mM NaClO4; pH 8.8) and disrupted by French Press 
procedure. The supernatant of the centrifuged lysate was used for sulfonamide affinity protein 
purification using an ÄKTA purifier system. The self-packed 3 mL column of p-
Aminomethylbenzenesulfonamide-Agarose resin (Sigma-Aldrich, A0796) was equilibrated with 
washing buffer. After binding (0.75 mL/min) of the protein solution, the column was washed with 7 
column volumes of washing buffer. HCA was eluted by lowering the pH by elution buffer (100 mM 
NaOAc; 200 mM NaClO4; pH 5.6). The protein containing fractions were combined, analyzed by 
SDS-PAGE, dialyzed against water and lyophilized. Typical yields of the pure norbornene amino 
acid 4 containing protein HCA H36X were 20 mg/L expression medium.  
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8.6. Tryptic digestion and MS/MS of norbornene–containing HCA 
The sequence of HCA II is shown in Table S5. Position His36 which was chosen for the incorporation 
of amino acid 4 is shown in red. The peptide generated after tryptic digestion is emphasized in bold 
letters. Figure S11 shows the corresponding MS/MS spectrum. Table S6 shows the expected and 
identified MS/MS fragments of the relevant tryptic peptide. 
Table S5: Amino acid sequence of HCA II.  
 
        10         20         30         40         50         60  
MAHHWGYGKH NGPEHWHKDF PIAKGERQSP VDIDTHTAKY DPSLKPLSVS YDQATSLRIL  
 
        70         80         90        100        110        120  
NNGHAFNVEF DDSQDKAVLK GGPLDGTYRL IQFHFHWGSL DGQGSEHTVD KKKYAAELHL  
 
       130        140        150        160        170        180  
VHWNTKYGDF CKAVQQPDGL AVLGIFLKVG SAKPGLQKVV DVLDSIKTKG KSADFTNFDP  
 
       190        200        210        220        230        240  
RGLLPESLDY WTYPGSLTTP PLLESVTWIV LKEPISVSSE QVLKFRKLNF NGEGEPEELM  
 
       250        260  
VDNWRPAQPL KNRQIKASFK 
 
Figure S11: MS/MS spectrum of the tryptic peptide QSPVDIDTXTAK (X = 4). Parent ion: 
[M+2H]
2+
calc. = 726.8829, [M+2H]
2+
obs. = 726.8807 (ΔM = 3 ppm). 
Table S6: Expected and identified MS/MS fragments of the tryptic peptide QSPVDIDTXTAK 
(X = 4). Identified fragments are shown in red for b ions and blue for y ions. 
#1 b⁺ Seq. y⁺ #2 
1 129.06586 Q 
 
12 
2 216.09789 S 1324.69949 11 
3 313.15066 P 1237.66746 10 
4 412.21908 V 1140.61469 9 
5 527.24603 D 1041.54627 8 
6 640.33010 I 926.51932 7 
7 755.35705 D 813.43525 6 
8 856.40473 T 698.40830 5 
9 1134.56774 X 597.36062 4 
10 1235.61542 T 319.19761 3 
11 1306.65254 A 218.14993 2 
12 
 
K 147.11281 1 
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9. Protein labeling studies 
The purified Trx and HCA proteins were used for modification using different sulfonyl azide reagents. 
The final concentrations of the proteins were 40 µM (in 50 mM Tris buffer pH 7.5 for Trx or 50 mM 
MES buffer pH 5.5 for HCA). The sulfonyl azide derivatives were added to a final concentration of 
2 mM. In case of dansyl sulfonyl azide 6 a 10 mM stock solution in DMF was prepared. The final 
DMF concentration in this case was therefore 20% (v/v). Biotin sulfonyl azide 5 is water soluble and 
was therefore added without any organic solvent. After overnight incubation at 37 °C the samples 
were used for SDS-PAGE and/or intact mass spectrometry analysis. To visualize the modification of 
HCA H36X with the fluorophore 6 the SDS gel was analyzed using an image reader (Fujifilm LAS-
3000). The excitation wavelength was 312 nm. The SDS-gels are shown in the main text (Figure 3). 
The raw intact MS spectrum of Trx labeled with 5 is shown in Figure S12. The deconvoluted spectrum 
is shown in blue in Figure 3A in the main text. 
 
 
Figure S12: Raw intact MS spectrum of biotinylated Trx N65X (X = norbornene amino acid 4 
aziridinated with 5). 
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9.3 Selected supplementary information corresponding to section 7.5 
 
Orchestrating the biosynthesis of an unnatural pyrrolysine amino 
Acid for its direct incorporation into proteins inside living cells 
 
Pages S-3-S-9 and S17-S-22 of the supplementary information of the corresponding original 
publication are shown since they contain methods and data generated by the author of this 
thesis. 
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1. Supporting Figures 
 
 
Supporting Figure 1: Scheme of natural and hijacking biosynthetic pathways of pyrrolysine, ethynylpyrrolysine and 
desmethylpyrrolysine. L-lysine is converted to pyrrolysine via PylB, PylC and PylD (grey) in the natural biosynthesis 
pathway. 3S-ethynyl-D-ornithine or D-ornithine are converted to ethynylpyrrolysine (blue) and desmethylpyrrolysine (black) 
respectively via PylC and PylD in the unnatural hitchhiking pathway. 
 
 
Supporting Figure 2: Biosynthetic conversion of 3S-ethynyl-D-ornithine to ethynylpyrrolysine and incorporation into 
chloramphenicol acetyltransferase (CAT) using E. coli expressing the biosynthesis machinery of Pyl: (PylC, PylD, PylRS, 
PylT) and CAT-A69amber (a) or CAT-D111amber (b). Growth curves of E. coli cells in growth media containing 
chloramphenicol and supplemented with D-ornithine (2 mM / 5 mM) or 3S-ethynyl-D-ornithine (2 mM / 5 mM) or 3R-ethynyl-
D-ornithine (2 mM / 5 mM). 
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Supporting Figure 3: Molecular Modelling of a) 3S-ethynyl-D-ornithine and b) 3R-ethynyl-D-ornithine in the catalytic 
active site of PylC (PDB:4FFN). In a) the 3S-configurated ethynyl moiety is located in a hydrophobic pocket whereas in b) 
3R-configurated ethynyl moiety clashes with glutamate residue (Glu227). Molecular modeling was performed with the 
software MOLOC.[1] 
 
 
Supporting Figure 4: Expression of hCA-ePyl131 and hCA-dmPyl131. Sample analysis by SDS-PAGE and Coomassie 
staining. lane 1: lysate of expression of hCA-ePyl131; lane 2: purified hCA-ePyl131; lane 3: lysate of expression of hCA-
dmPyl131; lane 4: purified hCA-dmPyl131; Mk: Page Ruler unstained protein ladder (Thermo). 
 
 
Supporting Figure 5: LC-MS analysis of the incorporated ethynylpyrrolysine in hCA-ePyl131. Intact mass spectrum of 
hCA-ePyl131 FT-ICR LC-MS measurement. 
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Supporting Figure 6: LC-MS analysis of the incorporated ethynylpyrrolysine in hCA-ePyl131 after tryptic digestion. 
a) Amino acid sequence of hCA. Sequence coverage of 88.03% was achieved and identified peptides are depicted in bold 
letters. Peptide with incorporated ethynylpyrrolysine (X) is marked in green. b) Table of calculated and identified fragment 
ions. Identified b-ions are marked in red, identified y-ions are marked in blue. c) MS/MS spectrum showing MS/MS 
fragments of peptide YGDFXK (X = ePyl). Parent ion: [M+2H]2+obs. = 438.71616 Da (ΔM = -0.01 ppm). 
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Supporting Figure 7: LC-MS analysis of the incorporated ethynylpyrrolysine in CAT-ePyl111 after chymotryptic 
digestion. a) Amino acid sequence of CAT. 32.88% of the protein were identified. These peptides are depicted in bold 
letters. The peptide with incorporated ethynylpyrrolysine (X) is marked yellow. b) Table of calculated and identified 
fragment ions. Identified b-ions are marked in red, identified y-ions are marked in blue. c) MS/MS spectrum showing 
MS/MS-fragments of fragment HXDF (X = ePyl). Parent ion: [M+2H]2+obs. = 333.15567 Da (ΔM = -0.16 ppm).   
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Supporting Figure 8: LC-MS analysis of the incorporated desmethylpyrrolysine in hCA-dmPyl131 after tryptic 
digestion. a) Amino acid sequence of hCA. Sequence coverage of 87.26% was achieved and identified peptides are depicted 
in bold letters. Peptide with incorporated desmethylpyrrolysine (X) is marked in green. b) Table of calculated and identified 
fragment ions. Identified b-ions are marked in red, identified y-ions are marked in blue. c) MS/MS spectrum showing 
MS/MS fragments of peptide YGDFXK (X = dmPyl). Parent ion: [M+2H]2+obs. = 426.7166 Da (ΔM = 0.92 ppm). 
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Supporting Figure 9: Analysis of the click labeled hCA-ePyl131 with HC-N3 tryptic digest and mass analysis. a) 
MS/MS spectra of peptide fragment YGDFXK (X: CuAAC product of ePyl with HC-N3). The base peak chromatogram (top) 
of the whole LC-MS run is shown as well as the extracted ion chromatograms (EIC) of the co-eluting 2+ (middle) and 3+ 
(bottom) charged peptides. Inlets show the MS spectra of the respective peptides. b) MS/MS spectrum showing MS/MS-
fragments of peptide YGDFXK (X: CuAAC product of ePyl and HC-N3). Identified a- and b-ions are marked in red, 
identified x- and y- ions are marked in blueThe inlet shows the identified peptide fragments. [M+2H]2+obs. = 540.23444 Da 
(ΔM = 2.18 ppm). 
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Supporting Figure 10: Analysis of the double labeled hCA-ePyl131 with HC-N3 and ABA-bio after tryptic digest and 
mass analysis. MS/MS spectra of peptide fragment YGDFXK (X: CuAAC and ABA reaction product of ePyl with HC-N3 
and ABA-bio). The base peak chromatogram (top) of the whole LC-MS run is shown as well as the extracted ion 
chromatograms (EIC) of the co-eluting 2+ (middle) and 3+ (bottom) charged peptides. Inlets show the MS spectra of the 
respective peptides. [M+2H]2+obs. = 962.94875 Da (ΔM = 9.56 ppm). 
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4. Biochemical procedures 
4.1. General remarks 
For hCA-ePyl131 expression three plasmids were required. Plasmid 1 contains the Pyl 
biosynthesis genes pylC and pylD under the control of an arabinose promoter (araBAD) from 
the pBAD-vector and a Kanamycin resistance gene. Plasmid 2 includes the Pyl-tRNA 
aminoacyl synthetase gene pylS under control of a constitutive E. coli glutamin aminoacyl 
synthetase promoter (pGlnRS), three copies of the Pyl tRNA gene (pylT) under control of an 
E. coli proK promoter and a chloramphenicol acetyltransferase (CAT) gene with an amber 
codon at position A69 or D111 in a pACyc-vector. Plasmid 3 contains the hCA gene with an 
amber codon at position G131 (hCA-G131amber) induced via a T7-promoter on a pACA-
vector containing an AmpR gene.
[3]
 
 
4.2. Incorporation assay 
The successful incorporation of ethynylpyrrolysine was verified using the following 
incorporation assay: The E. coli strain BL21(DE3) was transformed with two vectors coding 
for the pyrrolysine biosynthesis cluster and the chloramphenicol acetyltransferase (CAT) with 
an amber codon (A69O or D111O) in the sequence preliminary to the active site as selection 
marker (plasmid 1: pylC and pylD. plasmid 2: pylS, 3x pylT and CAT-A69amber or CAT-
D111amber).
[4]
 The LB-medium was supplemented with the antibiotic chloramphenicol 
(5 ng/µL) and one of the tested amino acids: 3S-ethynyl-D-ornithine (5 mM or 2 mM), 
3R-ethynyl-D-ornithine (5 mM or 2 mM) or D-ornithine (5 mM or 2 mM). The bacteria were 
grown at 37°C with shaking (200 rpm) and the OD600 was recorded at various time points. 
Cultures supplemented with 3S-ethynyl-D-ornithine showed faster growth than cultures 
supplemented with D-ornithine. Cultures supplemented with 3R-ethynyl-D-ornithine showed 
no increase in the OD600 at the recorded time points. Cells from the culture expressing CAT-
D111amber supplemented with 3S-ethynyl-D-ornithine (5 mM) were harvested, sonicated on 
ice and the lysate was separated using SDS-PAGE. The corresponding CAT band was cut out 
for chymotryptic digestion (18 h, 37 °C) and subjected to mass analysis. 
 
4.3. hCA expression 
For the expression of hCA the E. coli strain BL21(DE3) was transformed with the described 
plasmids described in 4.2 and an additional plasmid 3 coding for the hCA-G131amber. 
LB medium (250 mL) containing arabinose (0.2%) to induce the pyrrolysine biosynthesis 
cluster, chloramphenicol (15 ng/µL), carbenicillin (50 ng/µL) and either 3S-ethynyl-D-
ornithine (5 mM) or D-ornithine (5 mM) was inoculated with an overnight culture (2mL) of the 
transformed bacteria as described previously. The cells were shaken at 37 °C until an OD600 
of 1.5. At this optical density ZnSO4 (1 mM) for the active site and IPTG (1 mM) for the 
expression of the hCA-G131amber gene were added. After 10 h at 37 °C the cells were 
harvested and stored at -20 °C until further use. The harvested cells were resuspended in wash 
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buffer (25 mM Tris; 50 mM Na2SO4; 50 mM NaClO4; pH 8.8) supplemented with lysozyme 
(0.5 mg/L) and lysed by sonication on ice. Then 2.5 U Benzonase (Novagen) per mL of 
original culture was added and centrifuged. The supernatant of the centrifuged lysate was 
used for sulfonamide affinity protein purification using an ÄKTA purifier system. The self-
packed 5 mL column of p-aminomethylbenzenesulfonamide-agarose resin (Sigma-Aldrich) 
was equilibrated with hCA wash buffer. After binding (0.75 mL/min) of the lysate, the 
column was washed with 7 column volumes of hCA wash buffer. hCA was eluted by hCA 
elution buffer (100 mM NaOAc; 200 mM NaClO4; pH 5.6). The protein containing fractions 
were analyzed by SDS-PAGE, combined and rebuffered to phosphate buffered saline (PBS) 
buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.76 mM KH2PO4; pH 7.4) and used for 
modification reactions. For long time storage at ‒80 °C 10% glycerol was added. The correct 
incorporation of ethnylpyrrolysine or desmethylpyrrolysine was verified via LC-MS and LC-
MS/MS analysis. 
 
4.4. Protein modification 
The versatility of the new incorporated ethynylpyrrolysine was verified in two orthogonal 
labeling reactions. We conjugated the fluorophore 3-Azido-7-hydroxycoumarin, (Baseclick) 
and/or the synthesized aminobenzaldehyde biotin conjugate ABA-bio with the hCA with 
ethynylpyrrolysine incorporated at position 131. The coupling reactions were carried out in 
PBS at pH 7.4 and 25 °C. The single conjugation reaction was started by the addition of 
hCA-ePyl131 (20 µM) to premixed reaction mixture containing the azide (400 µM, stock 
4 mM in DMSO) or aminobenzaldehyde biotin conjugate (10 mM) and the catalyst master mix 
CuSO4 (200 µM), THPTA (500 µM) and freshly dissolved sodium ascorbate (1 mM). For 
single labeling the reaction mixture was incubated for 16 h. For double labeling the 
aminobenzaldehyde biotin conjugate was added after 2 h incubation time and further 
incubated for 14 h. The reaction of the aminobenzaldehyde labeling was quenched by adding 
an aqueous solution of NaCNBH3 (20 mM) and incubated for 2 h. The samples were 
rebuffered to (NH4)2CO3 solution (50 mM) using 10 kDa amicon filter ultracel 0.5 mL 
(Millipore). Formation of the protein conjugates were verified by mass spectrometrical 
analysis (see section mass analysis) and by SDS-PAGE with fluorescence detection using an 
image reader LAS-3000 (Fujifilm) and after transfer to a nitrocellulose membrane and 
Western Blot using an anti-biotin, HRP-linked antibody (Cell signaling) and detection via the 
SuperSignal West Pico Chemiluminescence Substrate (Thermo Scientific). 
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4.5. Mass analysis 
 
Sample preparation: 
For intact protein mass analysis the protein was desalted using 10 kDa Amicon filter ultracel 
0.5 mL (Millipore) to ddD2O with 2% MeCN and 0.1% formic acid (FA) and subsequently 
subjected to mass analysis. 
Mass spectrimetrical analysis after digestion was either performed directly on the purified 
protein solution or the visible protein band was cut out of a PAGE-gel. The protein was in-gel 
alkylated and tryptically or chymotryptically digested.[5] Trypsin activity was stopped by 
heatshock and further processed via the stage tip method[6] and analyzed via LC-MS/MS. 
 
LC-MS/MS analysis of peptides: 
The samples were analyzed using an UltiMate 3000 nano liquid chromatography system 
(Dionex, Fisher Scientific) coupled to an LTQ-Orbitrap XL (Fisher Scientific). For the 
analysis 12 µl of each sample were injected. The samples were desalted and concentrated on a 
µ-precolumn cartridge (PepMap100, C18, 5 µM, 100 Å, size 300 µm i.d. x 5 mm) and further 
processed on a custom made analytical column (ReproSil-Pur, C18, 1.9 µm, 120 Å, packed 
into a 75 µm i.d. x 150 mm and 8 µm picotip emitter).  
The samples were processed via a 127 min multi-step analytical separation at a flow rate 
300 nl/min. The gradient with percentages of solvent B was programmed as follows: 1% for 1 
minutes; 1%-4% over 1 minute; 4% - 24% over 100 minutes; 24% - 60% over 8 minutes; 
60%-85% over 2 minutes; 85% for 5 minutes; 85% - 1% over 2 minutes; 1% for 8 minutes.  
Mass spectrometric analyses were perfomed starting with a full mass scan in the mass range 
between m/z 150 and 2000 at a resolution of 200000. This survey scan was followed by five 
scans using the ion trap mass analyzer and CID fragmentation with a normalized collision 
energy 35. To avoid repeated sequencing of the same peptides, a dynamic exclusion list was 
used. 
 
Protein identification and proof of incorporporation of unnatural amino acids: 
The Thermo Proteome Discoverer 1.1 software (Fisher Scientific) was used for protein 
identification. The Sequest search engine was used to identify the proteins from a uniprot “full 
proteome” data set or the hCA 2 fasta file. As limit of detection a ratio of threefold signal over 
the noise filter was applied. A maximum of three missed cleavage sites was allowed. The 
mass tolerances were 20 ppm for the precursor mass and 0.3 Da for the fragment ion mass. As 
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dynamic modifications ethynylpyrrolysine (K), Pyrrolysine (K) and desmethylpyrrolysine (K) 
and the corresponding labeling adducts were defined and applied. The integration window 
tolerance was 15 ppm and the integration method was set to “most confident centroid”. 
 
LC-MS analysis of intact proteins: 
The samples were analyzed using an UltiMate 3000 nano liquid chromatography system 
(Dionex, Fisher Scientific) coupled to a LTQ-FTICR mass spectrometer (Finnigan). 100 ng of 
each sample were injected for the analysis. The samples were desalted and concentrated on a 
µ-precolumn cartridge (PepMap300, C4, 5 µM, 300 Å, size 300 µm i.d. x 5 mm) and further 
processed on a custom made analytical column (ReproSil-Pur, C4, 3 µm, 300 Å, packed into a 
75 µm i.d. x 150 mm and 8 µm picotip emitter).  
A 127 min multi-step analytical separation was performed at a flow rate of 300 nl/min. After 
holding the gradient on 2% solvent B (acetonitrile containing 0.1% formic acid) and 99% 
solvent A (water containing 0.1% formic acid) for one minute, it was ramped up to 24% over 
100 minutes. After this linear gradient solvent B was increased to 60% over 8 min and 
subsequent to 85% over 2 min. This level was held for 5 min, then ramped down again to 1% 
solvent B within 2 min and held for 8 min.  
The Thermo Xcalibur 2.1 and Protein deconvolution 3.0 software (Fisher Scientific) were 
used for protein mass analysis and intact mass spectra deconvolution. 
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